


**CUMULATIVE
SUPPLEMENT 6
JUNE 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 6
June 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**CUMULATIVE SUPPLEMENT 6
June 2018**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
IDT AUSTRALIA LTD (IDT AUSTRALIA LTD)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)

SILARX PHARMACEUTICALS INC
(SILARX PHARMS INC)

LANNETT CO INC
(LANNETT CO INC)

SAGENT AGILA LLIC
(SAGENT AGILA)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT AGILA LLC
(SAGENT AGILA LLC)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT STRIDES LLC
(SAGENT STRIDESC)

MYLAN ASI LLC
(MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001

LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294	19359	19529		
	2758	2763	2703		
	(14.3%)	(14.3%)	(13.8%)		
MULTISOURCE	16536	16596	16826		
	(85.7%)	(85.7%)	(86.2%)		
THERAPEUTICALLY EQUIVALENT	16431	16501	16735		
	(85.2%)	(85.2%)	(85.7%)		
NOT THERAPEUTICALLY EQUIVALENT	105	95	91		
	(0.5%)	(0.5%)	(0.5%)		
EXCEPTIONS ¹	73	72	72		
	(0.4%)	(0.4%)	(0.4%)		
NEW MOLECULAR ENTITIES APPROVED	25	6	26		
NUMBER OF APPLICANTS	1075	1084	1091		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full

applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
 ABACAVIR SULFATE
 AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL
 YONSA
 +! SUN PHARMA GLOBAL 125MG N210308 001 May 22, 2018 May NEWA
 ZYTIGA
 + JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011 Feb CHRS
 +! 500MG N202379 002 Apr 14, 2017 Feb CHRS

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
 ACEBUTOLOL HYDROCHLORIDE
 >D> AB AMNEAL PHARM EQ 200MG BASE A 075047 001 Dec 30, 1999 Jun CHRS
 >A> AB ! EQ 200MG BASE A 075047 001 Dec 30, 1999 Jun CHRS
 >D> AB EQ 400MG BASE A 075047 002 Dec 30, 1999 Jun CHRS
 >A> AB ! EQ 400MG BASE A 075047 002 Dec 30, 1999 Jun CHRS
 >D> SECTRAL
 >D> AB + PROMIUS PHARMA EQ 200MG BASE N 018917 001 Dec 28, 1984 Jun DISC
 >A> + @ EQ 200MG BASE N 018917 001 Dec 28, 1984 Jun DISC
 >D> AB +! EQ 400MG BASE N 018917 003 Dec 28, 1984 Jun DISC
 >A> + @ EQ 400MG BASE N 018917 003 Dec 28, 1984 Jun DISC

ACETAMINOPHEN

>A> SOLUTION;INTRAVENOUS
 >A> ACETAMINOPHEN
 >A> AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A 202605 001 Jun 13, 2016 Jun CDFR
 >A> FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Jun CDFR
 >A> AP SANDOZ INC 1GM/100ML (10MG/ML) A 204052 001 Mar 22, 2016 Jun CDFR
 >A> OFIRMEV
 >A> AP +! MALLINCKRODT IP 1GM/100ML (10MG/ML) N 022450 001 Nov 02, 2010 Jun CDFR
 >D> SOLUTION;IV (INFUSION)
 >D> ACETAMINOPHEN
 >D> AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A 202605 001 Jun 13, 2016 Jun CDFR
 >D> FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Jun CDFR
 >D> AP SANDOZ INC 1GM/100ML (10MG/ML) A 204052 001 Mar 22, 2016 Jun CDFR
 >D> OFIRMEV
 >D> AP +! MALLINCKRODT IP 1GM/100ML (10MG/ML) N 022450 001 Nov 02, 2010 Jun CDFR

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
 APADAZ
 + KEMPHARM 325MG;EQ 6.12MG BASE N 208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
 BUTALBITAL AND ACETAMINOPHEN
 MAYNE PHARMA INC 300MG;50MG A 207313 001 Dec 27, 2017 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AA NUVO PHARM INC 300MG;50MG;40MG A 207118 001 Oct 28, 2016 Apr CTEC
 AA TEDOR PHARMA INC 300MG;50MG;40MG A 206615 001 Aug 04, 2017 Apr CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 AA LANNETT CO INC 120MG/5ML;12MG/5ML A 091238 001 Nov 10, 2011 May CAHN
 TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ FOSUN PHARMA 300MG;30MG A 081250 001 Jul 16, 1992 Jan CAHN
 @ 300MG;60MG A 081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	EPIC PHARMA LLC	325MG; 5MG	A203863	001	Mar 30, 2018	Mar	NEWA
AA		325MG; 7.5MG	A203863	002	Mar 30, 2018	Mar	NEWA
AA		325MG; 10MG	A203863	003	Mar 30, 2018	Mar	NEWA
AA	RHODES PHARMS	300MG; 5MG	A207808	001	Mar 30, 2018	Mar	NEWA
AA		300MG; 7.5MG	A207808	002	Mar 30, 2018	Mar	NEWA
AA		300MG; 10MG	A207808	003	Mar 30, 2018	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

@ SPECGX LLC 325MG/5ML; 5MG/5ML

A040680 001 Sep 29, 2006 Jan DISC

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

@ VINTAGE PHARMS 325MG/5ML; 5MG/5ML

A203573 001 Dec 18, 2014 Jan DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ABHAI LLC	325MG; 2.5MG	A210644	001	Feb 09, 2018	Jan	NEWA	
AA		325MG; 5MG	A210644	002	Feb 09, 2018	Jan	NEWA	
AA		325MG; 7.5MG	A210644	003	Feb 09, 2018	Jan	NEWA	
AA		325MG; 10MG	A210644	004	Feb 09, 2018	Jan	NEWA	
>A>	AA	ELITE LABS INC	325MG; 5MG	A209385	001	Jul 02, 2018	Jun	NEWA
>A>	AA		325MG; 7.5MG	A209385	002	Jul 02, 2018	Jun	NEWA
>A>	AA		325MG; 10MG	A209385	003	Jul 02, 2018	Jun	NEWA
>A>	AA	EPIC PHARMA LLC	325MG; 5MG	A203864	001	Jul 02, 2018	Jun	NEWA
>A>	AA		325MG; 7.5MG	A203864	002	Jul 02, 2018	Jun	NEWA
>A>	AA		325MG; 10MG	A203864	003	Jul 02, 2018	Jun	NEWA
AA	WES PHARMA INC	325MG; 5MG	A207510	001	Mar 21, 2018	Mar	NEWA	
AA		325MG; 7.5MG	A207510	002	Mar 21, 2018	Mar	NEWA	
AA		325MG; 10MG	A207510	003	Mar 21, 2018	Mar	NEWA	

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT +! ICU MEDICAL INC 250MG/100ML N017656 001 Mar CRLD

SOLUTION/DROPS; OTIC

ACETIC ACID

AT	LANNETT CO INC	2%	A040607	001	Feb 24, 2005	May	CAHN
AT	RISING PHARMS INC	2%	A207280	001	Mar 09, 2018	Feb	NEWA

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT TARO PHARM INDS LTD 2%; 1% A088759 001 Mar 04, 1985 May CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB HERITAGE PHARMS INC 200MG A074889 001 Oct 31, 1997 Mar CMFD

OINTMENT; TOPICAL

ACYCLOVIR

AB ALEMBIC PHARMS LTD 5% A209000 001 Apr 06, 2018 Mar NEWA

TABLET; ORAL

ACYCLOVIR

>D>	AB	MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Jun	DISC
>A>		@	400MG	A075211	001	Sep 28, 1998	Jun	DISC
>D>	AB		800MG	A075211	002	Sep 28, 1998	Jun	DISC
>A>		@	800MG	A075211	002	Sep 28, 1998	Jun	DISC
AB		YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb	NEWA
AB			800MG	A210401	002	Mar 07, 2018	Feb	NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	!	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Jun	DISC
>D>	AP		HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Jun	DISC
>D>	AP	!		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Jun	DISC
>A>		@		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Jun	DISC

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	Jun DISC
>A>	@		EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	Jun DISC
>D>	AP		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	Jun DISC
>A>	@		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	Jun DISC

ADAPALENE

>D>		SOLUTION; TOPICAL					
>D>		ADAPALENE					
>D>	AB	CALL INC	0.1%	A203981	001	Sep 23, 2016	Jun DISC
>A>	@		0.1%	A203981	001	Sep 23, 2016	Jun DISC
>D>	AB	!	0.1%	A204593	001	Jan 05, 2016	Jun DISC
>A>	@		0.1%	A204593	001	Jan 05, 2016	Jun DISC

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		PERRIGO ISRAEL	0.1%; 2.5%	A205033	001	Jan 23, 2018	Jan NEWA
AB		TARO	0.1%; 2.5%	A206959	001	Jan 24, 2018	Jan NEWA
AB		TOLMAR	0.1%; 2.5%	A206164	001	May 23, 2018	May NEWA

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

>A>	AB	APOTEX INC	10MG	A205459	001	Jul 06, 2018	Jun NEWA
-----	----	------------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

		+ @ ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989	May DISC
		ADENOSINE					

AP	!	AKORN	3MG/ML	A078076	001	Oct 31, 2008	May CHRS
AP		FRESENIUS KABI USA	3MG/ML	A205568	001	Apr 16, 2018	Apr NEWA
AP		GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb NEWA

>A>		SOLUTION; INTRAVENOUS					
>A>		ADENOSCAN					
>A>		+ @ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Jun CDFR
>A>		+ @	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Jun CDFR
>A>		ADENOSINE					
>A>	AP	AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Jun CDFR
>A>	AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Jun CDFR
>A>	AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Jun CDFR
>A>	AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Jun CDFR
>A>	AP	HOSPIRA INC	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Jun CDFR
>A>	AP	MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Jun CDFR
>A>	AP		90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Jun CDFR
>A>	AP	! TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Jun CDFR
>A>	AP	!	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Jun CDFR

SOLUTION; IV (INFUSION)

ADENOSCAN

>D>		+ @ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Jun CDFR
>D>		+ @	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Jun CDFR
>D>		ADENOSINE					
>D>	AP	AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Jun CDFR
>D>	AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Jun CDFR
>D>	AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Jun CDFR
>D>	AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Jun CDFR
>D>	AP	HOSPIRA INC	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Jun CDFR
>D>	AP	MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Jun CDFR
>D>	AP		90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Jun CDFR
>D>	AP	! TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Jun CDFR

>D>	SOLUTION;IV (INFUSION)							
>D>	ADENOSINE							
>D>	AP !	90MG/30ML (3MG/ML)		A 077425	002	Aug 29, 2013	Jun	CDFR
	<u>ALBUTEROL SULFATE</u>							
	SOLUTION;INHALATION							
	PROVENTIL							
>D>	@ SCHERING	EQ 0.083% BASE		N 019243	002	Jan 14, 1987	Jun	CRLD
>A>	+ @	EQ 0.083% BASE		N 019243	002	Jan 14, 1987	Jun	CRLD
>D>	@	EQ 0.5% BASE		N 019243	001	Jan 14, 1987	Jun	CRLD
>A>	+ @	EQ 0.5% BASE		N 019243	001	Jan 14, 1987	Jun	CRLD
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
AA	LANNETT CO INC	EQ 2MG BASE/5ML		A 078105	001	Dec 27, 2006	May	CAHN
	TABLET;ORAL							
	ALBUTEROL SULFATE							
AB	AMNEAL PHARMS CO	EQ 2MG BASE		A 208804	001	May 21, 2018	May	NEWA
AB		EQ 4MG BASE		A 208804	002	May 21, 2018	May	NEWA
>A>	AB APPCO PHARMA LLC	EQ 2MG BASE		A 207046	001	Jun 29, 2018	Jun	NEWA
>A>	AB	EQ 4MG BASE		A 207046	002	Jun 29, 2018	Jun	NEWA
	@ YAOPHARMA CO LTD	EQ 2MG BASE		A 072151	001	Dec 05, 1989	Jan	CAHN
	@	EQ 4MG BASE		A 072152	001	Dec 05, 1989	Jan	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	ALBUTEROL SULFATE							
	! MYLAN	EQ 8MG BASE		A 078092	001	Jan 29, 2007	May	CTEC
	VOSPIRE ER							
	@ DAVA PHARMS INC	EQ 8MG BASE		A 076130	003	Sep 26, 2002	May	DISC
	<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
	SOLUTION;INHALATION							
	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
	@ FOSUN PHARMA	EQ 0.083% BASE;0.017%		A 076867	001	Dec 21, 2006	Jan	CAHN
	<u>ALCOHOL</u>							
>A>	SOLUTION;INTRA-ARTERIAL							
>A>	ABLYSINOL							
>A>	+ BELCHER PHARMS LLC	99% (1ML)		N 207987	001	Jun 21, 2018	Jun	NEWA
>A>	+!	99% (5ML)		N 207987	002	Jun 21, 2018	Jun	NEWA
	<u>ALENDRONATE SODIUM</u>							
	TABLET;ORAL							
	ALENDRONATE SODIUM							
AB	HANGZHOU BINJIANG	EQ 5MG BASE		A 090258	001	Sep 24, 2009	Jan	CAHN
AB		EQ 10MG BASE		A 090258	002	Sep 24, 2009	Jan	CAHN
AB		EQ 35MG BASE		A 090258	003	Sep 24, 2009	Jan	CAHN
AB		EQ 70MG BASE		A 090258	004	Sep 24, 2009	Jan	CAHN
	@ MYLAN	EQ 35MG BASE		A 076584	003	Aug 04, 2008	Apr	DISC
	@	EQ 70MG BASE		A 076584	004	Aug 04, 2008	Apr	DISC
	<u>ALISKIREN HEMIFUMARATE</u>							
>D>	CAPSULE, PELLET;ORAL							
>D>	TEKTURNA							
>D>	+! NODEN PHARMA	EQ 37.5MG BASE		N 210709	001	Nov 14, 2017	Jun	DISC
>A>	+ @	EQ 37.5MG BASE		N 210709	001	Nov 14, 2017	Jun	DISC
	<u>ALLOPURINOL</u>							
	TABLET;ORAL							
	ALLOPURINOL							
	@ FOSUN PHARMA	100MG		A 070268	001	Dec 31, 1985	Jan	CAHN
	<u>ALOSETRON HYDROCHLORIDE</u>							
	TABLET;ORAL							
	ALOSETRON HYDROCHLORIDE							
AB	PAR PHARM INC	EQ 0.5MG BASE		A 206113	001	Feb 23, 2018	Feb	NEWA
AB		EQ 1MG BASE		A 206113	002	Feb 23, 2018	Feb	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

>D>	INJECTABLE; INJECTION							
>D>	INFUVITE ADULT							
>D>	+! SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40	N021163	001	May 18, 2000	Jun	CDFR	
		IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG						
		/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 66						
		0 IU/ML; 0.03MG/ML						
>D>	INJECTABLE; IV (INFUSION)							
>D>	INFUVITE ADULT							
>D>	+! SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40	N021559	001	Jun 16, 2003	Jun	CDFR	
		IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG						
		/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 66						
		0 IU/ML; 30MCG/ML						
>A>	SOLUTION; INTRAVENOUS							
>A>	INFUVITE ADULT							
>A>	+! SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40	N021163	001	May 18, 2000	Jun	CDFR	
		IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG						
		/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 66						
		0 IU/ML; 0.03MG/ML						
>A>	+!	2 IU/ML; 40MG/ML; 12MCG/ML; 40	N021559	001	Jun 16, 2003	Jun	CDFR	
		IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG						
		/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 66						
		0 IU/ML; 30MCG/ML						

ALPRAZOLAM

	TABLET; ORAL							
	ALPRAZOLAM							
>A>	AB CENTAUR PHARMS PVT	0.25MG	A207507	001	Jul 09, 2018	Jun	NEWA	
>A>	AB	0.5MG	A207507	002	Jul 09, 2018	Jun	NEWA	
>A>	AB	1MG	A207507	003	Jul 09, 2018	Jun	NEWA	
>A>	AB	2MG	A207507	004	Jul 09, 2018	Jun	NEWA	

ALPROSTADIL

	INJECTABLE; INJECTION							
	CAVERJECT							
>D>	+ PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jun	DISC	
>A>	+ @	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jun	DISC	

AMANTADINE HYDROCHLORIDE

	CAPSULE; ORAL							
	AMANTADINE HYDROCHLORIDE							
>D>	AB LANNETT CO INC	100MG	A209221	001	Jun 15, 2017	Jun	DISC	
>A>	@	100MG	A209221	001	Jun 15, 2017	Jun	DISC	
	TABLET; ORAL							
	AMANTADINE HYDROCHLORIDE							
AB	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	Jan	NEWA	
	TABLET, EXTENDED RELEASE; ORAL							
	OSMOLEX ER							
	+ OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018	Feb	NEWA	
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Feb	NEWA	
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Feb	NEWA	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET; ORAL							
	AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@ YAOPHARMA CO LTD	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Jan	CAHN	

AMINO ACIDS

	INJECTABLE; INJECTION							
	AMINOSYN-HF 8%							
	@ ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Mar	DISC	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

	INJECTABLE; INJECTION							
	AMINOSYN II 8.5% W/ ELECTROLYTES							
	@ ICU MEDICAL INC	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	005	Apr 03, 1986	May	DISC	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002	May NEWA
-----------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002	May NEWA
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

@ ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		May DISC
-------------------	--	---------	-----	--	----------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D> AP	!	AKORN	50MG/ML	A076232	001	Jul 05, 2006	Jun DISC
>A>	@		50MG/ML	A076232	001	Jul 05, 2006	Jun DISC
>D>		NEXTERONE					
>D> AP	+	BAXTER HLTHCARE	50MG/ML	N022325	001	Dec 24, 2008	Jun DISC
>A>	+ @		50MG/ML	N022325	001	Dec 24, 2008	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	10MG	A089399	002	Jul 14, 1987	Jan CMFD
AB		25MG	A089399	001	Jul 14, 1987	Jan CMFD
AB		50MG	A089399	003	Jul 14, 1987	Jan CMFD
AB		75MG	A089399	004	Jul 14, 1987	Jan CMFD
AB		100MG	A089399	005	Jul 14, 1987	Jan CMFD
AB		150MG	A089399	006	Jul 14, 1987	Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@ FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987	Jan CAHN
@	10MG;4MG	A071862	001	Dec 21, 1987	Jan CAHN
@	25MG;2MG	A071063	001	Nov 27, 1987	Jan CAHN
@	25MG;4MG	A071064	001	Nov 27, 1987	Jan CAHN
@	50MG;4MG	A071863	001	Dec 21, 1987	Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018	Apr NEWA
AB		EQ 5MG BASE	A206524	002	May 04, 2018	Apr NEWA
AB		EQ 10MG BASE	A206524	003	May 04, 2018	Apr NEWA
	@ YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
	@	EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
	@	EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

+	KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	May NEWA
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	May NEWA
+!		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	May NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Feb CAHN
>D> AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun DISC
>A>	@	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun DISC

AMMONIUM LACTATECREAM; TOPICAL
LAC-HYDRIN

@ SUN PHARM INDS INC EQ 12% BASE N020508 001 Aug 29, 1996 Feb CAHN

LOTION; TOPICAL
LAC-HYDRIN

+ @ SUN PHARM INDS INC EQ 12% BASE N019155 001 Apr 24, 1985 Feb CAHN

AMOXAPINETABLET; ORAL
AMOXAPINEWATSON LABS 25MG A072691 002 Aug 28, 1992 Mar CMS1
50MG A072691 003 Aug 28, 1992 Mar CMS1
100MG A072691 004 Aug 28, 1992 Mar CMS1AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLECAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

>D>	AB		RISING PHARMS INC	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	A206006	001	Oct 07, 2016	Jun	CHRS
>A>	AB	!		500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	A206006	001	Oct 07, 2016	Jun	CHRS
>D>	AB		TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Jun	DISC
>A>		@		500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Jun	DISC
>D>			PREVPAC						
>D>	AB	+!	TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Jun	DISC
>A>		+ @		500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Jun	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
MYDAYIS

+! SHIRE DEV LLC 12.5MG; 12.5MG; 12.5MG; 12.5MG N022063 004 Jun 20, 2017 May CHRS

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

@ ISTITUTO BIO ITA SPA EQ 125MG BASE/VIAL A062797 001 Jul 12, 1993 Mar DISC

ANASTROZOLETABLET; ORAL
ARIMIDEX

AB +! ANI PHARMS INC 1MG N020541 001 Dec 27, 1995 Jan CAHN

ANGIOTENSIN II ACETATE

>A>			SOLUTION; INTRAVENOUS						
>A>			GIAPREZA						
>A>		+!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun	CDFR
>A>		+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun	CDFR
>A>		+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun	CAHN
>A>		+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun	CAHN
>D>		+!	SOLUTION; IV (INFUSION)						
>D>		+!	GIAPREZA						
>D>		+!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun	CDFR
>D>		+!		EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan	CAIN
>D>		+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun	CDFR
>D>		+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan	CAIN

ANIDULAFUNGIN

>D>			INJECTABLE; IV (INFUSION)						
>D>			ERAXIS						
>D>		+!	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jun	CDFR
>D>		+!		100MG/VIAL	N021632	002	Nov 14, 2006	Jun	CDFR

>A>	POWDER; INTRAVENOUS							
>A>	ERAXIS							
>A>	+! VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jun	CDFR	
>A>	+!	100MG/VIAL	N021632	002	Nov 14, 2006	Jun	CDFR	
<u>APALUTAMIDE</u>								
	TABLET; ORAL							
	ERLEADA							
	+! JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	NEWA	
<u>APREPITANT</u>								
	CAPSULE; ORAL							
	APREPITANT							
AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan	CAHN	
AB		80MG	A207777	002	Oct 12, 2017	Jan	CAHN	
AB		125MG	A207777	003	Oct 12, 2017	Jan	CAHN	
<u>ARGATROBAN</u>								
	INJECTABLE; INJECTION							
	ARGATROBAN							
AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan	NEWA	
<u>ARIPIPIRAZOLE</u>								
	TABLET, ORALLY DISINTEGRATING; ORAL							
	ARIPIPIRAZOLE							
AB	SCIEGEN PHARMS INC	10MG	A207240	001	Apr 18, 2018	Apr	NEWA	
AB		15MG	A207240	002	Apr 18, 2018	Apr	NEWA	
<u>ARIPIPIRAZOLE LAUROXIL</u>								
	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
	ARISTADA INITIO KIT							
>A>	+ ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018	Jun	NEWA	
<u>ARMODAFINIL</u>								
	TABLET; ORAL							
	ARMODAFINIL							
AB	AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb	NEWA	
AB		150MG	A206069	002	Mar 06, 2018	Feb	NEWA	
AB		250MG	A206069	003	Mar 06, 2018	Feb	NEWA	
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE</u>								
	FOR SOLUTION; ORAL							
	PLENVU							
	+! SALIX PHARMS INC	7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9 GM	N209381	001	May 04, 2018	May	NEWA	
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>								
	TABLET; ORAL							
	BUTALBITAL, ASPIRIN AND CAFFEINE							
	@ FOSUN PHARMA	325MG; 50MG; 40MG	A086398	002	Apr 06, 1984	Jan	CAHN	
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>								
	TABLET; ORAL							
	ORPHENGESIC							
	@ GALT PHARMS	385MG; 30MG; 25MG	A075141	001	May 29, 1998	Feb	CAHN	
	ORPHENGESIC FORTE							
	@ GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Feb	CAHN	
<u>ASPIRIN; DIPYRIDAMOLE</u>								
	CAPSULE, EXTENDED RELEASE; ORAL							
	ASPIRIN AND DIPYRIDAMOLE							
AB	ANI PHARMS INC	25MG; 200MG	A206964	001	Jan 18, 2017	May	CAHN	
<u>ASPIRIN; OMEPRAZOLE</u>								
	TABLET, DELAYED RELEASE; ORAL							
	YOSPRALA							
	+ @ ARALEZ PHARMS	81MG; 40MG	N205103	001	Sep 14, 2016	Apr	DISC	
	+ @	325MG; 40MG	N205103	002	Sep 14, 2016	Apr	DISC	

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

>A>	AB	AUROBINDO PHARMA LTD	EQ 100MG BASE	A204806	001	Jun 25, 2018	Jun	NEWA
>A>	AB		EQ 150MG BASE	A204806	002	Jun 25, 2018	Jun	NEWA
>A>	AB		EQ 200MG BASE	A204806	003	Jun 25, 2018	Jun	NEWA
>A>	AB		EQ 300MG BASE	A204806	004	Jun 25, 2018	Jun	NEWA
>D>		TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Jun	CTEC
>A>	AB		EQ 100MG BASE	A091673	001	Apr 22, 2014	Jun	CTEC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb	NEWA
AB			18MG	A090609	002	Feb 23, 2018	Feb	NEWA
AB			25MG	A090609	003	Feb 23, 2018	Feb	NEWA
AB			40MG	A090609	004	Feb 23, 2018	Feb	NEWA
AB			60MG	A090609	005	Feb 23, 2018	Feb	NEWA
AB			80MG	A090609	006	Feb 23, 2018	Feb	NEWA
AB			100MG	A090609	007	Feb 23, 2018	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar	NEWA
AB			EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar	NEWA
AB			EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar	NEWA
AB			EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar	NEWA
>A>	AB	GRAVITI PHARMS	EQ 10MG BASE	A209912	001	Jun 18, 2018	Jun	NEWA
>A>	AB		EQ 20MG BASE	A209912	002	Jun 18, 2018	Jun	NEWA
>A>	AB		EQ 40MG BASE	A209912	003	Jun 18, 2018	Jun	NEWA
>A>	AB		EQ 80MG BASE	A209912	004	Jun 18, 2018	Jun	NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>D>	AB	APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Jun	DISC
>A>		@	750MG/5ML	A209750	001	Oct 11, 2017	Jun	DISC

ATROPINE SULFATE

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

>D>	+	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jun	DISC
>A>	+	@	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jun	DISC

SOLUTION;IV (INFUSTION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+! FRESENIUS KABI USA 8MG/20ML (0.4MG/ML)

N209260 001 Jan 26, 2018 Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

@ ALCON LABS INC

1%

N208151 001 Dec 01, 2016 Apr DISC

1%

N208151 001 Dec 01, 2016 Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ FOSUN PHARMA 0.025MG;2.5MG

A086173 001 Jan CAHN

LONOX

@ FOSUN PHARMA 0.025MG;2.5MG

A085311 002 Jan CAHN

AVATROMBOPAG MALEATE

TABLET;ORAL

DOPTELET

+! AKARX INC EQ 20MG BASE

N210238 001 May 21, 2018 May NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+! ALLERGAN SALES LLC EQ 0.5GM BASE;2GM/VIAL

N206494 001 Feb 25, 2015 Jan CAHN

AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

>A>	AP	ACCORD HLTHCARE	100MG/VIAL	A207475	001	Jul 02, 2018	Jun	NEWA
	AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	May	CDFR
	AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	May	CDFR
	AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	May	CDFR
	AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	May	CDFR
	AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	May	CDFR
	AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	May	CDFR
		VIDAZA						
	AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	May	CDFR
		POWDER; IV (INFUSION), SUBCUTANEOUS						
		AZACITIDINE						
	AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	Apr	NEWA

AZITHROMYCINFOR SUSPENSION; ORAL
AZITHROMYCIN

	AB	EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar	NEWA
	AB		EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar	NEWA
		FOR SUSPENSION, EXTENDED RELEASE; ORAL						
		ZMAX						
>D>	+!	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Jun	DISC
>A>	+ @		EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Jun	DISC
		TABLET; ORAL						
		AZITHROMYCIN						
		@ APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar	DISC
		@	EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar	DISC
		@	EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar	DISC

BACITRACININJECTABLE; INJECTION
BACITRACIN

		@ MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010	Jan	DISC
--	--	-------------	-------------------	---------	-----	--------------	-----	------

BACLOFENINJECTABLE; INTRATHECAL
BACLOFEN

	AP	MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar	NEWA
	AP		1MG/ML	A209594	001	Mar 06, 2018	Feb	NEWA
	AP		2MG/ML	A209592	002	Mar 21, 2018	Mar	NEWA
		GABLOFEN						
	AP	+! PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb	CFTG

BARICITINIBTABLET; ORAL
OLUMIANT

	+!	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	May	NEWA
--	----	------------------	-----	---------	-----	--------------	-----	------

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

	+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016	Apr	CPOT
		E-Z-PAQUE						
	+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017	Apr	CPOT
		PASTE; ORAL						
		VARIBAR						
>D>	+!	BRACCO	40% (92GM/230ML)	N208844	001	Oct 14, 2016	Jun	CTNA
		VARIBAR PUDDING						
>A>		BRACCO	40%	N208844	001	Oct 14, 2016	Jun	CPOT
>A>			40% (92GM/230ML)	N208844	001	Oct 14, 2016	Jun	CTNA
		SUSPENSION; ORAL						
		LIQUID E-Z-PAQUE						
	+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017	Apr	CPOT
		READI-CAT 2						
	+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016	Apr	CPOT
		READI-CAT 2 SMOOTHIES						
	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Apr	CPOT

SUSPENSION;ORAL
TAGITOL V

+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017	Apr	CPO7
	VARIBAR HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018	Mar	NEWA
	VARIBAR THIN HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018	Jan	NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

>D>	QVAR 40						
>D>	+!	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Jun DISC
>A>	+ @		0.04MG/INH	N020911	002	Sep 15, 2000	Jun DISC
>D>	QVAR 80						
>D>	+!	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Jun DISC
>A>	+ @		0.08MG/INH	N020911	001	Sep 15, 2000	Jun DISC
>D>	QVAR REDIHALER						
>D>	+!	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Jun DISC
>A>	+ @		0.04MG/INH	N207921	001	Aug 03, 2017	Jun DISC
	+!		0.04MG/INH	N207921	001	Aug 03, 2017	Jan CHRS
>D>	+!		0.08MG/INH	N207921	002	Aug 03, 2017	Jun DISC
>A>	+ @		0.08MG/INH	N207921	002	Aug 03, 2017	Jun DISC

BELINOSTAT

>A>	POWDER; INTRAVENOUS						
>A>	BELEODAQ						
>A>	+!	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Jun CDFR
>D>	POWDER; IV (INFUSION)						
>D>	BELEODAQ						
>D>	+!	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Jun CDFR

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

	BENZAEPRIIL HYDROCHLORIDE						
AB	CASI PHARMS INC	5MG	A076402	001	Feb 11, 2004	Mar	CAHN
AB		10MG	A076402	002	Feb 11, 2004	Mar	CAHN
AB		20MG	A076402	003	Feb 11, 2004	Mar	CAHN
AB		40MG	A076402	004	Feb 11, 2004	Mar	CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

	BENDAMUSTINE HYDROCHLORIDE						
AP	MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 26, 2018	Apr	NEWA
AP		100MG/VIAL	A204104	002	Apr 26, 2018	Apr	NEWA
	SOLUTION; IV (INFUSION)						
	BENDAMUSTINE HYDROCHLORIDE						
+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	May	NEWA
	TREANDA						
+ @	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	May	DISC
+ @		180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	May	DISC

BENZONATATE

CAPSULE; ORAL

	BENZONATATE						
AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar	NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May	NEWA
AB		5%;EQ 1% BASE	A208776	001	May 25, 2018	May	NEWA
AB	TARO PHARMS	5%;1.2%	A206218	001	Dec 15, 2017	May	CAHN
	ONEXTON						
AB	+!	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE						
	@	CHARTWELL RX	1MG	A081264	001	Jan 23, 1992	Jan CAHN
	@		2MG	A081265	001	Jan 23, 1992	Jan CAHN

BETAINEFOR SOLUTION;ORAL
CYSTADANE

+! ORPHAN EUROPE 1GM/SCOOPFUL N020576 001 Oct 25, 1996 May CAHN

BETAMETHASONE DIPROPIONATELOTION;TOPICAL
BETAMETHASONE DIPROPIONATE

AB HI-TECH PHARMACAL EQ 0.05% BASE A209896 001 Feb 06, 2018 Jan NEWA

LOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

AB TELIGENT PHARMA INC EQ 0.05% BASE A206389 001 Feb 13, 2018 Jan NEWA

BETAMETHASONE VALERATELOTION;TOPICAL
BETA-VAL

@ G AND W LABS INC EQ 0.1% BASE A070072 001 Jun 27, 1985 Jan DISC

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETOPTIC

AT +! SANDOZ INC EQ 0.5% BASE N019270 001 Aug 30, 1985 Jan CAHN

BEXAROTENECAPSULE;ORAL
BEXAROTENE

AB AMERIGEN PHARMS LTD 75MG A209861 001 May 08, 2018 Apr NEWA

BICALUTAMIDETABLET;ORAL
CASODEX

AB +! ANI PHARMS INC 50MG N020498 001 Oct 04, 1995 Jan CAHN

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL
BIKTARVY

+! GILEAD SCIENCES INC EQ 50MG BASE;200MG;EQ 25MG BASE N210251 001 Feb 07, 2018 Feb NEWA

>A> BINIMETINIBTABLET;ORAL
MEKTOVI

>A> +! ARRAY BIOPHARMA INC 15MG N210498 001 Jun 27, 2018 Jun NEWA

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEFOR SOLUTION, TABLET, DELAYED RELEASE;ORAL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL@ NOVEL LABS INC 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 A202217 001 Aug 20, 2014 May DISC
.86GM;N/A,5.6GMBISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

+! ALLERGAN SALES LLC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jan CAHN

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

AB CASI PHARMS INC 5MG A075643 001 Nov 16, 2000 Mar CAHN

AB 10MG A075643 002 Nov 16, 2000 Mar CAHN

BIVALIRUDININJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP MYLAN INSTITUTIONAL 250MG/VIAL A202471 001 Jun 01, 2018 May NEWA

SOLUTION;IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jan CAHN

+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jan CAHN

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	HONG KONG	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Apr	NEWA
AP		EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Apr	NEWA

BRIGATINIBTABLET; ORAL
ALUNBRIG

>D>	+!	ARIAD	90MG	N208772	002	Apr 28, 2017	Jun	CHRS
>A>	+		90MG	N208772	002	Apr 28, 2017	Jun	CHRS
>D>	+		180MG	N208772	003	Oct 02, 2017	Jun	CHRS
>A>	+!		180MG	N208772	003	Oct 02, 2017	Jun	CHRS

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

>D>	AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jun	DISC
>A>		@	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jun	DISC
>D>	AT1	! APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	DISC
>A>		@	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	DISC
>D>	AT1	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jun	DISC
>A>		@	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jun	DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDESYRUP; ORAL
BROMFED-DM

AA	!	WOCKHARDT BIO AG	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Apr	CAHN
----	---	------------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDETABLET, EXTENDED RELEASE; ORAL
BUDESONIDE

>A>	AB	ACTAVIS LABS FL INC	9MG	A205457	001	Jul 03, 2018	Jun	NEWA	
		UCERIS							
>D>		+!	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Jun	CFTG
>A>	AB	+!		9MG	N203634	001	Jan 14, 2013	Jun	CFTG

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

		@	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Apr	DISC
AP	!	WEST-WARD PHARMS INT		0.25MG/ML	A079196	001	Apr 30, 2008	Apr	CHRS

TABLET; ORAL

BUMETANIDE

AB		UPSHER-SMITH LABS	0.5MG	A209916	001	Jan 23, 2018	Jan	NEWA
AB			1MG	A209916	002	Jan 23, 2018	Jan	NEWA
AB			2MG	A209916	003	Jan 23, 2018	Jan	NEWA
AB		ZYDUS PHARMS USA INC	0.5MG	A202900	001	Apr 30, 2018	Apr	NEWA
AB			1MG	A202900	002	Apr 30, 2018	Apr	NEWA
AB			2MG	A202900	003	Apr 30, 2018	Apr	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

SENSORCAINE

>D>								
>D>	AP	FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987	Jun	DISC
>A>		@	0.75%	A071202	001	Apr 15, 1987	Jun	DISC

BUPRENORPHINE HYDROCHLORIDEIMPLANT; IMPLANTATION
PROBUPHINE

>D>		+!	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN
>A>		+!	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Mar	CAHN
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	Mar	CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A205299	001	Jun 14, 2018	May	NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A205806	001	Jun 14, 2018	May	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205299	002	Jun 14, 2018	May	NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A205806	002	Jun 14, 2018	May	NEWA
AB	MYLAN TECHNOLOGIES	EQ 8MG BASE;EQ 2MG BASE	A207607	001	Jun 14, 2018	May	NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A207607	002	Jun 14, 2018	May	NEWA
SUBOXONE							
AB	+ INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May	CFTG
AB	+	EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May	CFTG
AB	+	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May	CFTG
AB	+	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May	CFTG

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	75MG	A203013	001	Jun 08, 2018	May	NEWA
AB		100MG	A203013	002	Jun 08, 2018	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2	SCIENGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan	CAHN	
>A>	AB3	YICHANG HUMANWELL	150MG	A210015	001	Jun 14, 2018	Jun	NEWA
>A>	AB3		300MG	A210015	002	Jun 14, 2018	Jun	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
AB		10MG	A078246	002	Feb 27, 2009	Feb	CAHN
AB		15MG	A078246	003	Feb 27, 2009	Feb	CAHN
AB		30MG	A078246	004	Feb 27, 2009	Feb	CAHN
	@ FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan	CAHN
	@	10MG	A075413	002	Mar 19, 2002	Jan	CAHN
	@	15MG	A075413	003	Mar 19, 2002	Jan	CAHN
AB	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Apr	NEWA
AB		7.5MG	A209696	002	May 03, 2018	Apr	NEWA
AB		10MG	A209696	003	May 03, 2018	Apr	NEWA
AB		15MG	A209696	004	May 03, 2018	Apr	NEWA
AB		30MG	A209696	005	May 03, 2018	Apr	NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	! HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar	CHRS
AP	!	2MG/ML	A074626	002	Jan 23, 1997	Mar	CHRS
	STADOL						
+	@ APOTHECON	2MG/ML	N017857	004		Mar	CRLD
	STADOL PRESERVATIVE FREE						
+	@ APOTHECON	1MG/ML	N017857	001		Mar	CRLD
+	@	2MG/ML	N017857	002		Mar	CRLD

CABERGOLINE

TABLET;ORAL

CABERGOLINE

	@ APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar	DISC
--	---------------	-------	---------	-----	--------------	-----	------

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

>D>	+	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012	Jun	CHRS
>A>	+	!	EQ 20MG BASE	N203756	001	Nov 29, 2012	Jun	CHRS
>D>	+	!	EQ 80MG BASE	N203756	002	Nov 29, 2012	Jun	CHRS
>A>	+		EQ 80MG BASE	N203756	002	Nov 29, 2012	Jun	CHRS

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>D>	AB	ECI PHARMS LLC	667MG	A203298	001	Jul 26, 2016	Jun	CAHN
>A>	AB	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jun	CAHN

TABLET;ORAL

ELIPHOS

@ CYPRESS PHARM

667MG

A078502 001 Nov 25, 2008 Apr DISC

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		INTL MEDICATION SYS	100MG/ML	A203477	001	May 09, 2018	Apr	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

>D>		PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER							
>D>	+	!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jun	DISC

>A>	+	@		N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jun	DISC
-----	---	---	--	---	---------	-----	--------------	-----	------

>D>		PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER						
-----	--	--	--	--	--	--	--	--

>D>	+	!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jun	DISC
-----	---	---	----------------------	--	---------	-----	--------------	-----	------

>A>	+	@		3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jun	DISC
-----	---	---	--	--	---------	-----	--------------	-----	------

>D>		PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER						
-----	--	---	--	--	--	--	--	--

>D>	+	!	BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jun	DISC
-----	---	---	----------------------	---	---------	-----	--------------	-----	------

>A>	+	@		5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jun	DISC
-----	---	---	--	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988	Jan	CRLD
---	---	-----------------	--	---------	-----	--------------	-----	------

+	@		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988	Jan	CRLD
---	---	--	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988	Jan	CRLD
---	---	-----------------	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	002	Oct 17, 1988	Jan	CRLD
----	---	-----------------	--	---------	-----	--------------	-----	------

+	@		20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988	Jan	DISC
---	---	--	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988	Jan	CRLD
---	---	-----------------	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988	Jan	DISC
---	---	-----------------	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988	Jan	CRLD
---	---	-----------------	--	---------	-----	--------------	-----	------

CALCIUM GLUCONATESOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	May	CDFR
+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	May	CDFR
+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	May	CDFR

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	+	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN
AB	+		8MG	N020838	002	Jun 04, 1998	Jan	CAHN
AB	+		16MG	N020838	003	Jun 04, 1998	Jan	CAHN
AB	+!		32MG	N020838	004	Jun 04, 1998	Jan	CAHN

CANDESARTAN CILEXETIL

	@	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Mar	DISC
	@		8MG	A202079	002	Jan 10, 2014	Mar	DISC
	@		16MG	A202079	003	Jan 10, 2014	Mar	DISC
	@		32MG	A202079	004	Jan 10, 2014	Mar	DISC
AB		MYLAN PHARMS INC	4MG	A078702	001	May 03, 2013	Apr	CAHN
AB			8MG	A078702	002	May 03, 2013	Apr	CAHN
AB			16MG	A078702	003	May 03, 2013	Apr	CAHN
AB			32MG	A078702	004	May 03, 2013	Apr	CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

AB	+	ANI PHARMS INC	16MG;12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
AB	+		32MG;12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
AB	+!		32MG;25MG	N021093	003	May 16, 2008	Feb	CAHN

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

	@	APOTEX INC	16MG;12.5MG	A202884	001	Dec 04, 2012	Mar	DISC
	@		32MG;12.5MG	A202884	002	Dec 04, 2012	Mar	DISC
	@		32MG;25MG	A202884	003	Jun 03, 2013	Mar	DISC
AB		PRINSTON INC	16MG;12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA
AB			32MG;12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA
AB			32MG;25MG	A207455	003	Apr 11, 2018	Mar	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB		EUGIA PHARMA	150MG	A210604	001	Apr 17, 2018	Apr	NEWA
AB			500MG	A210604	002	Apr 17, 2018	Apr	NEWA
>A>	AB	MSN LABS PVT LTD	150MG	A209365	001	Jul 02, 2018	Jun	NEWA
>A>	AB		500MG	A209365	002	Jul 02, 2018	Jun	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	@	YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
	@		12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
	@		25MG	A074363	002	Nov 09, 1995	Jan	CAHN
	@		25MG	A074519	002	Feb 13, 1996	Jan	CAHN
	@		50MG	A074363	003	Nov 09, 1995	Jan	CAHN
	@		50MG	A074519	003	Feb 13, 1996	Jan	CAHN
	@		100MG	A074363	004	Nov 09, 1995	Jan	CAHN
	@		100MG	A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	@	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan	DISC
	@		25MG;25MG	A074827	002	Dec 29, 1997	Jan	DISC
	@		50MG;15MG	A074827	004	Dec 29, 1997	Jan	DISC
	@		50MG;25MG	A074827	003	Dec 29, 1997	Jan	DISC
		MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan	CTEC
!			25MG;25MG	A074896	002	Dec 29, 1997	Jan	CTEC
!			50MG;15MG	A074896	004	Dec 29, 1997	Jan	CTEC
			50MG;25MG	A074896	003	Dec 29, 1997	Jan	CTEC

CARBAMAZEPINE

>D>	SOLUTION;IV (INFUSION)								
>D>	CARNEXIV								
>D>	+! LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)		N206030	001	Oct 07, 2016	Jun	DISC	
>A>	+ @	200MG/20ML (10MG/ML)		N206030	001	Oct 07, 2016	Jun	DISC	

CARBIDOPA

	TABLET;ORAL								
	CARBIDOPA								
AB	ZYDUS PHARMS USA INC	25MG		A209910	001	May 07, 2018	Apr	NEWA	

CARBINOXAMINE MALEATE

	SOLUTION;ORAL								
	CARBINOXAMINE MALEATE								
	@ CYPRESS PHARM	4MG/5ML		A090418	001	May 04, 2010	Apr	DISC	
	TABLET;ORAL								
	CARBINOXAMINE MALEATE								
	@ CYPRESS PHARM	4MG		A090417	001	Aug 23, 2010	Apr	DISC	

CARBOPLATIN

	INJECTABLE;IV (INFUSION)								
	CARBOPLATIN								
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)		A205487	001	Mar 28, 2016	Apr	CAHN	
AP		150MG/15ML (10MG/ML)		A205487	002	Mar 28, 2016	Apr	CAHN	
AP		450MG/45ML (10MG/ML)		A205487	003	Mar 28, 2016	Apr	CAHN	
	@ MYLAN LABS LTD	1GM/100ML (10MG/ML)		A091478	001	Nov 23, 2011	May	DISC	

CARFILZOMIB

	POWDER;INTRAVENOUS								
	KYPROLIS								
>A>	+ ONYX THERAP	10MG/VIAL		N202714	003	Jun 07, 2018	Jun	NEWA	

CARIPRAZINE HYDROCHLORIDE

	CAPSULE;ORAL								
	VRAYLAR								
	+ ALLERGAN SALES LLC	EQ 1.5MG BASE		N204370	001	Sep 17, 2015	Jan	CAHN	
	+	EQ 3MG BASE		N204370	002	Sep 17, 2015	Jan	CAHN	
	+	EQ 4.5MG BASE		N204370	003	Sep 17, 2015	Jan	CAHN	
	+!	EQ 6MG BASE		N204370	004	Sep 17, 2015	Jan	CAHN	

CARISOPRODOL

	TABLET;ORAL								
	CARISOPRODOL								
	@ FOSUN PHARMA	350MG		A081025	001	Apr 13, 1989	Jan	CAHN	

CARVEDILOL

	TABLET;ORAL								
	CARVEDILOL								
AB	CHARTWELL MOLECULAR	3.125MG		A077474	001	Sep 05, 2007	Mar	CAHN	
AB		6.25MG		A077474	002	Sep 05, 2007	Mar	CAHN	
AB		12.5MG		A077474	003	Sep 05, 2007	Mar	CAHN	
AB		25MG		A077474	004	Sep 05, 2007	Mar	CAHN	

CARVEDILOL PHOSPHATE

	CAPSULE, EXTENDED RELEASE;ORAL								
	CARVEDILOL PHOSPHATE								
AB	IMPAX LABS INC	10MG		A204717	001	May 07, 2018	Apr	NEWA	
AB		20MG		A204717	002	May 07, 2018	Apr	NEWA	
AB		40MG		A204717	003	May 07, 2018	Apr	NEWA	
AB		80MG		A204717	004	May 07, 2018	Apr	NEWA	

CASPOFUNGIN ACETATE

	POWDER;INTRAVENOUS								
	CANCIDAS								
AP	+! MERCK	50MG/VIAL		N021227	001	Jan 26, 2001	May	CDFR	
AP	+!	70MG/VIAL		N021227	002	Jan 26, 2001	May	CDFR	
	CASPOFUNGIN ACETATE								
AP	FRESENIUS KABI USA	50MG/VIAL		N206110	001	Dec 30, 2016	May	CDFR	
AP		70MG/VIAL		N206110	002	Dec 30, 2016	May	CDFR	
AP	GLAND PHARMA LTD	50MG/VIAL		A207092	001	Sep 29, 2017	May	CDFR	
AP		70MG/VIAL		A207092	002	Sep 29, 2017	May	CDFR	

POWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

AP	MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017	May	CDFR
AP		70MG/VIAL	A207650	002	Sep 29, 2017	May	CDFR
>A>	SANDOZ INC	50MG/VIAL	A200833	001	Jun 28, 2018	Jun	NEWA
>A>		70MG/VIAL	A200833	002	Jun 28, 2018	Jun	NEWA
>A>	XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018	Jun	NEWA
>A>		70MG/VIAL	A205923	002	Jul 02, 2018	Jun	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

>D>	AB	CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jun	DISC
>A>		@	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jun	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN PLASTIC CONTAINER

>D>	!	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991	Jun	DISC
>A>		@	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991	Jun	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

@	FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jan	CAHN
@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jan	CAHN
@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP	!	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Apr	CHRS
AP	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Apr	CHRS
AP	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Apr	CHRS
AP	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Apr	CHRS
		CLAFORAN						
	+	@ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Apr	DISC
	+	@	EQ 1GM BASE/VIAL	N050547	002		Apr	DISC
	+	@	EQ 2GM BASE/VIAL	N050547	003		Apr	DISC
	+	@	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Apr	DISC

CEFPROZIL

TABLET; ORAL
CEFPROZIL

AB		CASI PHARMS INC	250MG	A065235	001	Nov 14, 2005	Mar	CAHN
AB			500MG	A065235	002	Nov 14, 2005	Mar	CAHN

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)
TEFLARO

+	!	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CAHN
			600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION
CEFTAZIDIME

>D>	AP	ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985	Jun	DISC
>A>		@	500MG/VIAL	A062640	001	Nov 20, 1985	Jun	DISC

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

+	@	TELIGENT	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May	DISC
+	@		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

@	SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jan	CAHN
---	-----------	---------------	---------	-----	--------------	-----	------

FOR SUSPENSION;ORAL
CEDAX

+ @	SI PHARMS	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jan CAHN
+ @		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jan CAHN

CEFTRIAOXONE SODIUMINJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFTRIAOXONE

AP	SAGENT PHARMS	EQ 250MG BASE/VIAL	A091049	001	Jun 11, 2018	May NEWA
AP		EQ 500MG BASE/VIAL	A091049	002	Jun 11, 2018	May NEWA
AP		EQ 1GM BASE/VIAL	A091049	003	Jun 11, 2018	May NEWA
AP		EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018	May NEWA

CEFUROXIME AXETILTABLET;ORAL
CEFTIN

+ @	GLAXOSMITHKLINE	EQ 125MG BASE	N050605	001	Dec 28, 1987	May DISC
+ @		EQ 250MG BASE	N050605	002	Dec 28, 1987	May DISC
+ @		EQ 500MG BASE	N050605	003	Dec 28, 1987	May DISC
	CEFUROXIME AXETIL					
@	FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003	Jan CAHN
@		EQ 500MG BASE	A065126	002	Oct 28, 2003	Jan CAHN
AB	! LUPIN	EQ 500MG BASE	A065135	002	Jul 25, 2003	May CHRS

CEFUROXIME SODIUMINJECTABLE;INJECTION
ZINACEF IN PLASTIC CONTAINER

+ @	TELIGENT	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May DISC
-----	----------	-----------------	---------	-----	--------------	----------

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	May NEWA
AB		100MG	A208833	002	May 31, 2018	May NEWA
AB		200MG	A208833	003	May 31, 2018	May NEWA
AB		400MG	A208833	004	May 31, 2018	May NEWA
AB	CSPC OUYI PHARM CO	50MG	A210071	001	Jan 23, 2018	Jan NEWA
AB		100MG	A210071	002	Jan 23, 2018	Jan NEWA
AB		200MG	A210071	003	Jan 23, 2018	Jan NEWA
AB	MICRO LABS	50MG	A204776	001	Apr 30, 2018	Apr NEWA
AB		100MG	A204776	002	Apr 30, 2018	Apr NEWA
AB		200MG	A204776	003	Apr 30, 2018	Apr NEWA
AB		400MG	A204776	004	Apr 30, 2018	Apr NEWA

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

AA	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May CAHN
----	----------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE
@ APOTEX INC

30MG

A091260	001	Aug 25, 2011	Mar DISC
---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREXSUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

>A>	+ @	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun DISC
>A>	+!		EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN
>D>	+!	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREXSUSPENSION, EXTENDED RELEASE;ORAL
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	! NEOS THERAP INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Apr CHRS
	TUSSIONEX PENNKINETIC					
+ @	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N019111	001	Dec 31, 1987	Apr DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SONAZINE

@ FOSUN PHARMA	30MG/ML	A 080983	004		Jan	CAHN
@	100MG/ML	A 080983	005		Jan	CAHN

SYRUP; ORAL

SONAZINE

@ FOSUN PHARMA	10MG/5ML	A 083040	001		Jan	CAHN
----------------	----------	----------	-----	--	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	UMEDICA LABS PVT LTD	25MG	A 207222	001	May 24, 2018	May	NEWA
AB		50MG	A 207222	002	May 24, 2018	May	NEWA

THALITONE

+ @ CASPER PHARMA LLC	15MG	N 019574	001	Dec 20, 1988	Apr	CRLD
-----------------------	------	----------	-----	--------------	-----	------

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

@ MYLAN	15MG; 0.1MG	A 071325	003	Feb 09, 1987	Mar	DISC
@	15MG; 0.2MG	A 071325	002	Feb 09, 1987	Mar	DISC
@	15MG; 0.3MG	A 071325	001	Feb 09, 1987	Mar	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>D>	@ ANI PHARMS INC	EQ 4GM RESIN/PACKET	A 074554	001	Oct 02, 1996	Jun	CMFD
>A>	AB	EQ 4GM RESIN/PACKET	A 074554	001	Oct 02, 1996	Jun	CMFD
>D>	@	EQ 4GM RESIN/SCOOPFUL	A 074554	002	Oct 02, 1996	Jun	CMFD
>A>	AB	EQ 4GM RESIN/SCOOPFUL	A 074554	002	Oct 02, 1996	Jun	CMFD
>A>	AB	ZYDUS PHARMS USA INC	A 202901	001	Jul 02, 2018	Jun	NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TELIGENT PHARMA INC	1%	A 209975	001	Apr 05, 2018	Mar	NEWA
----	---------------------	----	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	INGENUS PHARMS LLC	8%	A 078124	001	Sep 18, 2007	Jan	CAHN
----	--------------------	----	----------	-----	--------------	-----	------

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

!	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090577	001	Dec 21, 2011	Apr	CHRS
@	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090825	001	Nov 16, 2011	Apr	DISC
	PRIMAXIN						
+ @	MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N 050587	001	Nov 26, 1985	Apr	DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	CASI PHARMS INC	50MG	A 077310	001	Nov 08, 2005	Mar	CAHN
AB		100MG	A 077021	001	Nov 23, 2004	Mar	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A 074329	002	May 17, 1994	Jan	CMS1
@		300MG	A 074329	003	May 17, 1994	Jan	CMS1
@		400MG	A 074329	004	May 17, 1994	Jan	CMS1
@	YAOPHARMA CO LTD	200MG	A 074100	001	Jan 31, 1995	Jan	CAHN
@		300MG	A 074100	002	Jan 31, 1995	Jan	CAHN
@		400MG	A 074100	003	Jan 31, 1995	Jan	CAHN
@		800MG	A 074100	004	Jan 31, 1995	Jan	CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ LANNETT CO INC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994	May CAHN
------------------	-------------------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A206125	001	Mar 08, 2018	Feb NEWA
AB		EQ 60MG BASE	A206125	002	Mar 08, 2018	Feb NEWA
AB		EQ 90MG BASE	A206125	003	Mar 08, 2018	Feb NEWA
AB	CIPLA LTD	EQ 30MG BASE	A208915	001	Mar 08, 2018	Feb NEWA
AB		EQ 60MG BASE	A208915	002	Mar 08, 2018	Feb NEWA
AB		EQ 90MG BASE	A208915	003	Mar 08, 2018	Feb NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A209226	001	Apr 30, 2018	Apr NEWA
AB		EQ 60MG BASE	A209226	002	Apr 30, 2018	Apr NEWA
AB		EQ 90MG BASE	A209226	003	Apr 30, 2018	Apr NEWA
AB	ZYDUS PHARMS USA INC	EQ 30MG BASE	A208971	001	Apr 23, 2018	Apr NEWA
AB		EQ 60MG BASE	A208971	002	Apr 23, 2018	Apr NEWA
AB		EQ 90MG BASE	A208971	003	Apr 23, 2018	Apr NEWA
	SENSIPAR					
AB	+ AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb CFTG
AB	+	EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb CFTG
AB	+!	EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan CAHN
AP		400MG/200ML	A078252	002	Mar 18, 2008	Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT	ALTAIRE PHARMS INC	EQ 0.3% BASE	A204613	001	May 03, 2018	Apr NEWA
----	--------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

CIPRO

+ @	BAYER HLTHCARE	EQ 100MG BASE	N019537	001	Apr 08, 1996	Mar DISC
+ @		EQ 750MG BASE	N019537	004	Oct 22, 1987	Mar DISC

CIPROFLOXACIN HYDROCHLORIDE

@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
---	--------------	---------------	---------	-----	--------------	----------

@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
---	--	---------------	---------	-----	--------------	----------

@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN
---	--	---------------	---------	-----	--------------	----------

>D> AB	MYLAN	EQ 100MG BASE	A075817	001	Jun 25, 2007	Jun DISC
--------	-------	---------------	---------	-----	--------------	----------

>A>	@	EQ 100MG BASE	A075817	001	Jun 25, 2007	Jun DISC
-----	---	---------------	---------	-----	--------------	----------

>D> AB		EQ 250MG BASE	A075817	002	Jun 09, 2004	Jun DISC
--------	--	---------------	---------	-----	--------------	----------

>A>	@	EQ 250MG BASE	A075817	002	Jun 09, 2004	Jun DISC
-----	---	---------------	---------	-----	--------------	----------

>D> AB		EQ 750MG BASE	A075817	004	Jun 09, 2004	Jun DISC
--------	--	---------------	---------	-----	--------------	----------

>A>	@	EQ 750MG BASE	A075817	004	Jun 09, 2004	Jun DISC
-----	---	---------------	---------	-----	--------------	----------

>A> AB	YILING PHARM LTD	EQ 250MG BASE	A208921	001	Jun 22, 2018	Jun NEWA
--------	------------------	---------------	---------	-----	--------------	----------

>A> AB		EQ 500MG BASE	A208921	002	Jun 22, 2018	Jun NEWA
--------	--	---------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan CAHN
----------------	-------------------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP		EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Mar NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+ ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan CAHN
AB	+	EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan CAHN
AB	+!	EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan CAHN
	@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	CHARTWELL MOLECULAR	EQ 10MG BASE	A077044	001	Nov 05, 2004	Mar	CAHN
AB		EQ 20MG BASE	A077044	002	Nov 05, 2004	Mar	CAHN
AB		EQ 40MG BASE	A077044	003	Nov 05, 2004	Mar	CAHN
	@ FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan	CAHN
	@	EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan	CAHN
	@	EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan	CAHN
	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan	CAHN
	@	EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan	CAHN
	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017	Apr	CPOT
----	--------------------	-----------------------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

+ @	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993	Apr	DISC
+ @		250MG/5ML	N050698	002	Dec 23, 1993	Apr	DISC
AB	! SANDOZ	250MG/5ML	A065283	003	Sep 04, 2007	Apr	CHRS

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>A>	AB	SUNSHINE LAKE	500MG	A208987	001	Jul 09, 2018	Jun	NEWA
-----	----	---------------	-------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	May	CTEC
@	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	DISC
AA		EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	CAHN

TABLET;ORAL

TAVIST

+ @	NOVARTIS	2.68MG	N017661	001		May	CRLD
-----	----------	--------	---------	-----	--	-----	------

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

>D>	+!	CHIESI USA INC	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Jun	DISC
>A>	+ @		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Jun	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	APPCO PHARMA LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Apr	NEWA
----	------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001	Mar	CAHN
@		EQ 12MG BASE/ML	A065027	002	Jun 29, 2001	Mar	CAHN
@		EQ 18MG BASE/ML	A065027	003	Jun 29, 2001	Mar	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA
	@ WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997	May	DISC
AT		EQ 1% BASE	A063304	001	Jul 15, 1997	May	CAHN

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

>A>	AB1	CHEMO RESEARCH SL	0.05%	A210034	001	Jun 15, 2018	Jun	NEWA
	AB1	GLENMARK PHARMS	0.05%	A209095	001	May 10, 2018	Apr	NEWA
	AB1	LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
	AB1	TELLIGENT PHARMA INC	0.05%	A209974	001	Apr 17, 2018	Apr	NEWA
		IMPOYZ						
	+!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan	CAHN

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE							
AB	CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Apr	NEWA
AB	NOVEL LABS INC	0.05%	A208841	001	May 04, 2018	Apr	NEWA
SOLUTION;TOPICAL							
CLOBETASOL PROPIONATE							
AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Apr	NEWA
SPRAY;TOPICAL							
CLOBETASOL PROPIONATE							
AT	APOTEX INC	0.05%	A210446	001	Apr 17, 2018	Apr	NEWA
AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Mar	NEWA
AT	LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Mar	NEWA
AT	TARO	0.05%	A208842	001	Mar 26, 2018	Mar	NEWA

CLOFARABINE

SOLUTION;INTRAVENOUS							
CLOFARABINE							
AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	May	CDFR
AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	May	CDFR
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	May	CDFR
AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	May	CDFR
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	May	CDFR
CLOLAR							
AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	May	CDFR

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION							
CLONIDINE HYDROCHLORIDE							
AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	May	CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	May	CAHN
TABLET;ORAL							
CLONIDINE HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan	CMS1
	@	0.3MG	A070886	003	Aug 31, 1988	Jan	CMS1
	@ CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Apr	CMS1
	@	0.2MG	A071785	003	Apr 05, 1988	Apr	CMS1
TABLET, EXTENDED RELEASE;ORAL							
CLONIDINE HYDROCHLORIDE							
AB1	JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan	NEWA
AB1	MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Apr	NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL							
CLOPIDOGREL BISULFATE							
AB	PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018	Apr	NEWA
AB		EQ 300MG BASE	A206376	002	May 07, 2018	Apr	NEWA

CLOZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL							
CLOZAPINE							
AB	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Mar	NEWA
AB	FAZACLO ODT						
AB	+ JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007	Mar	CTEC

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL							
COLESEVELAM HYDROCHLORIDE							
AB	GLENMARK PHARMS LTD	625MG	A203480	001	May 18, 2018	May	NEWA
AB	IMPAX LABS INC	625MG	A091600	001	May 16, 2018	Apr	NEWA
WELCHOL							
AB	+! DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr	CFTG

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION							
COLISTIMETHATE SODIUM							
>A>	AP NEXUS PHARMS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Jun	CAHN
>D>	AP PADDOCK LLC	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Jun	CAHN

CROFELEMER

TABLET, DELAYED RELEASE;ORAL
MYTESI

+! NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012 Mar CTNA

CROMOLYN SODIUM

SOLUTION;INHALATION
CROMOLYN SODIUM

@ FERA PHARMS LLC 10MG/ML A075437 001 Apr 21, 2000 Mar CAHN

SOLUTION/DROPS;OPHTHALMIC
CROMOLYN SODIUM

AT SANDOZ INC 4% A075282 001 Jun 16, 1999 Jan CAHN

CROTAMITON

CREAM;TOPICAL
EURAX

+! SUN PHARM INDS INC 10% N006927 001 Feb CAHN

LOTION;TOPICAL
EURAX

AT +! SUN PHARM INDS INC 10% N009112 003 Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

AT ! ALCON LABS INC 0.5% A084109 001 Feb CAHN

AT ! 1% A084110 001 Feb CAHN

! 2% A084108 001 Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOMYDRIL

! ALCON LABS INC 0.2%;1% A084300 001 Feb CAHN

CYCLOPHOSPHAMIDE

CAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB AMERIGEN PHARMS LTD 25MG A207014 001 Mar 19, 2018 Mar NEWA

AB 50MG A207014 002 Mar 19, 2018 Mar NEWA

AB STI PHARMA LLC 25MG A209872 001 May 07, 2018 Apr NEWA

AB 50MG A209872 002 May 07, 2018 Apr NEWA

AB + WEST-WARD PHARMS INT 25MG N203856 001 Sep 16, 2013 Mar CFTG

AB +! 50MG N203856 002 Sep 16, 2013 Mar CFTG

INJECTABLE;INJECTION
CYCLOPHOSPHAMIDE

AP AMNEAL PHARMS CO 500MG/VIAL A210046 001 May 25, 2018 May NEWA

AP 1GM/VIAL A210046 002 May 25, 2018 May NEWA

AP 2GM/VIAL A210046 003 May 25, 2018 May NEWA

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

IVAX SUB TEVA PHARMS 50MG A065110 001 Mar 29, 2005 May CTEC

GENGRAF
@ ABBVIE 50MG A065003 002 May 12, 2000 May DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA APNAR PHARMA LP 4MG A207555 001 Jan 31, 2017 Apr CAHN

@ FOSUN PHARMA 4MG A086808 001 Jan CAHN

AA MOUNTAIN 4MG A040537 001 Sep 30, 2003 Jan CAHN

AA STRIDES PHARMA 4MG A209172 001 Apr 11, 2018 Mar NEWA

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE

AP MYLAN LABS LTD 20MG/ML A200916 001 Dec 13, 2011 Jan CAHN

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

>D>	+	BRISTOL-MYERS SQUIBB	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun CHRS
>A>	+		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun CHRS
>D>	+		EQ 90MG BASE	N206843	003	Apr 13, 2016	Jun CHRS
>A>	+		EQ 90MG BASE	N206843	003	Apr 13, 2016	Jun CHRS

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

>A>	AB	ACCORD HLTHCARE	10MG	A206863	001	Jul 11, 2018	Jun NEWA
-----	----	-----------------	------	---------	-----	--------------	----------

DAPAGLIFLOZINTABLET; ORAL
FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar CAIN
+	!	10MG	N202293	002	Jan 08, 2014	Mar CAIN

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
XIGDUO XR

+	ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017	Mar CAIN
+		5MG; 500MG	N205649	001	Oct 29, 2014	Mar CAIN
+		5MG; 1GM	N205649	002	Oct 29, 2014	Mar CAIN
+		10MG; 500MG	N205649	003	Oct 29, 2014	Mar CAIN
+	!	10MG; 1GM	N205649	004	Oct 29, 2014	Mar CAIN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

+	ASTRAZENECA AB	10MG; EQ 5MG BASE	N209091	001	Feb 27, 2017	Mar CAIN
---	----------------	-------------------	---------	-----	--------------	----------

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

AP	FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018	Mar NEWA
AP	MYLAN LABS LTD	500MG/VIAL	A205037	001	Jun 05, 2018	May NEWA
AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP	SAGENT PHARMS	50MG/VIAL	A207100	001	Mar 16, 2018	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

DEFERIPRONESOLUTION; ORAL
FERRIPROX

+	AOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018	Apr NEWA
---	--------------	---------	---------	-----	--------------	----------

DESLFLURANELIQUID; INHALATION
DESLFLURANE

AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Feb NEWA	
AN	+	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Feb CFTG

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	ANI PHARMS INC	10MG	A205153	001	Oct 28, 2016	May CAHN
	@	25MG	A071803	002	Dec 08, 1987	Apr CMS1
AB		25MG	A205153	002	Oct 28, 2016	May CAHN
	@	50MG	A071803	003	Dec 08, 1987	Apr CMS1
AB		50MG	A205153	003	Oct 28, 2016	May CAHN
	@	75MG	A071803	004	Dec 08, 1987	Apr CMS1
AB		75MG	A205153	004	Oct 28, 2016	May CAHN
AB		100MG	A205153	005	Oct 28, 2016	May CAHN
	@	150MG	A071803	005	May 29, 1997	Apr CMS1
AB		150MG	A205153	006	Oct 28, 2016	May CAHN
AB	MOUNTAIN	10MG	A205153	001	Oct 28, 2016	Feb CAHN

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESMOPRESSIN ACETATE

TABLET;SUBLINGUAL

>A>		NOCDURNA					
>A>	+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018	Jun NEWA
>A>	+	!	0.0553MG	N022517	002	Jun 21, 2018	Jun NEWA

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

>A>	AB		GROUPE PARIMA INC	0.25%	A205594	001	Jul 02, 2018	Jun NEWA	
			TOPICORT						
	AB	!	TARO PHARM INDS LTD	0.05%	A073210	001	Nov 30, 1990	May CAHN	
	AB	!		0.25%	A073193	001	Nov 30, 1990	May CAHN	
			+ @	0.25%	N017856	001		May CAHN	
			TOPICORT LP						
			+ @ TARO PHARM INDS LTD	0.05%	N018309	001		May CAHN	
			GEL;TOPICAL						
			TOPICORT						
	AB	!	TARO PHARM INDS LTD	0.05%	A074904	001	Jul 14, 1998	May CAHN	
			+ @	0.05%	N018586	001	Mar 29, 1982	May CAHN	
			OINTMENT;TOPICAL						
			TOPICORT						
	AB	+	!	TARO PHARM INDS LTD	0.05%	N018594	001	Jan 17, 1985	May CAHN
	AB	!		0.25%	A074286	001	Jun 07, 1996	May CAHN	
			+ @	0.25%	N018763	001	Sep 30, 1983	May CAHN	
			SPRAY;TOPICAL						
			DESOXIMETASONE						
	AT		LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar NEWA	
			TOPICORT						
	AT	+	!	TARO PHARMS	0.25%	N204141	001	Apr 11, 2013	May CAHN

>D> DESVENLAFAXINE FUMARATE

>D> TABLET, EXTENDED RELEASE;ORAL

>D> DESVENLAFAXINE

>D>	+	!	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun DISC
>A>			+ @	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun DISC
>D>	+	!		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun DISC
>A>			+ @	EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB			CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar CAHN
AB				EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar CAHN

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

AA			LANNETT CO INC	0.5MG/5ML	A091188	001	May 11, 2011	May CAHN
			HEXADROL					
			@ ASPEN GLOBAL INC	0.5MG/5ML	N012674	001		Feb CAHN
			SUSPENSION;INTRAOCULAR					
			DEXYCU KIT					
			+! EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Apr CAHN
			+! ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Feb NEWA
			TABLET;ORAL					
			DEXAMETHASONE					
BP			FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983	May CMS1
BP				0.75MG	A088481	003	Apr 28, 1983	May CMS1
BP				4MG	A088481	004	Apr 28, 1983	May CMS1
BP				6MG	A088481	001	Nov 28, 1983	Jan CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A209192	001	Jul 06, 2018	Jun	NEWA
	AP	SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	May	NEWA
		DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE						
	AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442	001	Apr 19, 2018	Apr	NEWA
		HEXADROL						
		+ @ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb	CAHN
		+ @	EQ 10MG PHOSPHATE/ML	N014694	003		Feb	CAHN
		@	EQ 20MG PHOSPHATE/ML	N014694	004		Feb	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

	AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb	NEWA
		SOLUTION; IV (INFUSION)						
		DEXMEDETOMIDINE HYDROCHLORIDE						
>A>		+ HQ SPCLT PHARMA	EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Jun	NEWA
>A>		+ @	EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Jun	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Apr	CAHN
AA			5MG	A090533	002	Oct 25, 2011	Apr	CAHN
			7.5MG	A090533	003	Oct 25, 2011	Apr	CAHN
AA			10MG	A090533	004	Oct 25, 2011	Apr	CAHN
			15MG	A090533	005	Oct 25, 2011	Apr	CAHN
			20MG	A090533	006	Oct 25, 2011	Apr	CAHN
			30MG	A090533	007	Oct 25, 2011	Apr	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH W/ DEXTROMETHORPHAN

		@ G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Jan	DISC
--	--	--------------------	----------------------	---------	-----	--------------	-----	------

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 20% IN PLASTIC CONTAINER

>D>	AP	+!	BAXTER HLTHCARE	20GM/100ML	N017521	004		Jun	DISC
>A>		+ @		20GM/100ML	N017521	004		Jun	DISC
>D>	AP	+!	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Jun	CTEC
>A>		+!		20GM/100ML	N018564	001	Mar 23, 1982	Jun	CTEC

DEXTROSE 30% IN PLASTIC CONTAINER

>D>	AP	+!	BAXTER HLTHCARE	30GM/100ML	N017521	003		Jun	DISC
>A>		+ @		30GM/100ML	N017521	003		Jun	DISC
>D>	AP	+!	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Jun	CTEC
>A>		+!		30GM/100ML	N019345	001	Jan 26, 1985	Jun	CTEC

DEXTROSE 40% IN PLASTIC CONTAINER

>D>	AP	+!	BAXTER HLTHCARE	40GM/100ML	N017521	002		Jun	DISC
>A>		+ @		40GM/100ML	N017521	002		Jun	DISC
>D>	AP	+!	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	Jun	CTEC
>A>		+!		40GM/100ML	N018562	001	Mar 23, 1982	Jun	CTEC

DEXTROSE 5% IN PLASTIC CONTAINER

		+ @ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984	Mar	DISC
AP		+!	50MG/ML	N019222	001	Jul 13, 1984	Feb	CAHN

DEXTROSE 50% IN PLASTIC CONTAINER

>D>	AP	+!	BAXTER HLTHCARE	50GM/100ML	N017521	001		Jun	DISC
>A>		+ @		50GM/100ML	N017521	001		Jun	DISC

DEXTROSE 60% IN PLASTIC CONTAINER

>D>		+!	BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982	Jun	DISC
>A>		+ @		60GM/100ML	N017521	005	Mar 26, 1982	Jun	DISC

DEXTROSE 70% IN PLASTIC CONTAINER

AP		+!	B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015	Feb	NEWA
----	--	----	---------	------------	---------	-----	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

		INJECTABLE; INJECTION							
		POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
AP	+	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Mar	CHRS
AP	+			5GM/100ML;149MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Mar	CPOT
		POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
		BAXTER HLTHCARE		5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985	Mar	CTEC
				5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985	Mar	CTEC
	+	@ ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Mar	DISC
	+	@		5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Mar	DISC
		POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
	+	@ ICU MEDICAL INC		5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Mar	DISC
		POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
	+	@ ICU MEDICAL INC		5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Mar	DISC
		POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
AP	+	ICU MEDICAL INC		5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Mar	CHRS
	+	@		5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Mar	DISC
		POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
		BAXTER HLTHCARE		5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985	Mar	CTEC
AP	+	ICU MEDICAL INC		5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Mar	CRLD
	+	@		5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Mar	DISC
		POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
AP	+	ICU MEDICAL INC		5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Mar	CHRS
		POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
		BAXTER HLTHCARE		5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985	Mar	CTEC
	+	@ ICU MEDICAL INC		5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Mar	DISC
		POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
AP	+	ICU MEDICAL INC		5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Mar	CHRS
		POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
AP	+	ICU MEDICAL INC		5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Mar	CRLD
		POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER			
		BAXTER HLTHCARE		5GM/100ML;150MG/100ML;450MG/100ML	N018008	004		Mar	CTEC
	+	@ ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Mar	DISC
	+	@		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Mar	DISC
		POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER			
		BAXTER HLTHCARE		5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985	Mar	CTEC
	+	@ ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Mar	DISC
	+	@		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Mar	DISC

DEXTROSE; SODIUM CHLORIDE

		INJECTABLE; INJECTION							
		DEXTROSE 5% AND SODIUM CHLORIDE		0.45%	IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC		5GM/100ML;450MG/100ML	N017607	001		Jan	CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

		INJECTABLE; INJECTION							
		RENOGRAFIN-76							
	+	@ BRACCO		66%;10%	N010040	001		May	DISC

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

		SOLUTION; INTRAUTERINE							
		SINOGRAFIN							
	+	@ BRACCO		52.7%;26.8%	N011324	002		May	DISC

DIAZEPAM

		TABLET; ORAL							
		DIAZEPAM							
	@	DAVA PHARMS INC		2MG	A070228	002	Sep 26, 1985	Apr	CMS1
	@			5MG	A070228	003	Sep 26, 1985	Apr	CMS1

DICLOFENAC POTASSIUM

		TABLET; ORAL							
		DICLOFENAC POTASSIUM							
AB		CASI PHARMS INC		50MG	A075229	001	Nov 20, 1998	Mar	CAHN

DICLOFENAC SODIUM

>D>	SOLUTION;INTRAVENOUS								
>D>	DYLOJECT								
>D>	+! JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)		N022396	001	Dec 23, 2014	Jun	DISC	
>A>	+ @	37.5MG/ML (37.5MG/ML)		N022396	001	Dec 23, 2014	Jun	DISC	
	SOLUTION;TOPICAL								
	DICLOFENAC SODIUM								
AT	ZYDUS PHARMS USA INC	1.5%		A206411	001	Apr 17, 2018	Apr	NEWA	
	TABLET, DELAYED RELEASE;ORAL								
	DICLOFENAC SODIUM								
AB	! CASI PHARMS INC	25MG		A074376	001	Sep 28, 1995	Mar	CAHN	
AB	!	50MG		A074376	002	Sep 28, 1995	Mar	CAHN	
AB	!	75MG		A074394	001	Nov 30, 1995	Mar	CAHN	

DICYCLOMINE HYDROCHLORIDE

	CAPSULE;ORAL								
	BENTYL								
AB	+! ALLERGAN SALES LLC	10MG		N007409	003	Oct 15, 1984	Jan	CAHN	
	INJECTABLE;INJECTION								
	BENTYL								
AP	+! ALLERGAN SALES LLC	10MG/ML		N008370	001	Oct 15, 1984	Jan	CAHN	
	BENTYL PRESERVATIVE FREE								
AP	+! ALLERGAN SALES LLC	10MG/ML		N008370	002	Oct 15, 1984	Jan	CAHN	
	DICYCLOMINE HYDROCHLORIDE								
AP	AKORN INC	10MG/ML		A207084	001	May 04, 2018	Apr	NEWA	
>A> AP	APC PHARMS LLC	10MG/ML		A210979	001	Jul 02, 2018	Jun	NEWA	
	TABLET;ORAL								
	BENTYL								
AB	+! ALLERGAN SALES LLC	20MG		N007409	001	Oct 15, 1984	Jan	CAHN	

DIDANOSINE

	CAPSULE, DELAYED REL PELLETS;ORAL								
	DIDANOSINE								
	@ BARR	200MG		A077167	001	Dec 03, 2004	Mar	DISC	
	@	250MG		A077167	002	Dec 03, 2004	Mar	DISC	
	@	400MG		A077167	003	Dec 03, 2004	Mar	DISC	

DIFLORASONE DIACETATE

	OINTMENT;TOPICAL								
	DIFLORASONE DIACETATE								
AB	TELIGENT PHARMA INC	0.05%		A210753	001	Jun 12, 2018	May	NEWA	

DIFLUNISAL

	TABLET;ORAL								
	DIFLUNISAL								
>D>	@ ALLIED PHARMA INC	250MG		A073562	001	Nov 27, 1992	Jun	CAHN	
>A>	@ SOCORRO	250MG		A073562	001	Nov 27, 1992	Jun	CAHN	

DIGOXIN

	TABLET;ORAL								
	LANOXIN								
	+ @ CONCORDIA PHARMS INC	0.1875MG		N020405	003	Sep 30, 1997	May	DISC	

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE;INJECTION								
	DIHYDROERGOTAMINE MESYLATE								
>A> AP	SAGENT PHARMS	1MG/ML		A207264	001	Jul 11, 2018	Jun	NEWA	

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL								
	DILTIAZEM HYDROCHLORIDE								
AB3	PAR PHARM	360MG		A209766	001	May 30, 2018	May	NEWA	

DIPHENHYDRAMINE HYDROCHLORIDE

	CAPSULE;ORAL								
	DIPHENHYDRAMINE HYDROCHLORIDE								
	@ FOSUN PHARMA	25MG		A080832	001		Jan	CAHN	
	@	25MG		A080845	002		Jan	CAHN	
	@	50MG		A080832	002		Jan	CAHN	
	@	50MG		A080845	001		Jan	CAHN	

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

AB	APOTEX INC	EQ 125MG VALPROIC ACID	A 077615	003	Jul 29, 2008	Apr	CAHN
AB		EQ 250MG VALPROIC ACID	A 077615	002	Jul 29, 2008	Apr	CAHN
AB		EQ 500MG VALPROIC ACID	A 077615	001	Jul 29, 2008	Apr	CAHN

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

>D>	+	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N 201195	001	Jun 08, 2011	Jun	DISC
>A>	+	@	20MG/0.5ML (40MG/ML)	N 201195	001	Jun 08, 2011	Jun	DISC
>D>	+		80MG/2ML (40MG/ML)	N 201195	002	Jun 08, 2011	Jun	DISC
>A>	+	@	80MG/2ML (40MG/ML)	N 201195	002	Jun 08, 2011	Jun	DISC
AP		AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A 209640	001	Jan 19, 2018	Jan	NEWA
AP			80MG/4ML (20MG/ML)	A 209640	002	Jan 19, 2018	Jan	NEWA
AP			160MG/8ML (20MG/ML)	A 209640	003	Jan 19, 2018	Jan	NEWA
>A>	AP	EAGLE PHARMS	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jun	CTEC
>A>			20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jun	CDFR
>A>	AP		80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jun	CTEC
>A>			80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jun	CDFR
>A>	AP		160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jun	CTEC
>A>			160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jun	CDFR
>A>	AP	MYLAN LABS LTD	20MG/2ML (10MG/ML)	A 210072	001	Jul 02, 2018	Jun	NEWA
>A>	AP		80MG/8ML (10MG/ML)	A 210848	001	Jul 06, 2018	Jun	NEWA

SOLUTION; IV (INFUSION)
DOCETAXEL

>D>		EAGLE PHARMS	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jun	CDFR
>D>			80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jun	CDFR
>D>			160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jun	CDFR

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP		MYLAN LABS LTD	160MG/16ML (10MG/ML)	A 208859	001	Apr 30, 2018	Apr	NEWA
----	--	----------------	----------------------	----------	-----	--------------	-----	------

DOFETILIDE

CAPSULE; ORAL
DOFETILIDE

AB		APICORE US	0.125MG	A 208625	001	Apr 10, 2018	Mar	NEWA
AB			0.25MG	A 208625	002	Apr 10, 2018	Mar	NEWA
AB			0.5MG	A 208625	003	Apr 10, 2018	Mar	NEWA
AB		BIONPHARMA INC	0.125MG	A 208625	001	Apr 10, 2018	May	CAHN
AB			0.25MG	A 208625	002	Apr 10, 2018	May	CAHN
AB			0.5MG	A 208625	003	Apr 10, 2018	May	CAHN
AB		SIGMAPHARM LABS LLC	0.125MG	A 207746	001	Mar 26, 2018	Mar	NEWA
AB			0.25MG	A 207746	002	Mar 26, 2018	Mar	NEWA
AB			0.5MG	A 207746	003	Mar 26, 2018	Mar	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

@	APOTEX	5MG	A 078841	001	Jun 02, 2011	Mar	DISC
@		10MG	A 078841	002	Jun 02, 2011	Mar	DISC
@	SUN PHARM INDS LTD	5MG	A 076786	001	Nov 26, 2010	Apr	DISC
@		10MG	A 076786	002	Nov 26, 2010	Apr	DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

>A>	+	ALLERGAN SALES LLC	10MG; 7MG	N 206439	003	Jul 18, 2016	Jun	CAHN
>A>	AB	+	10MG; 14MG	N 206439	001	Dec 23, 2014	Jun	CAHN
>A>		+	10MG; 21MG	N 206439	004	Jul 18, 2016	Jun	CAHN
>A>	AB	+	10MG; 28MG	N 206439	002	Dec 23, 2014	Jun	CAHN
>D>	+	FOREST LABS LLC	10MG; 7MG	N 206439	003	Jul 18, 2016	Jun	CAHN
>D>	AB	+	10MG; 14MG	N 206439	001	Dec 23, 2014	Jun	CAHN
>D>		+	10MG; 21MG	N 206439	004	Jul 18, 2016	Jun	CAHN
>D>	AB	+	10MG; 28MG	N 206439	002	Dec 23, 2014	Jun	CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS	40MG/ML	A207707	001	Apr 11, 2018	Mar	NEWA
AP		80MG/ML	A207707	002	Apr 11, 2018	Mar	NEWA

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

>D>	AT	TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008	Jun	DISC
>A>		@	EQ 2% BASE	A078756	001	Dec 04, 2008	Jun	DISC
		@ WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	May	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
@ WATSON LABS INC EQ 2% BASE; EQ 0.5% BASE

A202054	001	Sep 03, 2014	May	DISC
---------	-----	--------------	-----	------

DOXAZOSIN MESYLATETABLET; ORAL
DOXAZOSIN MESYLATE

AB	APPCO PHARMA LLC	EQ 1MG BASE	A209013	001	Apr 17, 2018	Apr	NEWA
AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Apr	NEWA
AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Apr	NEWA
AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Apr	NEWA
AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan	NEWA
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
AB	@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN

DOXEPIIN HYDROCHLORIDETABLET; ORAL
DOXEPIIN HYDROCHLORIDE
@ ACTAVIS ELIZABETH
@
SILENOR

EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan	DISC
EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan	DISC
EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan	CTEC
EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan	CTEC

DOXYCYCLINE HYCLATECAPSULE; ORAL
ACTICLATE CAP

+ @ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	May	DISC
-----------------	--------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210527	001	Jun 13, 2018	May	NEWA	
AB		EQ 100MG BASE	A210527	002	Jun 13, 2018	May	NEWA	
>A>	AB	SUN PHARM INDUSTRIES	EQ 50MG BASE	A062676	002	Jul 10, 1986	Jun	CMS1
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A207774	001	May 31, 2018	May	NEWA	
AB		EQ 100MG BASE	A207774	002	May 31, 2018	May	NEWA	

TABLET; ORAL

>A>	LYMEPAK						
>A>	+! CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018	Jun	NEWA

TABLET, DELAYED RELEASE; ORAL
DORYX

+ @ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
------------------	--------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

AB	ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018	May	NEWA
AB		EQ 200MG BASE	A090134	004	May 22, 2018	May	NEWA
	@ MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	DISC

DRONABINOLCAPSULE; ORAL
DRONABINOL

AB	LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	May	NEWA
AB		5MG	A201463	002	May 18, 2018	May	NEWA
AB		10MG	A201463	003	May 18, 2018	May	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

		TABLET; ORAL		DROSPIRENONE AND ETHINYL ESTRADIOL					
AB	JUBILANT CADISTA	3MG;0.02MG		A209423	001	Dec 22, 2017	Mar	CAHN	
		LO-ZUMANDIMINE							
AB	AUROBINDO PHARMA LTD	3MG;0.02MG		A209632	001	Feb 27, 2018	Feb	NEWA	
		TABLET; ORAL-28		ZUMANDIMINE					
AB	AUROBINDO PHARMA LTD	3MG;0.03MG		A209407	001	Mar 26, 2018	Mar	NEWA	

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

		TABLET; ORAL		DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM					
AB	LUPIN LTD	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG		A205947	001	Jun 13, 2018	May	NEWA	

DULOXETINE HYDROCHLORIDE

		CAPSULE, DELAYED REL PELLETS; ORAL		DULOXETINE HYDROCHLORIDE					
AB	BRECKENRIDGE PHARM	EQ 40MG BASE		A203088	004	May 18, 2018	May	NEWA	
AB	LUPIN LTD	EQ 40MG BASE		A090694	003	Dec 11, 2013	May	CTEC	

DUTASTERIDE

		CAPSULE; ORAL		DUTASTERIDE					
>D>	AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	Jun	DISC	
>A>		@	0.5MG	A203241	001	Jun 14, 2016	Jun	DISC	
>A>	AB	PHARMACEUTICS	0.5MG	A208227	001	Jun 22, 2018	Jun	NEWA	

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

		CAPSULE; ORAL		DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE					
AB	ZYDUS PHARMS USA INC	0.5MG;0.4MG		A207769	001	May 24, 2018	May	NEWA	

ECONAZOLE NITRATE

		CREAM; TOPICAL		ECONAZOLE NITRATE					
AB	CASI PHARMS INC	1%		A076075	001	Nov 26, 2002	Mar	CAHN	
AB	MYLAN PHARMS INC	1%		A210364	001	Apr 18, 2018	Apr	NEWA	

EFAVIRENZ

		TABLET; ORAL		EFAVIRENZ					
>A>	AB	CIPLA LTD	600MG	A204766	001	Jun 15, 2018	Jun	NEWA	
	AB	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Apr	NEWA	
	AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb	NEWA	

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

		TABLET; ORAL		ATRIPLA					
	+	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar	CAHN	

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

		TABLET; ORAL		SYMFI					
	+	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	Mar	NEWA	
		SYMFI LO							
	+	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb	NEWA	

ELETRIPTAN HYDROBROMIDE

		TABLET; ORAL		ELETRIPTAN HYDROBROMIDE					
AB	AMNEAL PHARMS CO	EQ 20MG BASE		A206787	001	May 25, 2018	May	NEWA	
AB		EQ 40MG BASE		A206787	002	May 25, 2018	May	NEWA	

EMTRICITABINE

		CAPSULE; ORAL		EMTRICITABINE					
>A>	AB	CIPLA LTD	200MG	A091168	001	Jul 02, 2018	Jun	NEWA	
		EMTRIVA							
>D>	+	GILEAD	200MG	N021500	001	Jul 02, 2003	Jun	CFTG	

	CAPSULE;ORAL							
	EMTRIVA							
>A>	AB	+!	200MG	N021500	001	Jul 02, 2003	Jun	CFTG
	<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
	TABLET;ORAL							
	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
	AB	AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan	NEWA
	AB	MYLAN PHARMS INC	200MG;300MG	A206436	001	Apr 09, 2018	Mar	NEWA
>A>	<u>ENCORAFENIB</u>							
>A>	CAPSULE;ORAL							
>A>	BRAFTOVI							
>A>	+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jun	NEWA
>A>	+	!	75MG	N210496	002	Jun 27, 2018	Jun	NEWA
	<u>ENTECAVIR</u>							
	TABLET;ORAL							
	ENTECAVIR							
	AB	BRECKENRIDGE PHARM	0.5MG	A208721	001	Mar 15, 2018	Apr	NEWA
	AB		1MG	A208721	002	Mar 15, 2018	Apr	NEWA
	AB	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Mar	CAHN
	AB		1MG	A206672	002	May 11, 2017	Mar	CAHN
	<u>EPHEDRINE SULFATE</u>							
	SOLUTION;INTRAVENOUS							
	CORPHEDRA							
	AP	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Apr	CDFR
	<u>EPINASTINE HYDROCHLORIDE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	EPINASTINE HYDROCHLORIDE							
	AT	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN
	<u>EPINEPHRINE</u>							
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
	ADRENALIN							
>D>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jun	CFTG
>A>	AP	+	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jun	CFTG
>A>	EPINEPHRINE							
>A>	AP	LUITPOLD PHARMS INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Jun	NEWA
	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
	EPINEPHRINE							
	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr	CRLD
	<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
	@	EASTMAN KODAK	0.01MG/ML;2%	A040057	002	Feb 26, 1993	Mar	DISC
	@		0.02MG/ML;2%	A040057	001	Feb 26, 1993	Mar	DISC
	<u>EPROSARTAN MESYLATE</u>							
	TABLET;ORAL							
	EPROSARTAN MESYLATE							
	AB	! MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar	CHRS
		TEVETEN						
	+	@ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar	DISC
	+	@	EQ 600MG BASE	N020738	006	May 27, 1999	Mar	DISC
	<u>EPTIFIBATIDE</u>							
	INJECTABLE;INJECTION							
	EPTIFIBATIDE							
	AP	SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb	NEWA
	AP		75MG/100ML	A204693	002	Mar 07, 2018	Feb	NEWA
	<u>ERTAPENEM SODIUM</u>							
	INJECTABLE;INTRAMUSCULAR, IV (INFUSION)							
	ERTAPENEM SODIUM							
	AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018	Apr	NEWA
>A>	AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Jun	NEWA

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
INVANZ

AP +! MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001 Apr CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL
STEGLUJAN

+ MERCK SHARP DOHME 5MG;EQ 100MG BASE N209805 001 Dec 19, 2017 Jan CMS1
+! 15MG;EQ 100MG BASE N209805 002 Dec 19, 2017 Jan CMS1

ERYTHROMYCIN

TABLET;ORAL
ERYTHROMYCIN

AB AMNEAL PHARMS CO 250MG A209720 001 Mar 09, 2018 Feb NEWA
AB 500MG A209720 002 Mar 09, 2018 Feb NEWA
AB ARBOR PHARMS LLC 250MG A061621 001 Feb CTEC
AB ! 500MG A061621 002 Feb CTEC
>D> TABLET, COATED PARTICLES;ORAL
>D> PCE
>D> + ARBOR PHARMS LLC 333MG N050611 001 Sep 09, 1986 Jun DISC
>A> + @ 333MG N050611 001 Sep 09, 1986 Jun DISC
>D> +! 500MG N050611 002 Aug 22, 1990 Jun DISC
>A> + @ 500MG N050611 002 Aug 22, 1990 Jun DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL
LEXAPRO

AA +! ALLERGAN SALES LLC EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Jan CAHN

TABLET;ORAL
LEXAPRO

AB + ALLERGAN SALES LLC EQ 5MG BASE N021323 001 Aug 14, 2002 Jan CAHN
AB + EQ 10MG BASE N021323 002 Aug 14, 2002 Jan CAHN
AB +! EQ 20MG BASE N021323 003 Aug 14, 2002 Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
ESMOLOL HYDROCHLORIDE

AP MYLAN LABS LTD 10MG/ML A206608 001 Jun 08, 2018 May NEWA
AP 20MG/ML A206608 002 Jun 08, 2018 May NEWA
AP SAGENT PHARMS 10MG/ML A207107 001 Jun 08, 2018 May NEWA
AP 20MG/ML A207107 002 Jun 08, 2018 May NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB HEC PHARM CO LTD EQ 20MG BASE A207265 002 May 18, 2018 May NEWA
AB EQ 40MG BASE A207265 001 May 18, 2018 May NEWA
AB SUN PHARM INDS LTD EQ 20MG BASE A209735 001 Apr 30, 2018 Apr NEWA
AB EQ 40MG BASE A209735 002 Apr 30, 2018 Apr NEWA

ESTRADIOL

CREAM;VAGINAL
ESTRADIOL

AB ALVOGEN PINE BROOK 0.01% A209767 001 Mar 05, 2018 Feb NEWA
AB PERRIGO UK FINCO 0.01% A210194 001 Jan 22, 2018 Jan NEWA
AB TEVA PHARMS USA 0.01% A210488 001 Mar 30, 2018 Mar NEWA

INSERT;VAGINAL
IMVEXXY

+ THERAPEUTICSMD INC 0.004MG N208564 001 May 29, 2018 May NEWA
+! 0.01MG N208564 002 May 29, 2018 May NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL
FEMRING

+ MILLICENT EQ 0.05MG BASE/24HR N021367 001 Mar 20, 2003 May CAHN
+! EQ 0.1MG BASE/24HR N021367 002 Mar 20, 2003 May CAHN

>D>	<u>ESTRADIOL HEMIHYDRATE</u>							
>D>	EMULSION;TOPICAL							
>D>	ESTRASORB							
>D>	+!	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	DISC
>A>	+	@	0.25%	N021371	001	Oct 09, 2003	Jun	DISC
	<u>ESTRADIOL VALERATE</u>							
	INJECTABLE;INJECTION							
	ESTRADIOL VALERATE							
	@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan	CAHN
	@		20MG/ML	A040628	002	Oct 04, 2007	Jan	CAHN
	@		40MG/ML	A040628	003	Oct 04, 2007	Jan	CAHN
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
	TABLET;ORAL							
	ESTRADIOL AND NORETHINDRONE ACETATE							
AB		ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb	NEWA
	<u>ESTROGENS, CONJUGATED</u>							
	CREAM;TOPICAL, VAGINAL							
	PREMARIN							
>A>	+!	WYETH PHARMS	0.625MG/GM	N020216	001		Jun	CAHN
>D>	+!	WYETH PHARMS INC	0.625MG/GM	N020216	001		Jun	CAHN
	INJECTABLE;INJECTION							
	PREMARIN							
>A>	+!	WYETH PHARMS	25MG/VIAL	N010402	001		Jun	CAHN
>D>	+!	WYETH PHARMS INC	25MG/VIAL	N010402	001		Jun	CAHN
	TABLET;ORAL							
	PREMARIN							
>A>	+	WYETH PHARMS	0.3MG	N004782	003		Jun	CAHN
>A>	+		0.45MG	N004782	006	Jul 16, 2003	Jun	CAHN
>A>	+!		0.625MG	N004782	004		Jun	CAHN
>A>	+!		0.9MG	N004782	005	Jan 26, 1984	Jun	CAHN
>A>	+!		1.25MG	N004782	001		Jun	CAHN
>A>	@		2.5MG	N004782	002		Jun	CAHN
>D>	+	WYETH PHARMS INC	0.3MG	N004782	003		Jun	CAHN
>D>	+		0.45MG	N004782	006	Jul 16, 2003	Jun	CAHN
>D>	+!		0.625MG	N004782	004		Jun	CAHN
>D>	+!		0.9MG	N004782	005	Jan 26, 1984	Jun	CAHN
>D>	+!		1.25MG	N004782	001		Jun	CAHN
>D>	@		2.5MG	N004782	002		Jun	CAHN
	<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE</u>							
	TABLET;ORAL-28							
	PREMPHASE 14/14							
>A>	+!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995	Jun	CAHN
>D>	+!	WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995	Jun	CAHN
	PREMPRO							
>A>	+!	WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003	Jun	CAHN
>A>	+!		0.45MG;1.5MG	N020527	004	Mar 12, 2003	Jun	CAHN
>A>	+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995	Jun	CAHN
>A>	+!		0.625MG;5MG	N020527	003	Jan 09, 1998	Jun	CAHN
>D>	+!	WYETH PHARMS INC	0.3MG;1.5MG	N020527	005	Jun 04, 2003	Jun	CAHN
>D>	+!		0.45MG;1.5MG	N020527	004	Mar 12, 2003	Jun	CAHN
>D>	+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995	Jun	CAHN
>D>	+!		0.625MG;5MG	N020527	003	Jan 09, 1998	Jun	CAHN
	<u>ETHACRYNIC ACID</u>							
	TABLET;ORAL							
	ETHACRYNIC ACID							
AB		AMNEAL PHARMS CO	25MG	A208805	001	May 08, 2018	Apr	NEWA
	<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>							
	TABLET;ORAL							
	BALCOLTRA							
		AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Feb	CAHN
		NEUVOSYN LABS LLC	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan	NEWA
>A>		ICLEVIA						
>A>	AB	AUROBINDO PHARMA LTD	0.03MG;0.15MG	A206850	001	Jun 29, 2018	Jun	NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL						
AB		LABS LEON FARMA	0.02MG,0.1MG;0.01MG,N/A	A205131	001	Dec 14, 2017	Apr	CPOT

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	0.02MG,0.1MG;0.01MG,N/A	A091674	001	Oct 26, 2011	Apr	CPOT
AB	MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Apr	CPOT
AB	MYLAN LABS LTD	0.02MG,0.1MG;0.01MG,N/A	A200493	001	Jun 17, 2015	Apr	CPOT
	LO SIMPESE						
AB	AUROBINDO PHARMA LTD	0.02MG,0.1MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr	CPOT
	LOSEASONIQUE						
AB	TEVA BRANDED PHARM	0.02MG,0.1MG;0.01MG,N/A	N022262	001	Oct 24, 2008	Apr	CPOT
	TABLET;ORAL-21						
	ALESSE						
+	@ WYETH PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	May	CAHN
	TRIPHASIL-21						
+	@ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019192	001	Nov 01, 1984	May	CAHN
	TABLET;ORAL-28						
	ALESSE						
+	@ WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	May	CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB	MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

	MODICON 28						
+	@ JANSSEN PHARMS	0.035MG;0.5MG	N017735	001		Feb	DISC
	WERA						
AB	! NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Feb	CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

LO LOESTRIN FE

+	! APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Apr	CTEC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
	@ MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	Apr	DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	APOTEX INC	0.02MG;1MG	A208639	001	Mar 21, 2018	Mar	NEWA
	TABLET;ORAL-28						
	HAILEY 1.5/30						
AB	GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	May	NEWA
	HAILEY FE 1.5/30						
AB	GLENMARK PHARMS	0.03MG;1.5MG	A209031	001	Jun 05, 2018	May	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
>A>	AB MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Jun	NEWA
	TABLET, CHEWABLE, TABLET;ORAL						
	LO MINASTRIN FE						
+	@ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	DISC

ETHIONAMIDE

TABLET;ORAL

TRECATOR

+	! WYETH PHARMS	250MG	N013026	002		May	CAHN
---	----------------	-------	---------	-----	--	-----	------

ETODOLAC

TABLET;ORAL

ETODOLAC

AB	AMNEAL PHARMS CO	400MG	A208834	001	Jun 07, 2018	May	NEWA
AB		500MG	A208834	002	Jun 07, 2018	May	NEWA

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB	WEST-WARD PHARMS INT	0.25MG	A206133	001	Apr 12, 2018	Apr	NEWA
AB		0.5MG	A206133	002	Apr 12, 2018	Apr	NEWA
AB		0.75MG	A206133	003	Apr 12, 2018	Apr	NEWA
	ZORTRESS						
AB	+ NOVARTIS	0.25MG	N021560	001	Apr 20, 2010	Apr	CFTG
AB	+	0.5MG	N021560	002	Apr 20, 2010	Apr	CFTG
AB	+	0.75MG	N021560	003	Apr 20, 2010	Apr	CFTG

EXEMESTANETABLET; ORAL
EXEMESTANE

AB	CIPLA LTD	25MG	A210323	001	Apr 27, 2018	Apr	NEWA
----	-----------	------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATINTABLET; ORAL
EZETIMIBE AND SIMVASTATIN

AB	ANI PHARMS INC	10MG;10MG	A201890	001	Apr 26, 2017	May	CAHN
AB		10MG;20MG	A201890	002	Apr 26, 2017	May	CAHN
AB		10MG;40MG	A201890	003	Apr 26, 2017	May	CAHN
AB		10MG;80MG	A201890	004	Apr 26, 2017	May	CAHN

FAMOTIDINETABLET; ORAL
FAMOTIDINE

@	PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001	Feb	CAHN
@		40MG	A075302	002	Apr 16, 2001	Feb	CAHN

FELBAMATETABLET; ORAL
FELBAMATE

AB	ANI PHARMS INC	400MG	A202284	001	Nov 04, 2015	May	CAHN
AB		600MG	A202284	002	Nov 04, 2015	May	CAHN

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018	Apr	NEWA	
AB		134MG	A209504	002	Apr 30, 2018	Apr	NEWA	
AB		200MG	A209504	003	Apr 30, 2018	Apr	NEWA	
>A>	AB	TORRENT PHARMS LTD	67MG	A210782	001	Jun 26, 2018	Jun	NEWA
>A>	AB		134MG	A210782	002	Jun 26, 2018	Jun	NEWA
>A>	AB		200MG	A210782	003	Jun 26, 2018	Jun	NEWA

TABLET; ORAL
FENOFIBRATE

AB	AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018	Jan	NEWA
AB		54MG	A209950	001	Mar 19, 2018	Mar	NEWA
AB		145MG	A209951	002	Feb 09, 2018	Jan	NEWA
AB		160MG	A209950	002	Mar 19, 2018	Mar	NEWA

FENOPROFEN CALCIUMCAPSULE; ORAL
NALFON

>D>	+	XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Jun	CHRS
>A>	+		EQ 200MG BASE	N017604	003		Jun	CHRS
>D>	+		EQ 400MG BASE	N017604	004	Jul 21, 2009	Jun	CHRS
>A>	+		EQ 400MG BASE	N017604	004	Jul 21, 2009	Jun	CHRS

FENTANYLFILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC-37

+	JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Jan	NEWA
---	----------------	------------	---------	-----	--------------	-----	------

FENTANYL CITRATETROCHE/LOZENGE; TRANSMUCOSAL
FENTANYL CITRATE

>D>	AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Jun	DISC
>A>	@		EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Jun	DISC
>D>	AB		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Jun	DISC
>A>	@		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Jun	DISC
>D>	AB		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Jun	DISC
>A>	@		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Jun	DISC
>D>	AB		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Jun	DISC
>A>	@		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Jun	DISC
>D>	AB		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Jun	DISC
>A>	@		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Jun	DISC
>D>	AB		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Jun	DISC
>A>	@		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Jun	DISC

>D>	<u>FENTANYL HYDROCHLORIDE</u>							
>D>	SYSTEM; IONTOPHORESIS, TRANSDERMAL							
>D>	IONSYS							
>D>	+!	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun DISC	
>A>	+	@	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun DISC	
	<u>FERRIC PYROPHOSPHATE CITRATE</u>							
	SOLUTION; IV (INFUSION)							
	TRIFERIC							
	+	@	ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	May DISC
	<u>FEXOFENADINE HYDROCHLORIDE</u>							
	SUSPENSION; ORAL							
	ALLEGRA							
	+	@	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	May DISC
			FEXOFENADINE HYDROCHLORIDE					
	!		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	May CHRS
	<u>FINASTERIDE</u>							
	TABLET; ORAL							
	FINASTERIDE							
		@	GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006	May DISC
	<u>FINGOLIMOD HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	GILENYA							
	+		NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	May NEWA
	+	!		EQ 0.5MG BASE	N022527	001	Sep 21, 2010	May CAIN
	<u>FLUCONAZOLE</u>							
	INJECTABLE; INJECTION							
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	!		INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Jan CAHN
AP	!			400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Jan CAHN
	<u>FLUCYTOSINE</u>							
	CAPSULE; ORAL							
	FLUCYTOSINE							
>A>	AB		RECIPHARM	250MG	A207536	001	Jun 18, 2018	Jun NEWA
>A>	AB			500MG	A207536	002	Jun 18, 2018	Jun NEWA
	<u>FLUDEOXYGLUCOSE F-18</u>							
	INJECTABLE; INTRAVENOUS							
	FLUDEOXYGLUCOSE F18							
	+	@	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	May DISC
		@	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	May DISC
AP	!		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	May CHRS
	<u>FLUNISOLIDE</u>							
	SPRAY, METERED; NASAL							
	FLUNISOLIDE							
>D>	!		APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun DISC
>A>		@		0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun DISC
	<u>FLUOCINOLONE ACETONIDE</u>							
	CREAM; TOPICAL							
	FLUOCINOLONE ACETONIDE							
		@	G AND W LABS	0.025%	A089525	001	Jul 26, 1988	Jan DISC
	OIL/DROPS; OTIC							
	FLAC							
AT			PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Mar NEWA
	SOLUTION; TOPICAL							
	FLUOCINOLONE ACETONIDE							
		@	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Jan DISC

FLUOCINONIDE

		CREAM; TOPICAL							
		FLUOCINONIDE							
AB		AMNEAL PHARMS LLC	0.1%	A211111	001	Jun 04, 2018	May	NEWA	
		FLUOCINONIDE EMULSIFIED BASE							
AB2	!	TARO PHARM INDS LTD	0.05%	A072494	001	Jan 19, 1989	May	CAHN	
		GEL; TOPICAL							
		FLUOCINONIDE							
>A>	AB	TELIGENT PHARMA INC	0.05%	A209030	001	Jun 19, 2018	Jun	NEWA	
		SOLUTION; TOPICAL							
		FLUOCINONIDE							
AT		GLASSHOUSE PHARMS	0.05%	A209118	001	Apr 23, 2018	Apr	NEWA	
AT		MACLEODS PHARMS LTD	0.05%	A209283	001	Apr 23, 2018	Apr	NEWA	

FLUORESCCEIN SODIUM

		INJECTABLE; INTRAVENOUS							
		FLUORESCITE							
AP	+!	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN	

FLUOXETINE HYDROCHLORIDE

		TABLET; ORAL							
		FLUOXETINE HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A076006	001	Jan 30, 2002	Apr	CAHN	
AB			EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr	NEWA	
AB			EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr	CAHN	
	@	FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan	CAHN	

FLUPHENAZINE DECANOATE

		INJECTABLE; INJECTION							
		FLUPHENAZINE DECANOATE							
>D>	@	MYLAN LABS LTD	25MG/ML	A075918	001	Aug 17, 2001	Jun	CMFD	
>A>	AO		25MG/ML	A075918	001	Aug 17, 2001	Jun	CMFD	

FLUTAMIDE

		CAPSULE; ORAL							
		FLUTAMIDE							
	@	YAOPHARMA CO LTD	125MG	A075818	001	Sep 18, 2001	Jan	CAHN	

FLUTEMETAMOL F-18

		INJECTABLE; INTRAVENOUS							
		VIZAMYL							
>D>	+!	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Jun	DISC	
>A>	+ @		40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Jun	DISC	

FLUTICASONE FUROATE

		POWDER; INHALATION							
		ARNUITY ELLIPTA							
	+!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018	May	NEWA	

FLUTICASONE PROPIONATE

		SPRAY, METERED; NASAL							
		XHANCE							
	+!	OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017	Jan	CMS1	

FOLIC ACID

		TABLET; ORAL							
		FOLIC ACID							
>A>	AA	CHARTWELL MOLECULAR	1MG	A090035	001	Jun 09, 2009	Jun	CAHN	
>D>	AA	INVAGEN PHARMS	1MG	A090035	001	Jun 09, 2009	Jun	CAHN	

FONDAPARINUX SODIUM

		INJECTABLE; SUBCUTANEOUS							
		FONDAPARINUX SODIUM							
AP		JIANGSU HENGRUI MED	2.5MG/0.5ML	A206812	001	May 15, 2018	Apr	NEWA	
AP			5MG/0.4ML	A206812	002	May 15, 2018	Apr	NEWA	
AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Apr	NEWA	
AP			10MG/0.8ML	A206812	004	May 15, 2018	Apr	NEWA	

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan	CAHN
AB	!	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CAHN

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

+	!	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018	Apr	NEWA
---	---	------------------	------------------------------	---------	-----	--------------	-----	------

FOSTAMATINIB DISODIUM

TABLET; ORAL

TAVALLISSE

+		RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018	Apr	NEWA
+	!		EQ 150MG BASE	N209299	002	Apr 17, 2018	Apr	NEWA

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	ACI HEALTHCARE LTD	100MG	A206943	001	May 14, 2018	Apr	NEWA
AB		300MG	A206943	002	May 14, 2018	Apr	NEWA
AB		400MG	A206943	003	May 14, 2018	Apr	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jun	DISC
>A>		@	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jun	DISC
>D>	AB		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jun	DISC
>A>		@	EQ 16MG BASE	A090900	002	Jan 24, 2011	Jun	DISC
>D>	AB		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jun	DISC
>A>		@	EQ 24MG BASE	A090900	003	Jan 24, 2011	Jun	DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT	MICRO LABS	0.5%	A206446	001	Jun 08, 2018	May	NEWA
----	------------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

@	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012	Mar	DISC
@		EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012	Mar	DISC

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

@	YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan	CMFD
----	------------------	--------------	---------	-----	--------------	-----	------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

GLATOPIA

AP	SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan	NEWA
----	------------	---------	---------	-----	--------------	-----	------

GLUCAGON

INJECTABLE; INJECTION

GLUCAGON

+	!	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998	Apr	CAIN
---	---	-------	----------	---------	-----	--------------	-----	------

GLUCAGON HYDROCHLORIDEINJECTABLE; INJECTION
GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL N020918 001 Jun 22, 1998 Apr CAHN

GLYBURIDETABLET; ORAL
GLYBURIDE (MICRONIZED)@ YAOPHARMA CO LTD 1.5MG A075174 001 Jun 22, 1998 Jan CAHN
@ 3MG A075174 002 Jun 22, 1998 Jan CAHNGLYCINESOLUTION; IRRIGATION
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT +! BAXTER HLTHCARE 1.5GM/100ML N017865 001 Mar CRLD

GLYCOPYRROLATETABLET; ORAL
GLYCOPYRROLATEAA ! PAR PHARM 1MG A040653 001 Aug 31, 2006 May CHRS
AA ! 2MG A040653 002 Aug 31, 2006 May CHRS
@ RENATA 1MG A040568 001 Dec 22, 2004 Apr CAHN
@ 2MG A040568 002 Dec 22, 2004 Apr CAHN
ROBINUL
+ @ CASPER PHARMA LLC 1MG N012827 001 May DISC
ROBINUL FORTE
+ @ CASPER PHARMA LLC 2MG N012827 002 May DISC>A> GLYCOPYRROLATE TOSYLATECLOTH; TOPICAL
QBREXZA

>A> +! DERMIRA INC EQ 2.4% BASE N210361 001 Jun 28, 2018 Jun NEWA

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 Feb DISC

TABLET; ORAL
GRANISETRON HYDROCHLORIDE

AB CHARTWELL MOLECULAR EQ 1MG BASE A078037 001 Feb 27, 2008 Mar CAHN

GRISEOFULVIN, ULTRAMICROSIZEDTABLET; ORAL
GRISEOFULVIN, ULTRAMICROSIZEDAB MOUNTAIN 125MG A204371 001 Jan 09, 2014 Jan CAHN
AB 250MG A204371 002 Jan 09, 2014 Jan CAHNGUAIFENESIN; HYDROCODONE BITARTRATESOLUTION; ORAL
FLOWTUSS

BKK PHARMS 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 May CAHN

TABLET; ORAL
HYDROCODONE BITARTRATE AND GUAIFENESIN

+! ECI PHARMS LLC 400MG; 5MG N208085 001 Apr 25, 2018 Apr NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYCOFENIX

+! BKK PHARMS 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 May CAHN

GUANABENZ ACETATETABLET; ORAL
GUANABENZ ACETATE@ YAOPHARMA CO LTD EQ 4MG BASE A074517 001 Sep 30, 1998 Jan CAHN
@ EQ 8MG BASE A074517 002 Sep 30, 1998 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

>D>	AB	MYLAN	EQ 1MG BASE	A 074796	001	Jan 27, 1997	Jun	CHRS
>A>	AB	!	EQ 1MG BASE	A 074796	001	Jan 27, 1997	Jun	CHRS
>D>	AB		EQ 2MG BASE	A 074796	002	Jan 27, 1997	Jun	CHRS
>A>	AB	!	EQ 2MG BASE	A 074796	002	Jan 27, 1997	Jun	CHRS
		TENEX						
>D>	AB	+ PROMIUS PHARMA	EQ 1MG BASE	N 019032	001	Oct 27, 1986	Jun	DISC
>A>		+ @	EQ 1MG BASE	N 019032	001	Oct 27, 1986	Jun	DISC
>D>	AB	+!	EQ 2MG BASE	N 019032	002	Nov 07, 1988	Jun	DISC
>A>		+ @	EQ 2MG BASE	N 019032	002	Nov 07, 1988	Jun	DISC

HALCINONIDE

CREAM; TOPICAL

HALOG

		+!	SUN PHARM INDS INC	0.1%	N 017556	001		Feb	CAHN
--	--	----	--------------------	------	----------	-----	--	-----	------

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

		+!	THERAPS INC	0.05%	N 210566	001	May 24, 2018	May	NEWA
--	--	----	-------------	-------	----------	-----	--------------	-----	------

CREAM; TOPICAL

ULTRAVATE

AB		+!	SUN PHARM INDS INC	0.05%	N 019967	001	Dec 27, 1990	Feb	CAHN
----	--	----	--------------------	-------	----------	-----	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB			TELIGENT PHARMA INC	0.05%	A 209978	001	Mar 20, 2018	Mar	NEWA
----	--	--	---------------------	-------	----------	-----	--------------	-----	------

ULTRAVATE

AB		+!	SUN PHARM INDS INC	0.05%	N 019968	001	Dec 17, 1990	Feb	CAHN
----	--	----	--------------------	-------	----------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

>A>	AO		SOMERSET THERAPS LLC	EQ 50MG BASE/ML	A 209101	001	Jul 03, 2018	Jun	NEWA
>A>	AO			EQ 100MG BASE/ML	A 209101	002	Jul 03, 2018	Jun	NEWA

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML

A 076464	001	Sep 29, 2004	Jan	CAHN
----------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP			CASI PHARMS INC	5,000 UNITS/ML	A 091659	001	Jun 08, 2011	Mar	CAHN
----	--	--	-----------------	----------------	----------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AA		APPCO PHARMA LLC	10MG	A 209251	001	Jul 09, 2018	Jun	NEWA
>A>	AA			25MG	A 209251	002	Jul 09, 2018	Jun	NEWA
>A>	AA			50MG	A 209251	003	Jul 09, 2018	Jun	NEWA
>A>	AA			100MG	A 209251	004	Jul 09, 2018	Jun	NEWA
	AA		SCIEGEN PHARMS INC	10MG	A 205236	001	May 26, 2017	Feb	CAHN
	AA			25MG	A 205236	002	May 26, 2017	Feb	CAHN
	AA			50MG	A 205236	003	May 26, 2017	Feb	CAHN
	AA			100MG	A 205236	004	May 26, 2017	Feb	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 12.5MG

A 078389	001	May 16, 2008	Mar	DISC
----------	-----	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 25MG

A 040774	001	Oct 03, 2007	Mar	DISC
----------	-----	--------------	-----	------

@ 50MG

A 040774	002	Oct 03, 2007	Mar	DISC
----------	-----	--------------	-----	------

AB			SCIEGEN PHARMS INC	25MG	A 203018	001	Jul 23, 2014	Jan	CAHN
----	--	--	--------------------	------	----------	-----	--------------	-----	------

AB				50MG	A 203018	002	Jul 23, 2014	Jan	CAHN
----	--	--	--	------	----------	-----	--------------	-----	------

@ YAOPHARMA CO LTD 25MG

A 087565	001	Mar 09, 1982	Jan	CAHN
----------	-----	--------------	-----	------

@ 50MG

A 084912	001		Jan	CAHN
----------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012	Jun	DISC
>A>		@	12.5MG;150MG	A077969	001	Sep 27, 2012	Jun	DISC
>D>	AB		12.5MG;300MG	A077969	002	Sep 27, 2012	Jun	DISC
>A>		@	12.5MG;300MG	A077969	002	Sep 27, 2012	Jun	DISC
>D>	AB		25MG;300MG	A077969	003	Jul 20, 2016	Jun	DISC
>A>		@	25MG;300MG	A077969	003	Jul 20, 2016	Jun	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

		@ APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004	Apr	DISC
		@	12.5MG;20MG	A076674	002	Oct 05, 2004	Apr	DISC
		@	25MG;20MG	A076674	003	Oct 05, 2004	Apr	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

+	@	MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Apr	DISC
+	@		25MG;100MG	N020387	002	Nov 10, 1998	Apr	DISC

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

		@ APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar	DISC
		@	12.5MG;100MG	A090150	002	Aug 11, 2010	Mar	DISC
		@	25MG;100MG	A090150	003	Oct 06, 2010	Mar	DISC
AB	!	AUROBINDO PHARMA	25MG;100MG	A091629	003	Jan 06, 2010	Apr	CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986	Jan	CAHN
		@	25MG;250MG	A070183	001	Jan 15, 1986	Jan	CAHN
		@	30MG;500MG	A070543	001	Jan 15, 1986	Jan	CAHN
		@	50MG;500MG	A070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987	Jan	CAHN
		@	25MG;80MG	A071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	25MG;25MG	A086881	001		Jan	CAHN
--	--	--------------------	-----------	---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	!	CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Mar	CAHN
----	---	-----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	AB	ZYDUS PHARMS USA INC	25MG;37.5MG	A208360	001	Jun 29, 2018	Jun	NEWA
>A>	AB		50MG;75MG	A208360	002	Jun 29, 2018	Jun	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

		@ APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	DISC
		@	12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	DISC
		@	12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	DISC
		@	25MG;160MG	A203026	004	Mar 21, 2013	Mar	DISC
		@	25MG;320MG	A203026	005	Mar 21, 2013	Mar	DISC

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT		LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	May	CAHN
		@ TARO PHARM INDS LTD	1%	A086155	001		May	CAHN
AT			2.5%	A088799	001	Nov 09, 1984	May	CAHN

	CREAM; TOPICAL								
	HYDROCORTISONE								
AT		2.5%		A088799	001	Nov 09, 1984	May	CAHN	
	LOTION; TOPICAL								
	HYDROCORTISONE								
AT	LANNETT CO INC	2.5%		A040417	001	Jul 30, 2003	May	CAHN	
	<u>HYDROCORTISONE VALERATE</u>								
	CREAM; TOPICAL								
	WESTCORT								
	+ @ SUN PHARM INDS INC	0.2%		N017950	001		Mar	CAHN	
	OINTMENT; TOPICAL								
	WESTCORT								
	+ @ SUN PHARM INDS INC	0.2%		N018726	001	Aug 08, 1983	Feb	CAHN	
	<u>HYDROMORPHONE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	HYDROMORPHONE HYDROCHLORIDE								
AP	EUROHLTH INTL SARL	2MG/ML		A202159	001	Apr 27, 2018	Apr	NEWA	
	TABLET; ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
AB	ASCENT PHARMS INC	2MG		A210506	001	Jan 17, 2018	Jan	NEWA	
AB		4MG		A210506	002	Jan 17, 2018	Jan	NEWA	
AB		8MG		A210506	003	Jan 17, 2018	Jan	NEWA	
	<u>HYDROXYCHLOROQUINE SULFATE</u>								
	TABLET; ORAL								
	HYDROXYCHLOROQUINE SULFATE								
AB	ALKALOIDA ZRT	200MG		A201691	001	May 08, 2018	Apr	NEWA	
AB	AMNEAL PHARMS CO	200MG		A210577	001	May 15, 2018	Apr	NEWA	
AB	APPCO PHARMA LLC	200MG		A210441	001	May 01, 2018	Apr	NEWA	
>A>	AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Jun	NEWA	
	<u>HYDROXYPROGESTERONE CAPROATE</u>								
	SOLUTION; INTRAMUSCULAR								
>A>	HYDROXYPROGESTERONE CAPROATE								
>A>	AP	LUITPOLD PHARMS INC	250MG/ML (250MG/ML)	A210723	001	Jun 21, 2018	Jun	NEWA	
		MAKENA PRESERVATIVE FREE							
>D>	+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CFTG	
>A>	AP	+	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CFTG	
	SOLUTION; SUBCUTANEOUS								
	MAKENA (AUTOINJECTOR)								
	+	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb	NEWA	
	<u>HYDROXYZINE HYDROCHLORIDE</u>								
	TABLET; ORAL								
	ATARAX								
	+ @ PFIZER	10MG		N010392	001		Feb	CRLD	
	+ @	25MG		N010392	004		Feb	CRLD	
	+ @	50MG		N010392	006		Feb	CRLD	
	+ @	100MG		N010392	005		Feb	CRLD	
	<u>IBRUTINIB</u>								
	TABLET; ORAL								
	IMBRUVICA								
	+ PHARMACYCLICS INC	140MG		N210563	001	Feb 16, 2018	Feb	NEWA	
	+	280MG		N210563	002	Feb 16, 2018	Feb	NEWA	
	+	420MG		N210563	003	Feb 16, 2018	Feb	NEWA	
	+	560MG		N210563	004	Feb 16, 2018	Feb	NEWA	
	<u>IBUPROFEN</u>								
	SUSPENSION; ORAL								
	IBUPROFEN								
	AUROBINDO PHARMA LTD	100MG/5ML		A209178	001	Feb 16, 2018	Feb	NEWA	
	<u>IBUTILIDE FUMARATE</u>								
	INJECTABLE; INJECTION								
	IBUTILIDE FUMARATE								
	@ MYLAN INSTITUTIONAL	0.1MG/ML		A090924	001	Jan 11, 2010	Jan	DISC	

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

	@ G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan	DISC
>D> AB	STRIDES PHARMA	5%	A202002	001	Jun 24, 2014	Jun	DISC
>A>	@	5%	A202002	001	Jun 24, 2014	Jun	DISC

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

	@ YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan	CAHN
	@	2.5MG	A074594	002	May 23, 1996	Jan	CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG FLEXTOUCH

>D>	+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Jun	DISC
>A>	+ @		300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Jun	DISC

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO MAX SOLOSTAR

	+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018	Mar	NEWA
	+!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar	CPOT

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240

	@ GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995	May	DISC
--	-----------------	-------	---------	-----	--------------	-----	------

SOLUTION; ORAL

OMNIPAQUE 12

>A>	+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018	Jun	NEWA
>A>	+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018	Jun	NEWA

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

ATROVENT

	+ @	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan	DISC
	+ @		0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan	DISC
AB	!	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan	CHRS
AB	!		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan	CHRS

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB		AMNEAL PHARMS	75MG	A204740	001	Apr 17, 2018	Apr	NEWA
AB			150MG	A204740	002	Apr 17, 2018	Apr	NEWA
AB			300MG	A204740	003	Apr 17, 2018	Apr	NEWA
	@	APOTEX INC	75MG	A200832	001	Oct 15, 2012	Mar	DISC
	@		150MG	A200832	002	Oct 15, 2012	Mar	DISC
	@		300MG	A200832	003	Oct 15, 2012	Mar	DISC
AB		CHARTWELL MOLECULAR	75MG	A077205	001	Nov 14, 2012	Apr	CAHN
AB			150MG	A077205	002	Nov 14, 2012	Apr	CAHN
AB			300MG	A077205	003	Nov 14, 2012	Apr	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

>A> AP		AMPHASTAR PHARMS INC	0.2MG/ML	A210106	001	Jun 18, 2018	Jun	NEWA
AP		CIPLA LTD	0.2MG/ML	A210322	001	Jun 12, 2018	May	NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

@	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Apr	DISC
@		60MG	A209684	002	Oct 24, 2017	Apr	DISC
@		120MG	A209684	003	Oct 24, 2017	Apr	DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET;ORAL
SYMDEKO (COPACKAGED)

+!	VERTEX PHARMS INC	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Feb	NEWA
----	-------------------	------------------------	---------	-----	--------------	-----	------

>D> KANAMYCIN SULFATE

>D> INJECTABLE; INJECTION
>D> KANAMYCIN SULFATE

>D>	FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002	Jun	DISC
>A>	@	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002	Jun	DISC
>D>	!	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002	Jun	DISC
>A>	@	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002	Jun	DISC

KETOCONAZOLE

TABLET;ORAL
KETOCONAZOLE

>A>	AB	STRIDES PHARMA	200MG	A210457	001	Jun 18, 2018	Jun	NEWA
-----	----	----------------	-------	---------	-----	--------------	-----	------

KETOPROFEN

CAPSULE;ORAL
KETOPROFEN

>D>	AB	MYLAN	50MG	A074035	002	Dec 31, 1996	Jun	DISC
>A>		@	50MG	A074035	002	Dec 31, 1996	Jun	DISC
>D>	AB		75MG	A074035	003	Dec 31, 1996	Jun	DISC
>A>		@	75MG	A074035	003	Dec 31, 1996	Jun	DISC

CAPSULE, EXTENDED RELEASE;ORAL
KETOPROFEN

>D>	AB	ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999	Jun	DISC
>A>		@	100MG	A075270	002	Mar 24, 1999	Jun	DISC
>D>	AB		150MG	A075270	003	Mar 24, 1999	Jun	DISC
>A>		@	150MG	A075270	003	Mar 24, 1999	Jun	DISC
>D>	AB		200MG	A075270	001	Mar 24, 1999	Jun	DISC
>A>		@	200MG	A075270	001	Mar 24, 1999	Jun	DISC
>D>	AB	MYLAN	100MG	A075679	003	Feb 20, 2002	Jun	DISC
>A>		@	100MG	A075679	003	Feb 20, 2002	Jun	DISC
>D>	AB		150MG	A075679	002	Feb 20, 2002	Jun	DISC
>A>		@	150MG	A075679	002	Feb 20, 2002	Jun	DISC
>D>	AB	!	200MG	A075679	001	Feb 20, 2002	Jun	CTEC
>A>		!	200MG	A075679	001	Feb 20, 2002	Jun	CTEC

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC
KETOROLAC TROMETHAMINE

AT		SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

TABLET;ORAL
LABETALOL HYDROCHLORIDE

>A>	AB	APPCO PHARMA LLC	100MG	A209603	001	Jun 20, 2018	Jun	NEWA
>A>	AB		200MG	A209603	002	Jun 20, 2018	Jun	NEWA
>A>	AB		300MG	A209603	003	Jun 20, 2018	Jun	NEWA

LACTULOSE

SOLUTION;ORAL
LACTULOSE

AA		BIO-PHARM INC	10GM/15ML	A207786	001	Jun 11, 2018	May	NEWA
AA		LANNETT CO INC	10GM/15ML	A075993	001	Jul 26, 2001	May	CAHN

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

AB		STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018	Apr	NEWA
AB			300MG	A090457	002	Apr 19, 2018	Apr	NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

CIMDUO

+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb	NEWA
	LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE						
	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	May	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>D>	BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Jun	DISC
>A>		@	150MG;300MG	N022018	001	Mar 17, 2017	Jun	DISC
	AB	SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Mar	NEWA

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

	@	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
	@		20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

>D>	AB	MYLAN	2.5MG	A078190	001	Dec 24, 2008	Jun	DISC
>A>		@	2.5MG	A078190	001	Dec 24, 2008	Jun	DISC

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Mar	NEWA
--	--------------------	-----------------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON

	+ @	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb	CRLD
		LUPRON DEPOT						
>D>	+!	ABBVIE ENDOCRINE INC	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CHRS
>A>		+	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CHRS
>D>		+	45MG/VIAL	N020517	003	Jun 17, 2011	Jun	CHRS
>A>		+!	45MG/VIAL	N020517	003	Jun 17, 2011	Jun	CHRS

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP		AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Apr	NEWA
AP		HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Mar	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA		ACI HEALTHCARE LTD	100MG/ML	A078582	001	Jan 15, 2009	May	CAHN
AA		LANNETT CO INC	100MG/ML	A090079	001	Apr 11, 2012	May	CAHN

TABLET; ORAL

LEVETIRACETAM

	@	FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan	CAHN
	@		500MG	A077324	002	Jan 15, 2009	Jan	CAHN
	@		750MG	A077324	003	Jan 15, 2009	Jan	CAHN
	@		1GM	A077324	004	Jan 15, 2009	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>D>	AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Jun	DISC
>A>		@	500MG	A091291	001	Sep 12, 2011	Jun	DISC
>D>	AB		750MG	A091291	002	Sep 12, 2011	Jun	DISC
>A>		@	750MG	A091291	002	Sep 12, 2011	Jun	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Jan	CAHN
--	---	--------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

	+ @	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb	DISC
	+ @		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb	DISC

LEVOFLOXACIN

AP	!	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar	CHRS
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar	CHRS
	@	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar	DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar	DISC
>D>	AP	MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	DISC
>A>	@		EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	DISC
>D>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	DISC
>A>	@		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	DISC
	@	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb	DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb	DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan	CAHN
AP	!		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan	CAHN
AP	!		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan	CAHN

SOLUTION; ORAL

LEVOFLOXACIN

AA	!	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	May	CTEC
AA		LANNETT CO INC	250MG/10ML	A205222	001	May 25, 2018	May	NEWA

TABLET; ORAL

LEVAQUIN

	+ @	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb	DISC
	+ @		500MG	N020634	002	Dec 20, 1996	Feb	DISC
	+ @		750MG	N020634	003	Sep 08, 2000	Feb	DISC

LEVOFLOXACIN

AB	!	AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb	CHRS
----	---	----------------------	-------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

AP	+!	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	CDFR
		LEVOLEUCOVORIN CALCIUM						
AP		ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	May	CDFR
	+!		EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May	CDFR
AP		AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	May	CDFR
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	May	CDFR

SOLUTION; INTRAVENOUS

FUSILEV

	+ @	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	May	CDFR
	+ @		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	May	CDFR

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	May	CDFR
AP		INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May	CDFR
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May	CDFR
AP		MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	May	CDFR
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	May	CDFR
AP		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	May	CDFR
AP	!		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	May	CDFR

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP		INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr	NEWA
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr	NEWA

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
FETZIMA

+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

LEVORPHANOL TARTRATETABLET;ORAL
LEVORPHANOL TARTRATE

>A>	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Jun NEWA
>A>		3MG	A074278	003	Jun 18, 2018	Jun NEWA

LEVOTHYROXINE SODIUMCAPSULE;ORAL
TIROSINT

+	INSTITUT BIOCHIMIQUE	0.15MG	N021924	007	Oct 13, 2006	May CHRS
+!		0.200MG	N021924	012	Apr 25, 2017	May CHRS

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan CAHN
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jan CAHN

LIDOCAINEOINTMENT;TOPICAL
LIDOCAINE

AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan NEWA
----	-----------------	----	---------	-----	--------------	----------

PATCH;TOPICAL
ZTLIDO

+!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP	SPECTRA MDCL DEVICES	1%	A208017	001	Apr 18, 2018	Apr NEWA
>D>	AP	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE	N017702	001		Jun DISC
>A>	@	20%	N017702	001		Jun DISC

SOLUTION;ORAL
LIDOCAINE HYDROCHLORIDE VISCOUS

AT	! LANNETT CO INC	2%	A040708	001	Feb 27, 2007	May CAHN
----	------------------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

AT	LANNETT CO INC	4%	A040710	001	Feb 27, 2007	May CAHN
----	----------------	----	---------	-----	--------------	----------

LIDOCAINE; PRILOCAINECREAM;TOPICAL
LIDOCAINE AND PRILOCAINE

>A>	AB	TELIGENT PHARMA INC	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun NEWA
-----	----	---------------------	-----------	---------	-----	--------------	----------

LINACLOTIDECAPSULE;ORAL
LINZESS

+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan CAHN
+		145MCG	N202811	001	Aug 30, 2012	Jan CAHN
+!		290MCG	N202811	002	Aug 30, 2012	Jan CAHN

LINDANELOTION;TOPICAL
LINDANE

>D>	AT	OLTA PHARMS	1%	A087313	001		Jun CTEC
>A>	!		1%	A087313	001		Jun CHRS
>A>			1%	A087313	001		Jun CTEC
>D>	AT	! WOCKHARDT	1%	A088190	001	Aug 16, 1984	Jun DISC
>A>	@		1%	A088190	001	Aug 16, 1984	Jun DISC

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	May	CDFR	
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	May	CDFR	
AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May	CDFR	
AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	May	CDFR	
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	May	CDFR	
AP	NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A207354	001	Dec 20, 2016	May	CDFR	
AP		600MG/300ML (2MG/ML)	A207354	002	Dec 20, 2016	May	CDFR	
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	May	CDFR	
AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	May	CDFR	
AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	May	CDFR	
AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May	CDFR	
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	May	CDFR
		ZYVOX						
AP	+	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May	CDFR
	+		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May	CDFR
AP	+!		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May	CDFR

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

	+	ALLERGAN SALES LLC	0.0125MG;0.0031MG	N016807	001		Apr	CAHN
		THYROLAR-0.5						
	+	ALLERGAN SALES LLC	0.025MG;0.0063MG	N016807	005		Apr	CAHN
		THYROLAR-1						
	+	ALLERGAN SALES LLC	0.05MG;0.0125MG	N016807	004		Apr	CAHN
		THYROLAR-2						
	+	ALLERGAN SALES LLC	0.1MG;0.025MG	N016807	002		Apr	CAHN
		THYROLAR-3						
	+!	ALLERGAN SALES LLC	0.15MG;0.0375MG	N016807	003		Apr	CAHN
		THYROLAR-5						
	@	ALLERGAN SALES LLC	0.25MG;0.0625MG	N016807	006		Apr	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	CASI PHARMS INC	2.5MG	A075994	001	Jul 01, 2002	Mar	CAHN
AB		5MG	A075994	002	Jul 01, 2002	Mar	CAHN
AB		10MG	A075994	003	Jul 01, 2002	Mar	CAHN
AB		20MG	A075994	004	Jul 01, 2002	Mar	CAHN
AB		30MG	A075994	005	Jul 01, 2002	Mar	CAHN
AB		40MG	A075994	006	Jul 01, 2002	Mar	CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LUCEMYRA

	+!	US WORLDMEDS LLC	EQ 0.18MG BASE	N209229	001	May 16, 2018	May	NEWA
--	----	------------------	----------------	---------	-----	--------------	-----	------

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

>D>	+	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jun	DISC
>A>	+	@	5MG	N017588	004	Dec 19, 2014	Jun	DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

>D>	@	J AND J CONSUMER INC	2MG	N017694	001		Jun	CRLD
>A>	+	@	2MG	N017694	001		Jun	CRLD
		LOPERAMIDE HYDROCHLORIDE						
	@	YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Jan	CAHN

LORAZEPAM

TABLET; ORAL

LORAZEPAM

@	ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991	May CMS1
@		1MG	A072555	003	Mar 29, 1991	May CMS1
@	MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan CMS1
@		1MG	A071591	003	Oct 13, 1987	Jan CMS1
@	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	May DISC
@		1MG	A076045	002	Aug 29, 2001	May DISC
@		2MG	A076045	003	Aug 29, 2001	May DISC

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

+	@	MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Apr DISC
+	@		50MG	N020386	002	Apr 14, 1995	Apr DISC
		LOSARTAN POTASSIUM					
@		APOTEX CORP	25MG	A090790	001	Oct 06, 2010	Mar DISC
@			50MG	A090790	002	Oct 06, 2010	Mar DISC
@			100MG	A090790	003	Oct 06, 2010	Mar DISC

LUTETIUM DOTATATE LU-177

SOLUTION; IV (INFUSION)

LUTATHERA

+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan NEWA
---	---	-------------	----------	---------	-----	--------------	----------

MACIMORELIN ACETATE

FOR SOLUTION; ORAL

MACRILEN

+	!	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May CMS1
+	!		EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Apr CRLD
		PLASMA-LYTE A IN PLASTIC CONTAINER					
+	!	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982	Apr CRLD

MALATHION

LOTION; TOPICAL

OVIDE

AT	+	!	TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---	---	---------------------	------	---------	-----	--------------	----------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar CRLD
---	---	---------	-----------------------	---------	-----	--------------	----------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	!	ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001		Mar CRLD
---	---	-----------------	--------------------------	---------	-----	--	----------

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

+	@	JANSSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb DISC
---	---	-----------------	-------	---------	-----	--------------	----------

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@		FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
@			EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEFENAMIC ACID

	CAPSULE;ORAL							
	MEFENAMIC ACID							
AB	MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN	

MELOXICAM

	TABLET;ORAL							
	MELOXICAM							
>D>	AB	MYLAN	7.5MG	A077923	001	Jul 19, 2006	Jun	DISC
>A>		@	7.5MG	A077923	001	Jul 19, 2006	Jun	DISC
>D>	AB		15MG	A077923	002	Jul 19, 2006	Jun	DISC
>A>		@	15MG	A077923	002	Jul 19, 2006	Jun	DISC

MEMANTINE HYDROCHLORIDE

	SOLUTION;ORAL							
	MEMANTINE HYDROCHLORIDE							
AA	APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA	
AA	! BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Apr	CHRS	
	NAMENDA							
	+ @ ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005	Apr	DISC	
AA	+!	2MG/ML	N021627	001	Apr 18, 2005	Jan	CAHN	
	TABLET;ORAL							
	MEMANTINE HYDROCHLORIDE							
>A>	AB	APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jun	NEWA
>A>	AB		10MG	A090244	002	Jul 11, 2018	Jun	NEWA
	AB	CSPC OUYI PHARM CO	5MG	A209527	001	May 07, 2018	Apr	NEWA
	AB		10MG	A209527	002	May 07, 2018	Apr	NEWA
	NAMENDA							
	+ ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan	CAHN	
	+!	10MG	N021487	002	Oct 16, 2003	Jan	CAHN	

MEROPENEM

	INJECTABLE;INJECTION							
	MEROPENEM							
AP	ACS DOBFAR SPA	500MG/VIAL	A204139	001	Jun 09, 2016	Apr	CAHN	
AP		1GM/VIAL	A204139	002	Jun 09, 2016	Apr	CAHN	

MEROPENEM; VABORBACTAM

	POWDER;IV (INFUSION)							
	VABOMERE							
	+! REMPEX PHARMS	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	Jan	CAHN	

MESALAMINE

	ENEMA;RECTAL							
	MESALAMINE							
	@ G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan	DISC	
	SUPPOSITORY;RECTAL							
	CANASA							
	@ ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan	CAHN	
AB	+!	1GM	N021252	002	Nov 05, 2004	Jan	CAHN	
	TABLET, DELAYED RELEASE;ORAL							
	MESALAMINE							
AB	ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018	Mar	NEWA	

MESNA

	INJECTABLE;INTRAVENOUS							
	MESNA							
	@ MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan	DISC	

METARAMINOL BITARTRATE

	INJECTABLE;INJECTION							
	METARAMINOL BITARTRATE							
	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb	DISC	

METAXALONE

	TABLET;ORAL							
	METAXALONE							
	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan	CAHN	
	@ PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Jan	CAHN	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	PROVIDENT PHARM	500MG	A 077853	001	Jul 28, 2006	Jun	DISC
>A>		@	500MG	A 077853	001	Jul 28, 2006	Jun	DISC
>D>	AB		850MG	A 077853	002	Jul 28, 2006	Jun	DISC
>A>		@	850MG	A 077853	002	Jul 28, 2006	Jun	DISC
>D>	AB		1GM	A 077853	003	Jul 28, 2006	Jun	DISC
>A>		@	1GM	A 077853	003	Jul 28, 2006	Jun	DISC
		@ SANDOZ	500MG	A 075985	001	Jan 25, 2002	Mar	DISC
		@	850MG	A 075985	002	Jan 25, 2002	Mar	DISC
		@	1GM	A 075985	003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1		ALIGNSCIENCE PHARMA	500MG	A 209303	001	Mar 19, 2018	Mar	NEWA
AB1		GRANULES INDIA LTD	500MG	A 209313	001	Mar 16, 2018	Mar	NEWA
AB			750MG	A 209313	002	Mar 16, 2018	Mar	NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

		@ LUPIN LTD	500MG;1MG	A 200624	001	Jul 15, 2015	May	DISC
		@	500MG;2MG	A 200624	002	Jul 15, 2015	May	DISC

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

		@ TEVA	500MG;EQ 2MG BASE	A 077337	001	May 07, 2014	Apr	DISC
		@	500MG;EQ 1MG BASE	A 077337	005	May 19, 2017	Apr	DISC
		@	500MG;EQ 4MG BASE	A 077337	002	May 07, 2014	Apr	DISC
		@	1GM;EQ 4MG BASE	A 077337	004	May 07, 2014	Apr	DISC
		@	1GM;EQ 2MG BASE	A 077337	003	May 07, 2014	Apr	DISC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA		SUN PHARM INDUSTRIES	5MG	A 208305	001	Mar 30, 2018	Mar	NEWA
AA			10MG	A 208305	002	Mar 30, 2018	Mar	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		CASI PHARMS INC	5MG	A 040411	001	Mar 27, 2001	Mar	CAHN
AB			10MG	A 040411	002	Mar 27, 2001	Mar	CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP		FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A 209331	001	Apr 17, 2018	Apr	NEWA
----	--	--------------------	---------------------	----------	-----	--------------	-----	------

TABLET; ORAL

METHOCARBAMOL

AA		ALLIED PHARMA INC	500MG	A 203550	001	Feb 08, 2017	Feb	CAHN
AA			750MG	A 203550	002	Feb 08, 2017	Feb	CAHN
AA		DBL PHARMS	500MG	A 203550	001	Feb 08, 2017	May	CAHN
AA			750MG	A 203550	002	Feb 08, 2017	May	CAHN
		@ FOSUN PHARMA	500MG	A 084616	001		Jan	CAHN
		@	750MG	A 084615	001		Jan	CAHN
AA		GRANULES INDIA LTD	500MG	A 209312	001	May 07, 2018	Apr	NEWA
AA			750MG	A 209312	002	May 07, 2018	Apr	NEWA

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+	!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N 205776	001	Jul 10, 2014	Apr	CHRS
+	!		10MG/0.20ML (10MG/0.20ML)	N 205776	002	Jul 10, 2014	Apr	CHRS
+	!		12.5MG/0.25ML (12.5MG/0.25ML)	N 205776	003	Jul 10, 2014	Apr	CHRS
+	!		15MG/0.30ML (15MG/0.30ML)	N 205776	004	Jul 10, 2014	Apr	CHRS
+	!		17.5MG/0.35ML (17.5MG/0.35ML)	N 205776	005	Jul 10, 2014	Apr	CHRS
+	!		20MG/0.4ML (20MG/0.4ML)	N 205776	006	Jul 10, 2014	Apr	CHRS
+	!		22.5MG/0.45ML (22.5MG/0.45ML)	N 205776	007	Jul 10, 2014	Apr	CHRS
+	!		25MG/0.5ML (25MG/0.5ML)	N 205776	008	Jul 10, 2014	Apr	CHRS

SOLUTION;SUBCUTANEOUS
RASUVO

+!	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CHRS
----	-------------------------	---------	-----	--------------	----------

METHSUXIMIDECAPSULE;ORAL
CELONTIN

>D>	+ PARKE DAVIS	150MG	N010596	007	Jun DISC
>A>	+ @	150MG	N010596	007	Jun DISC

METHYLCLOTHIAZIDETABLET;ORAL
METHYLCLOTHIAZIDE

@ YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988	Jan CAHN
@	5MG	A089837	001	Aug 18, 1988	Jan CAHN

METHYLDOPATABLET;ORAL
METHYLDOPA

@ YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988	Jan CAHN
@	250MG	N018934	001	Jun 29, 1984	Jan CAHN
@	500MG	N018934	002	Jun 29, 1984	Jan CAHN

METHYLERGONOVINE MALEATETABLET;ORAL
METHYLERGONOVINE MALEATE

AB	GRANULES PHARMS	0.2MG	A210424	001	May 15, 2018	Apr NEWA
AB	! NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr CTEC

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
METADATE CD

AB2	+ LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar CAHN
AB2	+	20MG	N021259	001	Apr 03, 2001	Mar CAHN
AB2	+	30MG	N021259	002	Jun 19, 2003	Mar CAHN
AB2	+	40MG	N021259	004	Feb 19, 2006	Mar CAHN
AB2	+	50MG	N021259	005	Feb 19, 2006	Mar CAHN
AB2	+!	60MG	N021259	006	Feb 19, 2006	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1	MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb NEWA
-----	--------------	------	---------	-----	--------------	----------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr NEWA
AB	+! NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Apr CFTG

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb NEWA
AB		10MG	A209753	002	Mar 02, 2018	Feb NEWA
AB		20MG	A209753	003	Mar 02, 2018	Feb NEWA
AB	LANNETT CO INC	5MG	A086429	001		Mar CAHN
AB		10MG	A085799	001		Mar CAHN
AB		20MG	A086428	001		Mar CAHN
AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan CAHN
AB		10MG	A091159	002	Mar 12, 2014	Jan CAHN
AB		20MG	A091159	003	Mar 12, 2014	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

AB	@ LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar CAHN
AB	!	20MG	A089601	001	Jun 01, 1988	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar NEWA
AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan NEWA
AB		27MG	A207515	002	Feb 01, 2018	Jan NEWA
AB		36MG	A207515	003	Feb 01, 2018	Jan NEWA
AB		54MG	A207515	004	Feb 01, 2018	Jan NEWA
AB	ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	May CAHN
AB		27MG	A208607	002	Jul 14, 2017	May CAHN
AB		36MG	A208607	003	Jul 14, 2017	May CAHN
AB		54MG	A208607	004	Jul 14, 2017	May CAHN
AB	MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan CAHN
AB		27MG	A208607	002	Jul 14, 2017	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

	METHYLPHENIDATE HYDROCHLORIDE						
AB		36MG	A208607	003	Jul 14, 2017	Jan	CAHN
AB		54MG	A208607	004	Jul 14, 2017	Jan	CAHN
!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS

METHYLPREDNISOLONE

TABLET;ORAL

	METHYLPREDNISOLONE						
AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr	NEWA
AB	ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr	NEWA
AB		8MG	A206751	002	Apr 23, 2018	Apr	NEWA
AB		16MG	A206751	003	Apr 23, 2018	Apr	NEWA
AB		32MG	A206751	004	Apr 23, 2018	Apr	NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

>D>	+	PHARMACIA AND UPJOHN	20MG/ML	N011757	002		Jun	CFTG
>A>	AB	+	20MG/ML	N011757	002		Jun	CFTG
>A>		METHYLPREDNISOLONE ACETATE						
>A>	AB	SAGENT PHARMS	20MG/ML	A201835	001	Jun 27, 2018	Jun	NEWA
>A>	AB		40MG/ML	A201835	002	Jun 27, 2018	Jun	NEWA
>A>	AB		80MG/ML	A201835	003	Jun 27, 2018	Jun	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@ YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan	CAHN
	@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan	CAHN
	@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	CAHN

METOLAZONE

TABLET;ORAL

MYKROX

	@ LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Apr	CAHN	
AB	+	LANNETT CO INC	2.5MG	N017386	001		Mar	CAHN
AB	+	!	5MG	N017386	002		Mar	CAHN
AB	+	!	10MG	N017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

>A>	+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jun	CTNA
>A>	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jun	CTNA
>A>	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jun	CTNA
>A>	+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jun	CTNA
>D>		METOPROLOL SUCCINATE						
>D>	+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jun	CTNA
	+		EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
>D>	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jun	CTNA
	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
>D>	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jun	CTNA
	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
>D>	+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jun	CTNA
	+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Mar	CMS1
AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA
AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA
AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A203894	001	Mar 23, 2018	Mar	NEWA
AB		EQ 50MG TARTRATE	A203894	002	Mar 23, 2018	Mar	NEWA
AB		EQ 100MG TARTRATE	A203894	003	Mar 23, 2018	Mar	NEWA
AB		EQ 200MG TARTRATE	A203894	004	Mar 23, 2018	Mar	NEWA

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN
@		100MG	A074453	002	Apr 27, 1995	Jan	CAHN
@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN
@		100MG	A073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan	CAHN
@		250MG	N018740	001	Oct 22, 1982	Jan	CAHN
@		500MG	N018620	002	Jun 02, 1983	Jan	CAHN
@		500MG	N018740	002	Oct 22, 1982	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+	@	GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997	May	DISC
	@	ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May	DISC

METYRAPONE

CAPSULE; ORAL

METOPIRONE

>D>	+	HRA PHARMA	250MG	N012911	002	Aug 09, 1996	Jun	CAHN
>A>	+	LABORATORIE HRA	250MG	N012911	002	Aug 09, 1996	Jun	CAHN

TABLET; ORAL

METOPIRONE

>D>	@	HRA PHARMA	250MG	N012911	001		Jun	CAHN
>A>	@	LABORATORIE HRA	250MG	N012911	001		Jun	CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MYCAMINE

+	!	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May	CDFR
+	!		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB		APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
AB			5MG	A077746	002	Sep 12, 2006	Feb	CTEC
AB			10MG	A077746	003	Sep 12, 2006	Feb	CTEC
AB		CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
AB			5MG	A076514	002	Sep 11, 2003	Mar	CAHN
AB			10MG	A076514	003	Jul 02, 2004	Mar	CAHN

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB		AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018	Apr	NEWA	
AB	+	!	ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003	Apr	CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar	CAHN
@		25MG	A205071	002	Jan 27, 2016	Mar	CAHN
@		50MG	A205071	003	Jan 27, 2016	Mar	CAHN
@		100MG	A205071	004	Jan 27, 2016	Mar	CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

+	!	REMPEX PHARMS	EQ 100MG BASE/VIAL	N050444	001		Jan	CAHN
---	---	---------------	--------------------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 65MG BASE	A204453	006	Mar 16, 2018	Mar	NEWA
AB			EQ 115MG BASE	A204453	007	Mar 16, 2018	Mar	NEWA
AB		BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Jan	CMFD

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		EQ 115MG BASE	A065485	005	May 18, 2012	Jan	CMFD
	SOLODYN						
AB	+ MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar	CTEC
AB	+!	EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar	CTEC

MINOXIDIL

TABLET;ORAL
MINOXIDIL

>A>	AB	SUN PHARM INDUSTRIES	2.5MG	A072709	002	Dec 14, 1995	Jun	CMS1
>D>		<u>MIPOMERSEN SODIUM</u>						
>D>		SOLUTION;SUBCUTANEOUS						
>D>		KYNAMRO						
>D>	+!	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	DISC
>A>	+ @		200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

>D>	AB	ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003	Jun	DISC
>A>	@		15MG	A076307	001	Dec 17, 2003	Jun	DISC
>D>	AB		30MG	A076307	002	Dec 17, 2003	Jun	DISC
>A>	@		30MG	A076307	002	Dec 17, 2003	Jun	DISC
>D>	AB		45MG	A076307	003	Feb 28, 2006	Jun	DISC
>A>	@		45MG	A076307	003	Feb 28, 2006	Jun	DISC

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

	@	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	May	DISC
	@		20MG/VIAL	A064117	002	Apr 19, 1995	May	DISC
	@		40MG/VIAL	A064117	003	Jun 02, 1999	May	CMS1
>D>		<u>MIVACURIUM CHLORIDE</u>						
>D>		SOLUTION;INTRAVENOUS						
>D>		MIVACRON						
>D>	+	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jun	DISC
>A>	+ @		EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jun	DISC
>D>	+!		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jun	DISC
>A>	+ @		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jun	DISC

MONTELUKAST SODIUM

TABLET;ORAL
MONTELUKAST SODIUM

	@	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012	Mar	DISC
		TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM						
	@	APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012	Mar	DISC
	@		EQ 5MG BASE	A201508	002	Aug 03, 2012	Mar	DISC
>A>	AB	UNICHEM LABS LTD	EQ 4MG BASE	A208621	001	Jul 02, 2018	Jun	NEWA
>A>	AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Jun	NEWA

MORPHINE SULFATE

SOLUTION;ORAL
MORPHINE SULFATE

AA		ANI PHARMS INC	10MG/5ML	A205509	001	Apr 17, 2018	Apr	NEWA
AA			20MG/5ML	A205509	002	Apr 17, 2018	Apr	NEWA
AA			100MG/5ML	A205509	003	Apr 17, 2018	Apr	NEWA
AA		LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	May	CAHN
AA			20MG/5ML	A202310	001	Oct 30, 2015	May	CAHN

>A>		<u>MOXIDECTIN</u>						
>A>		TABLET;ORAL						
>A>		MOXIDECTIN						
>A>	+!	MDGH	2MG	N210867	001	Jun 13, 2018	Jun	NEWA

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ @	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Apr	DISC
-----	-----------------	------------	---------	-----	--------------	-----	------

MUPIROICIN

!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CHRS
---	---------------------	------------	---------	-----	--------------	-----	------

OINTMENT; NASAL

BACTROBAN

+ @	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995	May	DISC
-----	-----------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

@	APOTEX CORP	250MG	A090419	001	Apr 22, 2009	Mar	DISC
---	-------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

@	APOTEX	500MG	A090499	001	Apr 22, 2009	Mar	DISC
---	--------	-------	---------	-----	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	CASI PHARMS INC	500MG	A075280	001	Feb 25, 2002	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

AB		750MG	A075280	002	Feb 25, 2002	Mar	CAHN
----	--	-------	---------	-----	--------------	-----	------

NADOLOL

TABLET; ORAL

NADOLOL

AB	RICONPHARMA LLC	20MG	A210786	001	Jun 01, 2018	May	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

AB		40MG	A210786	002	Jun 01, 2018	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		80MG	A210786	003	Jun 01, 2018	May	NEWA
----	--	------	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

>D>	AB	!	TARO	1%	A205975	001	Sep 08, 2016	Apr	CHRS
-----	----	---	------	----	---------	-----	--------------	-----	------

>D>	AB			2%	A206901	001	Jan 06, 2016	Jun	CAHN
-----	----	--	--	----	---------	-----	--------------	-----	------

>A>	AB	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016	May	CAHN
-----	----	---	-------------	----	---------	-----	--------------	-----	------

>A>	AB			2%	A206901	001	Jan 06, 2016	Jun	CAHN
-----	----	--	--	----	---------	-----	--------------	-----	------

NAFTIN

+ @	SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Apr	DISC
-----	--------------------	----	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NARCAN

+ @	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Apr	DISC
-----	-------	-----------	---------	-----	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000	Jan	CAHN
---	--------------	------	---------	-----	--------------	-----	------

>D> NAPHAZOLINE HYDROCHLORIDE

>D> SOLUTION/DROPS; OPHTHALMIC

>D> NAPHAZOLINE HYDROCHLORIDE

>D>		!	AKORN INC	0.1%	A083590	001		Jun	DISC
-----	--	---	-----------	------	---------	-----	--	-----	------

>A>		@		0.1%	A083590	001		Jun	DISC
-----	--	---	--	------	---------	-----	--	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

@	FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993	Jan	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

@		375MG	A074140	002	Dec 21, 1993	Jan	CAHN
---	--	-------	---------	-----	--------------	-----	------

@		500MG	A074140	003	Dec 21, 1993	Jan	CAHN
---	--	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@	FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998	Jan	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

@		500MG	A075061	002	Feb 18, 1998	Jan	CAHN
---	--	-------	---------	-----	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018	Feb NEWA
		TREXIMET					
>D>	+	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun DISC
>A>	+ @		60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun DISC
AB	+!		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Feb CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

	@	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar DISC
	@		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar DISC
AB		CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar CAHN
AB			EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar CAHN

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

>A>	AB	INDICUS PHARMA	60MG	A205544	001	Jun 18, 2018	Jun NEWA
>A>	AB		120MG	A205544	002	Jun 18, 2018	Jun NEWA
>A>	AB	WILSHIRE PHARMS INC	60MG	A205544	001	Jun 18, 2018	Jun CAHN
>A>	AB		120MG	A205544	002	Jun 18, 2018	Jun CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

AB	+	ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Feb CFTG
	+		EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Jan CAHN
AB	+		EQ 5MG BASE	N021742	003	Dec 17, 2007	Feb CFTG
	+		EQ 5MG BASE	N021742	003	Dec 17, 2007	Jan CAHN
AB	+		EQ 10MG BASE	N021742	004	Dec 17, 2007	Feb CFTG
	+		EQ 10MG BASE	N021742	004	Dec 17, 2007	Jan CAHN
AB	+!		EQ 20MG BASE	N021742	005	Oct 08, 2008	Feb CFTG
	+!		EQ 20MG BASE	N021742	005	Oct 08, 2008	Jan CAHN

NEBIVOLOL HYDROCHLORIDE

	@	TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar DISC
AB			EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Feb NEWA
	@		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar DISC
AB			EQ 5MG BASE	A203966	002	Mar 02, 2018	Feb NEWA
	@		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar DISC
AB			EQ 10MG BASE	A203966	003	Mar 02, 2018	Feb NEWA
	@		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar DISC
AB			EQ 20MG BASE	A203966	004	Mar 02, 2018	Feb NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

	+!	ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jan CAHN
--	----	--------------------	------------------	---------	-----	--------------	----------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	@	FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jan CAHN
	@		100MG	A076302	002	Sep 16, 2003	Jan CAHN
	@		150MG	A076302	003	Sep 16, 2003	Jan CAHN
	@		200MG	A076302	004	Sep 16, 2003	Jan CAHN
	@		250MG	A076302	005	Sep 16, 2003	Jan CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN

NEOSTIGMINE METHYLSULFATE

>A>	AP	AMNEAL PHARMS CO	5MG/10ML (0.5MG/ML)	A210051	001	Jun 15, 2018	Jun NEWA
>A>	AP		10MG/10ML (1MG/ML)	A210051	002	Jun 15, 2018	Jun NEWA
>A>	AP	DR REDDYS LABS LTD	5MG/10ML (0.5MG/ML)	A209135	001	Jul 10, 2018	Jun NEWA
>A>	AP		10MG/10ML (1MG/ML)	A209135	002	Jul 10, 2018	Jun NEWA
AP		LUITPOLD PHARMS INC	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr NEWA

SOLUTION; INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

AP 10MG/10ML (1MG/ML) A209182 002 May 04, 2018 Apr NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

@ APOTEX INC 200MG A203021 001 May 22, 2012 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

@ APOTEX INC 400MG A205258 001 Apr 03, 2014 Jan DISC

@ TECH ORGANIZED 100MG A207467 001 Jul 31, 2017 Mar DISC

@ 400MG A207467 002 Jul 31, 2017 Mar DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB AUROBINDO PHARMA LTD 500MG A209236 001 Feb 01, 2018 Jan NEWA

AB 750MG A209236 002 Feb 01, 2018 Jan NEWA

AB 1GM A209236 003 Feb 01, 2018 Jan NEWA

AB JUBILANT GENERICS 500MG A209156 001 May 14, 2018 Apr NEWA

AB 750MG A209156 002 May 14, 2018 Apr NEWA

AB 1GM A209156 003 May 14, 2018 Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

+ @ CHIESI USA INC 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992 May DISC

NICARDIPINE HYDROCHLORIDE

EXELA PHARMA SCIENCE 25MG/10ML (2.5MG/ML) N022276 001 Jul 24, 2008 May CTEC

@ LUITPOLD PHARMS INC 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 May DISC

@ MYLAN INSTITUTIONAL 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 May DISC

@ NAVINTA LLC 25MG/10ML (2.5MG/ML) A090125 001 Nov 17, 2009 May DISC

@ SUN PHARMA GLOBAL 25MG/10ML (2.5MG/ML) N078405 001 Nov 17, 2009 May DISC

@ WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML) A078714 001 Dec 28, 2009 May DISC

@ WOCKHARDT 25MG/10ML (2.5MG/ML) A090671 001 Nov 17, 2009 May DISC

INJECTABLE; INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ @ CHIESI USA INC 40MG/200ML (0.2MG/ML) N019734 005 Nov 07, 2008 Mar DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>A> AB1 ZYDUS PHARMS USA INC 30MG A210184 001 Jun 29, 2018 Jun NEWA

>A> AB1 60MG A210184 002 Jun 29, 2018 Jun NEWA

>A> AB1 90MG A210184 003 Jun 29, 2018 Jun NEWA

>A> NILOTINIB HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> TASIGNA

>A> + NOVARTIS EQ 50MG BASE N022068 003 Mar 22, 2018 Jun CAIN

>A> + EQ 150MG BASE N022068 002 Jun 17, 2010 Jun CAIN

>A> +! EQ 200MG BASE N022068 001 Oct 29, 2007 Jun CAIN

>D> NILOTINIB HYDROCHLORIDE MONOHYDRATE

>D> CAPSULE; ORAL

>D> TASIGNA

>D> + NOVARTIS EQ 50MG BASE N022068 003 Mar 22, 2018 Jun CAIN

+ EQ 50MG BASE N022068 003 Mar 22, 2018 Mar NEWA

>D> + EQ 150MG BASE N022068 002 Jun 17, 2010 Jun CAIN

>D> +! EQ 200MG BASE N022068 001 Oct 29, 2007 Jun CAIN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

>A> AB NOVEL LABS INC 50MG A203233 001 Jul 09, 2018 Jun NEWA

>A> AB 100MG A203233 002 Jul 09, 2018 Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		SUNNY PHARMTECH INC	75MG;25MG	A208516	001	May 24, 2018	May NEWA
----	--	---------------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

>D>	AP	HOSPIRA	10MG/100ML	A071846	001	Aug 31, 1990	Jun DISC
>A>		@	10MG/100ML	A071846	001	Aug 31, 1990	Jun DISC
>D>	AP		20MG/100ML	A071847	001	Aug 31, 1990	Jun DISC
>A>		@	20MG/100ML	A071847	001	Aug 31, 1990	Jun DISC
>D>	AP		40MG/100ML	A071848	001	Aug 31, 1990	Jun DISC
>A>		@	40MG/100ML	A071848	001	Aug 31, 1990	Jun DISC

OINTMENT;INTRA-ANAL

RECTIV

+	!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan CAHN
---	---	--------------------	------	---------	-----	--------------	----------

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan CAHN
AB			0.4MG	A206391	002	Sep 19, 2017	Jan CAHN
AB			0.6MG	A206391	003	Sep 19, 2017	Jan CAHN
AB		SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Apr NEWA
AB			0.4MG	A207745	002	May 07, 2018	Apr NEWA
AB			0.6MG	A207745	003	May 07, 2018	Apr NEWA

NORETHINDRONE ACETATE

TABLET;ORAL

AYGESTIN

+	@	DURAMED RES	5MG	N018405	001	Apr 21, 1982	May DISC
---	---	-------------	-----	---------	-----	--------------	----------

NORETHINDRONE ACETATE

AB	!	BARR	5MG	A075951	001	May 25, 2001	May CHRS
----	---	------	-----	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992	Mar CMS1
AB			EQ 25MG BASE	A073556	003	Mar 30, 1992	Mar CMS1
AB			EQ 50MG BASE	A073556	004	Mar 30, 1992	Mar CMS1

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

		@ G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Jan DISC
AT		LYNE	100,000 UNITS/GM	A209082	001	May 21, 2018	May NEWA
AT		ZYDUS PHARMS USA INC	100,000 UNITS/GM	A207767	001	May 25, 2018	May NEWA

POWDER;TOPICAL

NYSTATIN

AT		EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Apr NEWA
----	--	-----------------	------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

NYSTATIN

>D>		@ ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN
		@ G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Jan DISC
AA		LANNETT CO INC	100,000 UNITS/ML	A065148	001	Jun 28, 2005	May CAHN
>A>		@ SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN

>D> TABLET;VAGINAL

>D> NYSTATIN

>D>	!	ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985	Jun DISC
>A>		@	100,000 UNITS	A062615	001	Oct 17, 1985	Jun DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AMNEAL PHARMS LLC	100,000 UNITS/GM;0.1%	A209990	001	Feb 15, 2018	Feb NEWA
AT		LUPIN LTD	100,000 UNITS/GM;0.1%	A208205	001	May 31, 2018	May NEWA

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Jan NEWA
----	--	----------------	-----------------------	---------	-----	--------------	----------

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

	@ AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	Mar	DISC
	@	10MG	A204320	002	May 30, 2017	Mar	DISC
	@	15MG	A204320	003	May 30, 2017	Mar	DISC
	@	20MG	A204320	004	May 30, 2017	Mar	DISC
>A>	AB	HEC PHARM CO LTD	5MG	A208146	001	Jul 02, 2018	Jun NEWA
>A>	AB		10MG	A208146	002	Jul 02, 2018	Jun NEWA
>A>	AB		15MG	A208146	003	Jul 02, 2018	Jun NEWA
>A>	AB		20MG	A208146	004	Jul 02, 2018	Jun NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>A>	AB	SCIEGEN PHARMS INC	5MG	A208130	001	Jun 29, 2018	Jun NEWA
>A>	AB		20MG	A208130	002	Jun 29, 2018	Jun NEWA
>A>	AB		40MG	A208130	003	Jun 29, 2018	Jun NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT		MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar NEWA
AT		MYLAN PHARMS INC	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CAHN
	@	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar DISC

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

>D>							
>D>	+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	Jun DISC
>A>	+	@	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	Jun DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>A>	AB	MYLAN PHARMS INC	10MG	A205070	001	Jun 29, 2018	Jun NEWA
>A>	AB		20MG	A205070	002	Jun 29, 2018	Jun NEWA
>A>	AB		40MG	A205070	003	Jun 29, 2018	Jun NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		ZYDUS PHARMS USA INC	20MG;1.1GM	A203290	001	May 25, 2018	May NEWA
AB			40MG;1.1GM	A203290	002	May 25, 2018	May NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@ CHARTWELL MOLECULES

@

4MG

8MG

A077406	003	Dec 26, 2006	Mar	CMS1
A077406	004	Dec 26, 2006	Mar	CMS1

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar CAHN
AB			EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar CAHN
AB			EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar CAHN

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

+	!	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan CAHN
+	!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb	NEWA
AB		EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb	NEWA
AB		EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb	NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A209421	001	Jun 08, 2018	May	NEWA
AB		EQ 45MG BASE	A209421	002	Jun 08, 2018	May	NEWA
AB		EQ 75MG BASE	A209421	003	Jun 08, 2018	May	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb	NEWA
----	----------------	----------------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>D>	AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Jun	CHRS
>A>	AP	!	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Jun	CHRS
>D>	AP		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Jun	CHRS
>A>	AP	!	EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Jun	CHRS
>D>	AP		EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Jun	CHRS
>A>	AP	!	EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Jun	CHRS
		@ SANDOZ	EQ 1GM BASE/VIAL	A061490	003		May	DISC
		@	EQ 2GM BASE/VIAL	A061490	004		May	DISC
		@	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991	May	DISC

POWDER;INTRAVENOUS

OXACILLIN SODIUM

@ SANDOZ

@

		EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986	May	DISC
		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986	May	DISC

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	NEWA
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	NEWA
AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr	CAHN
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr	CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB	TARO PHARMS	EQ 1% BASE	A205076	001	Mar 07, 2016	May	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

AB	+!	ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	May	CFTG
AB		PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	May	NEWA

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	May	CAHN
----	--	----------------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

>D>		+ @ JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Jun	CMFD
>A>	AB	+	5MG	N020897	001	Dec 16, 1998	Jun	CMFD
		+ @	5MG	N020897	001	Dec 16, 1998	Feb	DISC
>D>		+ @	10MG	N020897	002	Dec 16, 1998	Jun	CMFD
>A>	AB	+	10MG	N020897	002	Dec 16, 1998	Jun	CMFD
		+ @	10MG	N020897	002	Dec 16, 1998	Feb	DISC
		+ @	15MG	N020897	003	Jun 22, 1999	Feb	DISC

OXYBUTYNIN CHLORIDE

AB	!	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb	CHRS
----	---	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	+!	GENUS LIFESCIENCES	5MG	N200534	001	Oct 20, 2010	Apr	CAHN
----	----	--------------------	-----	---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	+	GENUS LIFESCIENCES	5MG/5ML	N200535	002	Aug 22, 2013	Apr CAHN
AA	+	!	100MG/5ML	N200535	001	Oct 20, 2010	Apr CAHN
AA		SPECGX LLC	5MG/5ML	A210758	001	Apr 30, 2018	Apr NEWA
AA			100MG/5ML	A210758	002	Apr 30, 2018	Apr NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan NEWA
AB			10MG	A210175	002	Feb 02, 2018	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

>D>	AB	IMPAX LABS	40MG	A079087	007	Jun 14, 2010	Jun CHRS
>A>	!		40MG	A079087	007	Jun 14, 2010	Jun CHRS
	@	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Mar DISC
	@		7.5MG	A203506	002	Apr 24, 2015	Mar DISC
	@		10MG	A203506	003	Apr 24, 2015	Mar DISC
	@		15MG	A203506	004	Apr 24, 2015	Mar DISC
	@		20MG	A203506	005	Apr 24, 2015	Mar DISC
	@		30MG	A203506	006	Apr 24, 2015	Mar DISC
	@		40MG	A203506	007	Apr 24, 2015	Mar DISC

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB		SUN PHARMA GLOBAL	1.5mg	A205618	001	Apr 06, 2018	Mar NEWA
AB			3MG	A205618	002	Apr 06, 2018	Mar NEWA
AB			6MG	A205618	003	Apr 06, 2018	Mar NEWA
AB			9MG	A205618	004	Apr 06, 2018	Mar NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PANCREAZE

>D>	+	JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014	Jun CAHN
>D>	+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Jun CAHN
	+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar CPOT
>D>	+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Jun CAHN
	+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar CPOT
>D>	+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Jun CAHN
	+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar CPOT
>D>	+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Jun CAHN
	+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar CPOT
>A>	+	VIVUS INC	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014	Jun CAHN
>A>	+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Jun CAHN
>A>	+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Jun CAHN
>A>	+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Jun CAHN
>A>	+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Jun CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Apr	NEWA
	TABLET, DELAYED RELEASE;ORAL						
	PANTOPRAZOLE SODIUM						
	@ SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	DISC
	@	EQ 40MG BASE	A200794	002	May 02, 2012	Apr	DISC

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

>D>	AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016	Jun	CAHN
>D>	AB		2MCG	A206710	002	Feb 24, 2016	Jun	CAHN
>D>	AB		4MCG	A206710	003	Feb 24, 2016	Jun	CAHN
>A>	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Jun	CAHN
>A>	AB		2MCG	A206710	002	Feb 24, 2016	Jun	CAHN
>A>	AB		4MCG	A206710	003	Feb 24, 2016	Jun	CAHN

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB	SCIECURE PHARMA INC	EQ 12.5MG BASE	A209293	001	Jun 12, 2018	May	NEWA
AB		EQ 25MG BASE	A209293	002	Jun 12, 2018	May	NEWA
AB		EQ 37.5MG BASE	A209293	003	Jun 12, 2018	May	NEWA

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT

>A>	+	NOVARTIS PHARMS CORP	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Jun	NEWA
>A>	+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun	CDFR
>A>	+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Jun	NEWA
>A>	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun	CDFR
>A>	+		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun	CDFR
>D>		POWDER;INTRAMUSCULAR						
>D>		SIGNIFOR LAR						
>D>	+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun	CTNA
>D>	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun	CTNA
>D>	+		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun	CTNA
>A>		SIGNIFOR LAR KIT						
>A>	+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun	CTNA
>A>	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun	CTNA
>A>	+		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun	CTNA

PEGADEMASE BOVINE

INJECTABLE;INJECTION
ADAGEN

>A>	+	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Jun	CAHN
>D>	+	SIGMA TAU	250 UNITS/ML	N019818	001	Mar 21, 1990	Jun	CAHN

PEMETREXED DISODIUM

>D>	INJECTABLE;IV (INFUSION)							
>D>	ALIMTA							
>D>	+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	Jun	CDFR
>D>	+		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	Jun	CDFR
>A>	POWDER;INTRAVENOUS							
>A>	ALIMTA							
>A>	+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	Jun	CDFR
>A>	+		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	Jun	CDFR

PEMOLINE

TABLET;ORAL
PEMOLINE

@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
@		37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
@		75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINEINJECTABLE; INJECTION
BICILLIN L-A

>D>	+	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		Jun	DISC
>A>	+	@	300,000 UNITS/ML	N050141	003		Jun	DISC

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINEINJECTABLE; INJECTION
BICILLIN C-R

>D>	+	KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML	N050138	002		Jun	DISC
>A>	+	@	150,000 UNITS/ML; 150,000 UNITS/ML	N050138	002		Jun	DISC

PENTAZOCINE LACTATEINJECTABLE; INJECTION
TALWIN

>D>	+	HOSPIRA	EQ 30MG BASE/ML	N016194	001		Jun	DISC
>A>	+	@	EQ 30MG BASE/ML	N016194	001		Jun	DISC

PERAMIVIRSOLUTION; INTRAVENOUS
RAPIVAB

>A>	+	BIOCRYS	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014	Jun	CDFR
>D>			SOLUTION; IV (INFUSION)					
>D>			RAPIVAB					
>D>	+	BIOCRYS	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014	Jun	CDFR

PERINDOPRIL ERBUMINETABLET; ORAL
PERINDOPRIL ERBUMINE

	@	APOTEX	2MG	A090463	001	Aug 30, 2010	Jan	DISC
	@		4MG	A090463	002	Aug 30, 2010	Jan	DISC
	@		8MG	A090463	003	Aug 30, 2010	Jan	DISC
AB		AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	Mar	CHRS
AB			4MG	A079070	002	Nov 10, 2009	Mar	CHRS

PHENDIMETRAZINE TARTRATECAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

	@	VIRTUS PHARMS	35MG	A085695	001		May	CAHN
			CAPSULE, EXTENDED RELEASE; ORAL					
	@	VIRTUS PHARMS	105MG	A087378	001		May	CAHN
	+		105MG	N018074	001		Mar	CAHN
			CAPSULE; ORAL					
	@	VIRTUS PHARMS	35MG	A085497	001		May	CAHN
AA			35MG	A085588	001		Mar	CAHN
	@		35MG	A086365	001		May	CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

	@	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003	Jan	CAHN
--	---	----------------	------	---------	-----	--------------	-----	------

PHENYLBUZAZONECAPSULE; ORAL
PHENYLBUZAZONE

	@	FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Jan	CAHN
--	---	--------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

	@	FOSUN PHARMA	100MG	A084339	001		Jan	CAHN
--	---	--------------	-------	---------	-----	--	-----	------

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

>A>	AP	AMNEAL PHARMS CO	10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018	Jun	NEWA
>A>	AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun	CDFR
>A>	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun	CDFR
>A>	AP	+	WEST WARD PHARM CORP	N203826	001	Dec 20, 2012	Jun	CDFR

>A>	SOLUTION;INTRAVENOUS							
>A>	PHENYLEPHRINE HYDROCHLORIDE							
>A>	AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun CDFR	
		VAZCULEP						
>A>	AP	+ AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun CTEC	
>A>		+	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun CDFR	
>A>	AP	+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun CDFR	
>A>	AP	+	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun CDFR	
>D>	SOLUTION;IV (INFUSION)							
>D>	PHENYLEPHRINE HYDROCHLORIDE							
>D>	AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun CDFR	
	AP		10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Apr NEWA	
>D>	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun CDFR	
	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Apr NEWA	
>D>	AP	+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jun CDFR
	AP	+		10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr CFTG
>D>	PHENYLEPHRINE HYDROCHLORIDE							
>D>	AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun CDFR	
	AP		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Apr NEWA	
		VAZCULEP						
>D>		+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun CDFR
>D>	AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun CDFR
	AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr CFTG
>D>	AP	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun CDFR
	AP	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr CFTG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE						
AA	!	VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan CHRS
		PROMETH VC PLAIN					
		@ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan DISC

PHENYTOIN

SUSPENSION;ORAL

	PHENYTOIN						
AB		WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN

PHYTONADIONE

TABLET;ORAL

	MEPHYTON						
AB	+	VALEANT PHARMS	5MG	N010104	003		Apr CFTG
		PHYTONADIONE					
AB		AMNEAL PHARMS CO	5MG	A209373	001	May 11, 2018	Apr NEWA

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

>A>	NUPLAZID							
>A>		+	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jun NEWA
>A>		+	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jun NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

	PIOGLITAZONE HYDROCHLORIDE						
AB		PRINSTON INC	EQ 15MG BASE	A207806	001	Apr 17, 2018	Apr NEWA
AB			EQ 30MG BASE	A207806	002	Apr 17, 2018	Apr NEWA
AB			EQ 45MG BASE	A207806	003	Apr 17, 2018	Apr NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

	PIPERACILLIN AND TAZOBACTAM						
AP		FRESENIUS KABI	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A203719	001	May 18, 2018	May NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A203719	002	May 18, 2018	May NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A203719	003	May 18, 2018	May NEWA
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203720	001	May 11, 2018	Apr NEWA
AP		FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Apr NEWA

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr	CDFR
AP	WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CPOT

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb	NEWA
AB		20MG	A208991	002	Feb 21, 2018	Feb	NEWA
AB	MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb	CRLD
AB		20MG	A206152	002	Dec 29, 2017	Feb	CRLD
AB	STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan	NEWA
AB		20MG	A210347	002	Jan 26, 2018	Jan	NEWA

>A> PLAZOMICIN SULFATE

>A> SOLUTION; INTRAVENOUS

>A> ZEMDRI

>A>	+! ACHAAGEN INC	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jun	NEWA
-----	-----------------	---	---------	-----	--------------	-----	------

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan	CDFR
----	-----------	-------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

+ @	NESHER PHARMS	8MEQ	N018238	001		Apr	DISC
-----	---------------	------	---------	-----	--	-----	------

MICRO-K 10

+ @	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Apr	DISC
-----	---------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

K-TAB

AB3	+ ABBVIE	10MEQ	N018279	001		Jan	CTEC
AB2	+!	20MEQ	N018279	003	Nov 25, 2013	Jan	CTEC

POTASSIUM CHLORIDE

AB3	PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan	NEWA
AB2		20MEQ	A209688	002	Jan 12, 2018	Jan	NEWA
>A>	AB2 YICHANG HUMANWELL	8MEQ	A209314	001	Jun 22, 2018	Jun	NEWA
>A>	AB2	10MEQ	A209314	002	Jun 22, 2018	Jun	NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

>D>		POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%					
>D>	+ BAXTER HLTHCARE	224MG/100ML; 900MG/100ML	N017648	003		Jun	DISC
>A>	+ @	224MG/100ML; 900MG/100ML	N017648	003		Jun	DISC

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB	MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan	CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Jan	CAHN
AB	TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb	NEWA
AB		10MEQ	A209758	002	Mar 05, 2018	Feb	NEWA
AB		15MEQ	A209758	003	Mar 05, 2018	Feb	NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

AB	ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan	NEWA
AB		EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan	NEWA
>A>	AB AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Jun	NEWA
>A>	AB	EQ 10MG BASE	A205913	002	Jun 19, 2018	Jun	NEWA
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan	CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan	CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@	60MG	A070666	001	Oct 10, 1986	Jan CAHN
@	80MG	A070667	001	Jun 13, 1986	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

CORPHED

@ FOSUN PHARMA	60MG;2.5MG	A088602	001	Apr 11, 1985	Jan CAHN
----------------	------------	---------	-----	--------------	----------

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+! VYERA PHARMS LLC	25MG	N008578	001		Jan CAHN
---------------------	------	---------	-----	--	----------

QUAZEPAM

TABLET;ORAL

DORAL

@ GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987	Feb CAHN
+!	15MG	N018708	001	Dec 27, 1985	Feb CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr DISC
@	EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr DISC
@	EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr DISC
@	EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr DISC
@ YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jan CAHN
@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Jan CAHN
@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Jan CAHN
@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Jan CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

@ G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Jan DISC
--------------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+ CERECOR INC	5MG	N204736	001	Mar 26, 2013	Feb CAHN
+!	10MG	N204736	002	Mar 26, 2013	Feb CAHN

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB	ALKEM LABS LTD	20MG	A208644	001	Apr 24, 2018	Apr NEWA
----	----------------	------	---------	-----	--------------	----------

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

+! MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May CHRS
----------------------	---------------	---------	-----	--------------	----------

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	DR REDDYS LABS SA	8MG	A091693	001	Jul 26, 2013	Mar CAHN
----	-------------------	-----	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>A>	AB	CHARTWELL MOLECULAR	1.25MG	A078745	001	Jun 18, 2008	Jun CAHN
>A>	AB		2.5MG	A078745	002	Jun 18, 2008	Jun CAHN
>A>	AB		5MG	A078745	003	Jun 18, 2008	Jun CAHN
>A>	AB		10MG	A078745	004	Jun 18, 2008	Jun CAHN
>D>	AB	INVAGEN PHARMS	1.25MG	A078745	001	Jun 18, 2008	Jun CAHN
>D>	AB		2.5MG	A078745	002	Jun 18, 2008	Jun CAHN
>D>	AB		5MG	A078745	003	Jun 18, 2008	Jun CAHN
>D>	AB		10MG	A078745	004	Jun 18, 2008	Jun CAHN
		@ WATSON LABS	5MG	A076549	003	Oct 24, 2005	Mar DISC
		@ YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008	Jan CAHN
		@	2.5MG	A077514	002	Jun 18, 2008	Jan CAHN
		@	5MG	A077514	003	Jun 18, 2008	Jan CAHN

	CAPSULE;ORAL								
	RAMIPRIL								
	@	10MG		A 077514	004	Jun 18, 2008		Jan	CAHN
	TABLET;ORAL								
	RAMIPRIL								
	@ APOTEX INC	1.25MG		A 091069	001	Dec 02, 2015		May	DISC
	@	2.5MG		A 091069	002	Dec 02, 2015		May	DISC
	@	5MG		A 091069	003	Dec 02, 2015		May	DISC
	@	10MG		A 091069	004	Dec 02, 2015		May	DISC
	<u>RANITIDINE HYDROCHLORIDE</u>								
	SYRUP;ORAL								
	RANITIDINE HYDROCHLORIDE								
AA	LANNETT CO INC	EQ 15MG BASE/ML		A 078890	001	Jul 01, 2010		May	CAHN
	TABLET;ORAL								
	ZANTAC 150								
	+ @ GLAXO GRP LTD	EQ 150MG BASE		N 018703	001	Jun 09, 1983		Apr	DISC
	<u>RASAGILINE MESYLATE</u>								
	TABLET;ORAL								
	RASAGILINE MESYLATE								
	@ APOTEX INC	EQ 0.5MG BASE		A 201950	001	Sep 12, 2013		Mar	DISC
	@	EQ 1MG BASE		A 201950	002	Sep 12, 2013		Mar	DISC
	<u>REMIFENTANIL HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	REMIFENTANIL HYDROCHLORIDE								
AP	FRESENIUS KABI USA	EQ 1MG BASE/VIAL		A 206223	001	Jan 16, 2018		Jan	NEWA
AP		EQ 2MG BASE/VIAL		A 206223	002	Jan 16, 2018		Jan	NEWA
AP		EQ 5MG BASE/VIAL		A 206223	003	Jan 16, 2018		Jan	NEWA
	ULTIVA								
AP	+ MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL		N 020630	001	Jul 12, 1996		Jan	CFTG
AP	+	EQ 2MG BASE/VIAL		N 020630	002	Jul 12, 1996		Jan	CFTG
AP	+	EQ 5MG BASE/VIAL		N 020630	003	Jul 12, 1996		Jan	CFTG
	<u>REPAGLINIDE</u>								
	TABLET;ORAL								
	REPAGLINIDE								
AB	CASI PHARMS INC	0.5MG		A 078555	001	Nov 22, 2013		Mar	CAHN
AB		1MG		A 078555	002	Jan 22, 2014		Mar	CAHN
AB		2MG		A 078555	003	Jan 22, 2014		Mar	CAHN
	<u>RIBAVIRIN</u>								
	CAPSULE;ORAL								
	RIBAVIRIN								
AB	CASI PHARMS INC	200MG		A 076192	001	Apr 06, 2004		Mar	CAHN
	TABLET;ORAL								
	COPEGUS								
	@ ROCHE	200MG		N 021511	001	Dec 03, 2002		Apr	DISC
	<u>RISEDRONATE SODIUM</u>								
	TABLET, DELAYED RELEASE;ORAL								
	RISEDRONATE SODIUM								
>A>	AB	IMPAX LABS INC	35MG	A 205066	001	Jun 29, 2018		Jun	NEWA
	<u>RISPERIDONE</u>								
	SOLUTION;ORAL								
	RISPERIDONE								
AA	LANNETT CO INC	1MG/ML		A 079158	001	Dec 03, 2010		May	CAHN
	@ PRECISION DOSE	1MG/ML		A 076797	001	Jun 28, 2010		Mar	DISC
	TABLET;ORAL								
	RISPERIDONE								
AB	CHARTWELL MOLECULAR	0.25MG		A 077543	001	May 18, 2011		Mar	CAHN
AB		0.5MG		A 077543	002	May 18, 2011		Mar	CAHN
AB		1MG		A 077543	003	May 18, 2011		Mar	CAHN
AB		2MG		A 077543	004	May 18, 2011		Mar	CAHN
AB		3MG		A 077543	005	May 18, 2011		Mar	CAHN
AB		4MG		A 077543	006	May 18, 2011		Mar	CAHN
AB	RENATA	0.25MG		A 078707	001	Dec 29, 2008		Jan	CAHN
AB		0.5MG		A 078707	002	Dec 29, 2008		Jan	CAHN
AB		1MG		A 078707	003	Dec 29, 2008		Jan	CAHN
AB		2MG		A 078707	004	Dec 29, 2008		Jan	CAHN

TABLET;ORAL
RISPERIDONE

AB		3MG	A078707	005	Dec 29, 2008	Jan	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Jan	CAHN

RITONAVIR

CAPSULE;ORAL
NORVIR

	+ @ ABBVIE	100MG	N020945	001	Jun 29, 1999	Apr	DISC
--	------------	-------	---------	-----	--------------	-----	------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

>A>	AB	MYLAN TECHNOLOGIES	4.6MG/24HR	A205622	001	Jun 20, 2018	Jun	NEWA
>A>	AB		9.5MG/24HR	A205622	002	Jun 20, 2018	Jun	NEWA
>A>	AB		13.3MG/24HR	A205622	003	Jun 20, 2018	Jun	NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL
MAXALT

	+ @ MERCK	EQ 5MG BASE	N020864	001	Jun 29, 1998	Apr	DISC
		RIZATRIPTAN BENZOATE					
	@ APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012	Mar	DISC
	@	EQ 10MG BASE	A202244	002	Dec 31, 2012	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
MAXALT-MLT

	+ @ MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998	Apr	DISC
		RIZATRIPTAN BENZOATE					
	@ APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Mar	DISC
	@	EQ 10MG BASE	A202477	002	Jul 01, 2013	Mar	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	GLAND CHEMS PVT	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Mar	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Apr	CAHN
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Apr	CAHN

ROFLUMILAST

TABLET;ORAL
DALIRESP

	+ ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018	Jan	NEWA
--	----------------------	--------	---------	-----	--------------	-----	------

ROLAPITANT HYDROCHLORIDE

>D>		EMULSION;IV (INFUSION)						
>D>		VARUBI						
>D>	+!	TESARO INC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jun	DISC
>A>	+ @		EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jun	DISC

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

	@ G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jan	DISC
	@	EQ 0.5MG BASE	A077460	002	May 05, 2008	Jan	DISC
	@	EQ 1MG BASE	A077460	003	May 05, 2008	Jan	DISC
	@	EQ 2MG BASE	A077460	004	May 05, 2008	Jan	DISC
	@	EQ 3MG BASE	A077460	005	May 05, 2008	Jan	DISC
	@	EQ 4MG BASE	A077460	006	May 05, 2008	Jan	DISC
	@	EQ 5MG BASE	A077460	007	May 19, 2008	Jan	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
NAROPIN

AP	+ FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	CTEC
AP	+	500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	May	CTEC
AP	+	1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	May	CTEC
		ROPIVACAINE HYDROCHLORIDE					
AP	AKORN	200MG/100ML (2MG/ML)	A204636	001	Mar 16, 2018	Mar	NEWA
AP		400MG/200ML (2MG/ML)	A204636	002	Mar 16, 2018	Mar	NEWA

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	INFORLIFE	200MG/100ML (2MG/ML)	A206166	001	Jun 11, 2018	May	NEWA
AP		400MG/200ML (2MG/ML)	A206166	002	Jun 11, 2018	May	NEWA
AP		500MG/100ML (5MG/ML)	A206166	003	Jun 11, 2018	May	NEWA
AP		1GM/200ML (5MG/ML)	A206166	004	Jun 11, 2018	May	NEWA
>A>	SOMERSET THERAPS LLC	20MG/10ML (2MG/ML)	A207636	001	Jun 15, 2018	Jun	NEWA
>A>		40MG/20ML (2MG/ML)	A207636	002	Jun 15, 2018	Jun	NEWA
>A>		100MG/20ML (5MG/ML)	A207636	003	Jun 15, 2018	Jun	NEWA
>A>		100MG/10ML (10MG/ML)	A207636	006	Jun 15, 2018	Jun	NEWA
>A>		150MG/30ML (5MG/ML)	A207636	004	Jun 15, 2018	Jun	NEWA
>A>		150MG/20ML (7.5MG/ML)	A207636	005	Jun 15, 2018	Jun	NEWA
>A>		200MG/20ML (10MG/ML)	A207636	007	Jun 15, 2018	Jun	NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

@ ACI HEALTHCARE LTD EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 May CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ CHARTWELL MOLECULAR EQ 25MG BASE

A077162 001 Feb 06, 2007 Mar CAHN

@ EQ 50MG BASE

A077162 002 Feb 06, 2007 Mar CAHN

@ EQ 100MG BASE

A077162 003 Feb 06, 2007 Mar CAHN

@ FOSUN PHARMA

@ EQ 25MG BASE

A077713 001 Feb 06, 2007 Jan CAHN

@ EQ 50MG BASE

A077713 002 Feb 06, 2007 Jan CAHN

@ EQ 100MG BASE

A077713 003 Feb 06, 2007 Jan CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

AB SANDOZ INC 800MG A200959 001 Mar 20, 2018 Mar NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A210394	001	May 04, 2018	Apr	NEWA
>A>	AMNEAL PHARMS NY	EQ 25MG BASE	A202023	001	Jun 27, 2018	Jun	NEWA
>A>		EQ 50MG BASE	A202023	002	Jun 27, 2018	Jun	NEWA
>A>		EQ 100MG BASE	A202023	003	Jun 27, 2018	Jun	NEWA
	@ APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A203962	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A203962	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A203962	003	Jun 11, 2018	May	NEWA
AB	HETERO LABS LTD V	EQ 25MG BASE	A202659	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A202659	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A202659	003	Jun 11, 2018	May	NEWA
AB	RUBICON RES PVT LTD	EQ 25MG BASE	A204882	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A204882	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A204882	003	Jun 11, 2018	May	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A091448	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A091448	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A091448	003	Jun 11, 2018	May	NEWA

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD AF

>D>								
>D>	BX	DR REDDYS LA	1%	N018578	003	Jul 11, 1990	Jun	DISC
>A>		@	1%	N018578	003	Jul 11, 1990	Jun	DISC

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+ @ JANSSEN PRODS EQ 150MG BASE N205123 001 Nov 22, 2013 May DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

@ HISUN PHARM HANGZHOU 10MG

A206557 001 Nov 13, 2017 May DISC

@ 20MG

A206557 002 Nov 13, 2017 May DISC

@ 40MG

A206557 003 Nov 13, 2017 May DISC

@ 80MG

A206557 004 Nov 13, 2017 May DISC

@ YAOPHARMA CO LTD 5MG

A077766 001 Dec 20, 2006 Jan CAHN

TABLET;ORAL
SIMVASTATIN

@	10MG	A077766	002	Dec 20, 2006	Jan CAHN
@	20MG	A077766	003	Dec 20, 2006	Jan CAHN
@	40MG	A077766	004	Dec 20, 2006	Jan CAHN
@	80MG	A077766	005	Dec 20, 2006	Jan CAHN

SINECATECHINS

OINTMENT;TOPICAL
VEREGEN

+!	FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan CAHN
----	--------------------	-----	---------	-----	--------------	----------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS
AMMONUL

AP	+!	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May CDFR
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP		AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May CDFR
AP		MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May CDFR
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May CDFR

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

@	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar DISC
@		0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar DISC

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

>D>	@	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun CRLD
>A>	+ @		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun CRLD
>D>	@		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun CRLD
>A>	+ @		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun CRLD
>D>	@		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun CRLD
>A>	+ @		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun CRLD
>D>	@		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun CRLD
>A>	+ @		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun CRLD
>D>			90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Jun CRLD
>A>	+		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Jun CRLD
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+ @	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr DISC
AP	+!		9MG/ML	N019217	001	Jul 13, 1984	Feb CAHN
>D>	@	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun CRLD
>A>	+ @		9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun CRLD

SOLUTION;IRRIGATION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	+!	B BRAUN	900MG/100ML	N016733	001		Mar CRLD
----	----	---------	-------------	---------	-----	--	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
>D>	AP	UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013	Jun DISC
>A>	@		10-200mCi/ML	A203247	001	Dec 23, 2013	Jun DISC

SODIUM IODIDE I-131

CAPSULE;ORAL

>D>			SODIUM IODIDE I 131				
>D>	+!	MALLINKRODT NUCLEAR	0.8-100mCi	N016517	001		Jun DISC
>A>	+ @		0.8-100mCi	N016517	001		Jun DISC

SOLUTION;ORAL

>D>			SODIUM IODIDE I 131				
>D>	+!	MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515	001		Jun DISC
>A>	+ @		3.5-150mCi/VIAL	N016515	001		Jun DISC

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

AP		MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr NEWA
>A>	AP	RENAISSANCE SSA LLC	25MG/ML	A209834	001	Jun 26, 2018	Jun NEWA

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
AA	APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN

SODIUM ZIRCONIUM CYCLOSILICATE

	FOR SUSPENSION;ORAL						
	LOKELMA						
	+ ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018	May	NEWA
	+!	10GM/PACKET	N207078	002	May 18, 2018	May	NEWA

SOMATROPIN

	INJECTABLE;INJECTION						
	BIO-TROPIN						
	@ FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb	CAIN
	ZOMACTON						
BX	+! FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
	+	10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN

SOMATROPIN RECOMBINANT

	INJECTABLE;INJECTION						
	GENOTROPIN PRESERVATIVE FREE						
>D> BX	+ PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995	Jun	DISC
>A>	+ @	1.5MG/VIAL	N020280	004	Aug 24, 1995	Jun	DISC
>D>	NUTROPIN AQ PEN						
>D>	+! GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Jun	DISC
>A>	+ @	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Jun	DISC
>D>	+!	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	DISC
>A>	+ @	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	DISC
>D>	VALTROPIN						
>D> BX	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun	DISC
>A>	@	5MG/VIAL	N021905	001	Apr 19, 2007	Jun	DISC

SPIRONOLACTONE

	TABLET;ORAL						
	SPIRONOLACTONE						
AB	CASI PHARMS INC	25MG	A086809	001		Mar	CAHN

STERILE WATER FOR IRRIGATION

	LIQUID;IRRIGATION						
	STERILE WATER IN PLASTIC CONTAINER						
AT	+ B BRAUN	100%	N016734	001		Mar	CRLD

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE;INJECTION						
	SUCCINYLCHOLINE CHLORIDE						
AP	RENAISSANCE SSA LLC	20MG/ML	A210231	001	Jun 04, 2018	May	NEWA
AP	ZYDUS PHARMS USA INC	20MG/ML	A209467	001	May 04, 2018	Apr	NEWA

SUCRALFATE

	SUSPENSION;ORAL						
	CARAFATE						
	+! ALLERGAN SALES LLC	1GM/10ML	N019183	001	Dec 16, 1993	Jan	CAHN
	TABLET;ORAL						
	CARAFATE						
AB	+! ALLERGAN SALES LLC	1GM	N018333	001		Jan	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

	SUSPENSION;ORAL						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB	LANNETT CO INC	200MG/5ML;40MG/5ML	A077785	001	Jan 24, 2007	May	CAHN
	TABLET;ORAL						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
	@ FOSUN PHARMA	400MG;80MG	A070889	001	Nov 13, 1986	Jan	CAHN
	@	400MG;80MG	N018598	003	May 19, 1982	Jan	CAHN
	@	800MG;160MG	A070890	001	Nov 13, 1986	Jan	CAHN
	@ SUN PHARM INDUSTRIES	400MG;80MG	A071017	002	Aug 25, 1986	Apr	CMS1
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
	@ FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982	Jan	CAHN

SULINDAC

TABLET; ORAL

SULINDAC

@ FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991	Jan CAHN
@	200MG	A072713	001	Aug 30, 1991	Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMAVEL DOSEPRO

+ @ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	Mar DISC
+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Mar DISC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@ FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009	Jan CAHN
@	EQ 50MG BASE	A076976	002	Aug 10, 2009	Jan CAHN
@	EQ 100MG BASE	A076976	003	Aug 10, 2009	Jan CAHN

TACROLIMUS

FOR SUSPENSION; ORAL

PROGRAF

+ ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018	May NEWA
+!	EQ 1MG BASE/PACKET	N210115	002	May 24, 2018	May NEWA

OINTMENT; TOPICAL

TACROLIMUS

AB	GLENMARK PHARMS LTD	0.1%	A210393	001	Apr 16, 2018	Apr NEWA
----	---------------------	------	---------	-----	--------------	----------

TADALAFIL

TABLET; ORAL

CIALIS

AB	+ LILLY	2.5MG	N021368	004	Jan 07, 2008	May CFTG
AB	+	5MG	N021368	001	Nov 21, 2003	May CFTG
AB	+	10MG	N021368	002	Nov 21, 2003	May CFTG
AB	+!	20MG	N021368	003	Nov 21, 2003	May CFTG

TADALAFIL

AB	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	May NEWA
AB		5MG	A090141	002	May 22, 2018	May NEWA
AB		10MG	A090141	003	May 22, 2018	May NEWA
AB		20MG	A090141	004	May 22, 2018	May NEWA

TALC

AEROSOL; INTRAPLEURAL

SCLEROSOL

+!	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Mar CPOT
----	-------------	-----------	---------	-----	--------------	----------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

	MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Mar CPOT
--	--------------------	-------------------	---------	-----	--------------	----------

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ @	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May DISC
-----	-------------	-----------------	---------	-----	--------------	----------

TAZAROTENE

CREAM; TOPICAL

TAZAROTENE

AB	TARO PHARMS	0.1%	A208258	001	Apr 03, 2017	May CAHN
----	-------------	------	---------	-----	--------------	----------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

+ @	JUBILANT DRAXIMAGE	N/A	N017776	001		Feb DISC
-----	--------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
CIS-MDP

PHARMALUCENCE	N/A	N018124	001		Jan	CTEC
MDP-BRACCO						
@ CARDINAL HEALTH 414	N/A	N018107	001		Jan	DISC

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION
DTPA

+! JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan	CAHN
-----------------------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb	NEWA
---------------------	----------------------	---------	-----	--------------	-----	------

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

>A> AB	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jun	NEWA
>A> AB		20MG	A204159	002	Jul 05, 2018	Jun	NEWA
>A> AB		100MG	A204159	003	Jul 05, 2018	Jun	NEWA
>A> AB		140MG	A204159	004	Jul 05, 2018	Jun	NEWA
>A> AB		180MG	A204159	005	Jul 05, 2018	Jun	NEWA
>A> AB		250MG	A204159	006	Jul 05, 2018	Jun	NEWA
	@ MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Apr	DISC
	@	20MG	A205227	002	Jun 29, 2016	Apr	DISC
	@	100MG	A205227	003	Jun 29, 2016	Mar	DISC
	@	140MG	A205227	004	Jun 29, 2016	Mar	DISC
	@	180MG	A205227	005	Jun 29, 2016	Mar	DISC
	@	250MG	A205227	006	Jun 29, 2016	Mar	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan	NEWA
AB		200MG	A090647	002	Jan 26, 2018	Jan	NEWA
AB		250MG	A090647	003	Jan 26, 2018	Jan	NEWA
AB		300MG	A090647	004	Jan 26, 2018	Jan	NEWA
AB	CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan	NEWA
AB	HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan	NEWA
AB	LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb	NEWA
AB	MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan	NEWA
AB	STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan	NEWA
AB	TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan	NEWA
AB		200MG	A091612	003	Jan 26, 2018	Jan	NEWA
AB		250MG	A091612	004	Jan 26, 2018	Jan	NEWA
	VIREAD						
AB	+ GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan	CFTG
AB	+	200MG	N021356	003	Jan 18, 2012	Jan	CFTG
AB	+	250MG	N021356	004	Jan 18, 2012	Jan	CFTG

TERCONAZOLECREAM; VAGINAL
TERAZOL 7

+ @ JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987	Feb	DISC
TERCONAZOLE						

AB	! TARO	0.4%	A076043	001	Jan 19, 2005	Feb	CHRS
----	--------	------	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL
TERAZOL 3

+ @ JANSSEN PHARMS	80MG	N019641	001	May 24, 1988	Feb	DISC
TERCONAZOLE						

AB	! PERRIGO NEW YORK	80MG	A077149	001	Mar 17, 2006	Feb	CHRS
----	--------------------	------	---------	-----	--------------	-----	------

TESTOSTERONESOLUTION, METERED; TRANSDERMAL
TESTOSTERONE

AT	CIPLA LTD	30MG/1.5ML ACTUATION	A209533	001	Jan 29, 2018	Jan	NEWA
----	-----------	----------------------	---------	-----	--------------	-----	------

TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

>A>	AO	CIPLA LTD	100MG/ML	A210362	001	Jun 19, 2018	Jun	NEWA
>A>	AO		200MG/ML	A210362	002	Jun 19, 2018	Jun	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

>D>		DELATESTRYL						
>D>	AO	+! ENDO PHARMS	200MG/ML	N009165	003		Jun	DISC
>A>		+ @	200MG/ML	N009165	003		Jun	DISC
		TESTOSTERONE ENANTHATE						
>D>	AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Jun	DISC
>A>		@	200MG/ML	A040647	001	Oct 05, 2009	Jun	DISC
>A>	AO	NEXUS PHARMS	200MG/ML	A040575	001	Jun 14, 2006	Jun	CAHN
>D>	AO	PADDOCK LLC	200MG/ML	A040575	001	Jun 14, 2006	Jun	CAHN
>D>	AO	WATSON PHARMS INC	200MG/ML	A085598	001		Jun	CHRS
>A>	AO	!	200MG/ML	A085598	001		Jun	CHRS

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB		LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Apr	NEWA
AB			25MG	A210544	002	Apr 20, 2018	Apr	NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

		+! ALCON LABS	0.5%	N208135	001	Feb 29, 2016	Mar	CAHN
--	--	---------------	------	---------	-----	--------------	-----	------

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+! B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992	Jun	CTEC
>A>		+!	40MG/100ML	N019826	001	Aug 14, 1992	Jun	CTEC
		THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	+! B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992	Jun	CTEC
>A>		+!	160MG/100ML	N019826	003	Aug 14, 1992	Jun	CTEC
		THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	+! B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992	Jun	CTEC
>A>		+!	320MG/100ML	N019826	006	Aug 14, 1992	Jun	CTEC
>D>		THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>		+! HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984	Jun	DISC
>A>		+ @	4MG/ML	N019211	007	Dec 14, 1984	Jun	DISC
>D>	AP	+!	40MG/100ML	N019211	001	Dec 14, 1984	Jun	DISC
>A>		+ @	40MG/100ML	N019211	001	Dec 14, 1984	Jun	DISC
>D>	AP	+!	160MG/100ML	N019211	003	Dec 14, 1984	Jun	DISC
>A>		+ @	160MG/100ML	N019211	003	Dec 14, 1984	Jun	DISC
>D>	AP	+!	320MG/100ML	N019211	006	Jan 20, 1988	Jun	DISC
>A>		+ @	320MG/100ML	N019211	006	Jan 20, 1988	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan	CTEC
AB			200MG	A087400	004	Feb 21, 1985	Jan	CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan	CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan	CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan	CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan	CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan	CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan	CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan	CAHN

THIOTEPAINJECTABLE; INJECTION
THIOTEPA

AP	DR REDDYS LABS LTD	15MG/VIAL	A210337	001	May 04, 2018	Apr	NEWA
AP	JIANGSU HENGRUI MED	15MG/VIAL	A209150	001	May 04, 2018	Apr	NEWA
AP	! WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Apr	CTEC

THIOTHIXENECAPSULE; ORAL
NAVANE

+ @	PFIZER	1MG	N016584	001		Jan	CRLD
+ @		2MG	N016584	002		Jan	CRLD
+ @		5MG	N016584	003		Jan	CRLD
+ @		10MG	N016584	004		Jan	CRLD
+ @		20MG	N016584	005		Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan	CAHN
@		250MG	A075326	001	Aug 20, 1999	Jan	CAHN

TIGECYCLINE

>A> POWDER; INTRAVENOUS

>A> TIGECYCLINE

>A>	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jun	CDFR
>A> AP	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Jun	CDFR
>A> AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Jun	CDFR
>A>	TYGACIL						
>A> AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Jun	CDFR
>D>	POWDER; IV (INFUSION)						
>D>	TIGECYCLINE						
>D>	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jun	CDFR
		50MG/VIAL	N208744	001	Jan 18, 2018	Jan	NEWA
>D> AP	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Jun	CDFR
>D> AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Jun	CDFR
>D>	TYGACIL						
>D> AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Jun	CDFR

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT	+ ATON	EQ 0.25% BASE	N018086	001		Jan	CMFD
AT1	+	EQ 0.5% BASE	N018086	002		Jan	CMFD

TABLET; ORAL

TIMOLOL MALEATE

@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan	CAHN
@		10MG	A072551	001	Apr 13, 1989	Jan	CAHN
@		20MG	A072552	001	Apr 13, 1989	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar	CAHN
AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar	CAHN
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	NEWA
AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

>A> AN	DR REDDYS LABS INTL	300MG/5ML	A207080	001	Jul 09, 2018	Jun	NEWA
--------	---------------------	-----------	---------	-----	--------------	-----	------

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+!	PF PRISM CV	EQ 10MG BASE	N203214	002	May 30, 2018	May	NEWA
----	-------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ YAOPHARMA CO LTD	100MG	A 071633	001	Dec 09, 1987	Jan CAHN
@	250MG	A 070289	001	Mar 13, 1986	Jan CAHN
@	500MG	A 070290	001	Mar 13, 1986	Jan CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ YAOPHARMA CO LTD	500MG	A 086574	001		Jan CAHN
--------------------	-------	----------	-----	--	----------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 400MG BASE	A 073462	001	Apr 30, 1992	Jan CAHN
----------------	---------------	----------	-----	--------------	----------

TABLET; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 200MG BASE	A 073588	001	Jul 31, 1992	Jan CAHN
@	EQ 600MG BASE	A 074002	001	Sep 27, 1993	Jan CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

@ APOTEX CORP	1MG	A 200164	001	Sep 25, 2012	Mar DISC
@	2MG	A 200164	002	Sep 25, 2012	Mar DISC

TOLVAPTAN

TABLET; ORAL

JYNARQUE

+ OTSUKA PHARM CO LTD	15MG	N 204441	001	Apr 23, 2018	Apr NEWA
+	30MG	N 204441	002	Apr 23, 2018	Apr NEWA
+	45MG	N 204441	003	Apr 23, 2018	Apr NEWA
+	60MG	N 204441	004	Apr 23, 2018	Apr NEWA
+!	90MG	N 204441	005	Apr 23, 2018	Apr NEWA

TOPIRAMATE

CAPSULE; ORAL

TOPIRAMATE

@ FOSUN PHARMA	15MG	A 079206	001	Oct 14, 2009	Jan CAHN
@	25MG	A 079206	002	Oct 14, 2009	Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A 075968	001	Jun 25, 2002	Jan CAHN
----------------	------	----------	-----	--------------	----------

TRANDOLAPRIL

TABLET; ORAL

MAVIK

+ @ ABBVIE	1MG	N 020528	001	Apr 26, 1996	Mar DISC
+ @	2MG	N 020528	002	Apr 26, 1996	Mar DISC
+ @	4MG	N 020528	003	Apr 26, 1996	Mar DISC

TRANDOLAPRIL

AB ! LUPIN	4MG	A 077522	003	Jun 12, 2007	Mar CHRS
@ WATSON LABS	1MG	A 077805	001	Jun 12, 2007	May DISC
@	2MG	A 077805	002	Jun 12, 2007	May DISC
@	4MG	A 077805	003	Jun 12, 2007	May DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP ACIC PHARMS	100MG/ML	A 202436	001	Feb 11, 2014	May CAHN
----------------	----------	----------	-----	--------------	----------

TRANLYCYPROMINE SULFATE

TABLET; ORAL

TRANLYCYPROMINE SULFATE

AB KINEDEXE UK	EQ 10MG BASE	A 206856	001	Apr 17, 2018	Apr NEWA
----------------	--------------	----------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ FOSUN PHARMA

100MG

A 072483 001 Apr 30, 1990 Jan CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT LANNETT CO INC

0.025%

A 040671 001 Jun 09, 2006 May CAHN

AT

0.1%

A 040671 002 Jun 09, 2006 May CAHN

AT MACLEODS PHARMS LTD

0.025%

A 209535 001 May 18, 2018 May NEWA

AT

0.1%

A 209535 002 May 18, 2018 May NEWA

AT

0.5%

A 209535 003 May 18, 2018 May NEWA

AT PERRIGO NEW YORK

0.025%

A 086413 002 Mar CMS1

AT

0.1%

A 086413 003 Mar CMS1

AT TARO PHARM INDS LTD

0.1%

A 040039 001 Nov 26, 1997 May CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT LANNETT CO INC

0.1%

A 040672 002 Dec 13, 2006 May CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT ! PERRIGO NEW YORK

0.025%

A 087385 002 Jun CMS1

>A> AT !

0.1%

A 087385 003 Jun CMS1

AT TARO PHARM INDS LTD

0.1%

A 040037 001 Sep 30, 1994 May CAHN

SPRAY; TOPICAL

KENALOG

AT +! SUN PHARM INDS INC

0.147MG/GM

N 012104 001 Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

AB +! ATON

250MG

N 019194 001 Nov 08, 1985 Jan CFTG

TRIENTINE HYDROCHLORIDE

AB WATSON LABS TEVA

250MG

A 207567 001 Feb 07, 2018 Jan NEWA

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@ FOSUN PHARMA

EQ 10MG BASE/ML

A 085787 001 Apr 15, 1982 Jan CAHN

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

TROPICAMIDE

AT BAUSCH AND LOMB

0.5%

A 040067 001 Jul 27, 1994 Apr CAHN

>D> UROFOLLITROPIN

>D> INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

>D> BRAVELLE

>D> +! FERRING 75 IU/VIAL

N 021289 001 May 06, 2002 Jun DISC

>A> + @ 75 IU/VIAL

N 021289 001 May 06, 2002 Jun DISC

URSODIOL

CAPSULE; ORAL

URSODIOL

AB ABHAI LLC

300MG

A 210707 001 May 17, 2018 May NEWA

TABLET; ORAL

URSO 250

AB + ALLERGAN SALES LLC

250MG

N 020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

AB +! ALLERGAN SALES LLC

500MG

N 020675 002 Jul 21, 2004 Apr CAHN

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

>D> +! NEUROCRINE 40MG

N 209241 001 Apr 11, 2017 Jun CPOT

>A> +! EQ 40MG BASE

N 209241 001 Apr 11, 2017 Jun CPOT

>D> + 80MG

N 209241 002 Oct 04, 2017 Jun CPOT

>A> + EQ 80MG BASE

N 209241 002 Oct 04, 2017 Jun CPOT

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

AA LANNETT CO INC 250MG/5ML A077960 001 Oct 13, 2006 May CAHN

>D> VALSARTAN

>D> SOLUTION;ORAL

>D> PREXXARTAN

>D> +! CARMEL BIOSCIENCES 20MG/5ML N209139 001 Dec 19, 2017 Jun DISC

>A> + @ 20MG/5ML N209139 001 Dec 19, 2017 Jun DISC

>D> +! 80MG/20ML N209139 002 Dec 19, 2017 Jun DISC

>A> + @ 80MG/20ML N209139 002 Dec 19, 2017 Jun DISC

TABLET;ORAL

VALSARTAN

AB SQUARE PHARMS LTD 40MG A205347 001 Apr 09, 2018 Mar NEWA

AB 80MG A205347 002 Apr 09, 2018 Mar NEWA

AB 160MG A205347 003 Apr 09, 2018 Mar NEWA

AB 320MG A205347 004 Apr 09, 2018 Mar NEWA

AB UNICHEM LABS LTD 40MG A209261 001 May 04, 2018 Apr NEWA

AB 80MG A209261 002 May 04, 2018 Apr NEWA

AB 160MG A209261 003 May 04, 2018 Apr NEWA

AB 320MG A209261 004 May 04, 2018 Apr NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@ FRESENIUS KABI USA EQ 125MG BASE A065453 001 Jun 18, 2012 Feb DISC

@ EQ 250MG BASE A065453 002 Jun 18, 2012 Feb DISC

FOR SOLUTION;ORAL

FIRVANQ KIT

+! RXMTM THERAPS LLC EQ 25MG BASE/ML N208910 001 Jan 26, 2018 Jan NEWA

+! EQ 50MG BASE/ML N208910 002 Jan 26, 2018 Jan NEWA

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE EQ 1GM BASE/200ML N050671 003 Mar 01, 1999 Apr NEWA

VANCOMYCIN HYDROCHLORIDE

@ MYLAN LABS LTD EQ 10GM BASE/VIAL A091469 001 Jul 01, 2011 Mar DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @ BAYER HLTHCARE 2.5MG N021400 003 Aug 19, 2003 Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

+ @ BAYER HLTHCARE 10MG N200179 001 Jun 17, 2010 Apr DISC

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+ PF PRISM CV EQ 0.5MG BASE N021928 001 May 10, 2006 Feb CAHN

+! EQ 1MG BASE N021928 002 May 10, 2006 Feb CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@ FOSUN PHARMA EQ 25MG BASE A077515 001 Jun 13, 2008 Jan CAHN

@ EQ 37.5MG BASE A077515 002 Jun 13, 2008 Jan CAHN

@ EQ 50MG BASE A077515 003 Jun 13, 2008 Jan CAHN

@ EQ 75MG BASE A077515 004 Jun 13, 2008 Jan CAHN

@ EQ 100MG BASE A077515 005 Jun 13, 2008 Jan CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP EXELA PHARMA SCS LLC 10MG/4ML (2.5MG/ML) N018925 002 Apr 05, 2018 May NEWA

AP ! HOSPIRA 5MG/2ML (2.5MG/ML) A070738 001 May 06, 1987 Jan CPOT

>A> AP SOMERSET THERAPS LLC 5MG/2ML (2.5MG/ML) A211015 001 Jun 18, 2018 Jun NEWA

>A> AP 5MG/2ML (2.5MG/ML) A211035 001 Jun 18, 2018 Jun NEWA

>A> AP 10MG/4ML (2.5MG/ML) A211015 002 Jun 18, 2018 Jun NEWA

>A> AP 10MG/4ML (2.5MG/ML) A211035 002 Jun 18, 2018 Jun NEWA

TABLET;ORAL							
ISOPTIN							
+ @	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CRLD
+ @		80MG	N018593	001	Mar 08, 1982	Apr	CRLD
+ @		120MG	N018593	002	Mar 08, 1982	Apr	CRLD
VERAPAMIL HYDROCHLORIDE							
@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan	CAHN
@		80MG	A071423	001	May 24, 1988	Jan	CAHN
@		120MG	A071424	001	May 25, 1988	Jan	CAHN
TABLET, EXTENDED RELEASE;ORAL							
VERAPAMIL HYDROCHLORIDE							
@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar	DISC
@		180MG	A200878	002	Apr 20, 2012	Mar	DISC
@		240MG	A200878	003	Apr 20, 2012	Mar	DISC
<u>VIGABATRIN</u>							
FOR SOLUTION;ORAL							
VIGABATRIN							
AA	AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb	NEWA
AA	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Apr	NEWA
VIGADRONE							
>A> AA	AUCTA PHARMS	500MG/PACKET	A210196	001	Jun 21, 2018	Jun	NEWA
<u>VILAZODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
VIIIBRYD							
+!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan	CAHN
+		20MG	N022567	002	Jan 21, 2011	Jan	CAHN
+		40MG	N022567	003	Jan 21, 2011	Jan	CAHN
<u>VINBLASTINE SULFATE</u>							
INJECTABLE;INJECTION							
VELBAN							
+ @	LILLY	10MG/VIAL	N012665	001		Apr	CRLD
<u>WARFARIN SODIUM</u>							
TABLET;ORAL							
WARFARIN SODIUM							
@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan	CAHN
@		2MG	A040196	002	Sep 30, 1997	Jan	CAHN
@		2.5MG	A040196	003	Sep 30, 1997	Jan	CAHN
@		3MG	A040196	008	Jul 26, 2000	Jan	CAHN
@		4MG	A040196	004	Sep 30, 1997	Jan	CAHN
@		5MG	A040196	005	Sep 30, 1997	Jan	CAHN
@		6MG	A040196	009	Jul 26, 2000	Jan	CAHN
@		7.5MG	A040196	006	Sep 30, 1997	Jan	CAHN
@		10MG	A040196	007	Sep 30, 1997	Jan	CAHN
<u>ZIPRASIDONE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
ZIPRASIDONE HYDROCHLORIDE							
@	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar	DISC
@		EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar	DISC
@		EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar	DISC
<u>ZOLEDRONIC ACID</u>							
INJECTABLE;IV (INFUSION)							
ZOLEDRONIC							
>A> AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Jun	NEWA
ZOLEDRONIC ACID							
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan	CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan	CAHN
<u>ZOLMITRIPTAN</u>							
TABLET;ORAL							
ZOLMITRIPTAN							
@	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar	DISC
@		5MG	A202078	002	May 14, 2013	Mar	DISC
>A> AB	ZYDUS PHARMS USA INC	2.5MG	A203019	001	Jul 11, 2018	Jun	NEWA
>A> AB		5MG	A203019	002	Jul 11, 2018	Jun	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

@ APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar	DISC
@	5MG	A202476	002	May 14, 2013	Mar	DISC

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@ SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	DISC
@	10MG	A078055	002	Apr 23, 2007	Apr	DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
@	50MG	A077645	003	Sep 29, 2006	Feb	CAHN
@	100MG	A077645	001	Dec 22, 2005	Feb	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ G AND W LABS

325MG

N018060 003 Dec 18, 1986

Jan DISC

@

650MG

N018060 002

Jan DISC

ACETAMINOPHEN

+ TARO PHARM INDS LTD

120MG

N018337 003 Sep 12, 1983

May CAHN

+

325MG

N018337 002

May CAHN

+!

650MG

N018337 001

May CAHN

INFANTS' FEVERALL

+ TARO PHARM INDS LTD

80MG

N018337 004 Aug 26, 1992

May CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

HERITAGE PHARMA

650MG

A207035 001 May 31, 2018

May NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

+ @ SANOFI AVENTIS US

160MG;40MG

N018685 002 Dec 09, 1983

May DISC

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS

1%

A205181 001 Nov 16, 2017

May CAHN

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PLD ACQUISITIONS

5MG

A077946 001 Dec 27, 2007

Feb CAHN

10MG

A077946 002 Dec 27, 2007

Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS

5MG;120MG

A077991 001 Mar 05, 2008

Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO

2%;70% (1ML)

N020832 008 Oct 23, 2008

Feb NEWA

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PLD ACQUISITIONS LLC

1.34MG

A073458 001 Oct 31, 1993

Jan CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

1%

N018230 002 Dec 26, 1991

Mar DISC

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC

1%,100MG

N020389 002 Jun 23, 1994

Feb DISC

TABLET;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

100MG

N018182 002 Dec 26, 1991

Mar DISC

>D> DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

>D>

TABLET, EXTENDED RELEASE;ORAL

>D>

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

>D>

! AVANTHI INC

6MG;120MG

A078648 001 Feb 27, 2013

Jun DISC

>A>

@

6MG;120MG

A078648 001 Feb 27, 2013

Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

PERRIGO R AND D

30MG;600MG

A207602 002 Mar 05, 2018

Apr NEWA

60MG;1.2GM

A207602 001 Mar 05, 2018

Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD EQ 20MG BASE A207673 001 May 15, 2018 Apr NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

>D> ALLEGRA HIVES
>D> + SANOFI AVENTIS US 60MG N020872 008 Jan 24, 2011 Jun DISC
>A> + @ 60MG N020872 008 Jan 24, 2011 Jun DISC
>D> +! 180MG N020872 009 Jan 24, 2011 Jun DISC
>A> + @ 180MG N020872 009 Jan 24, 2011 Jun DISC
>D> CHILDREN'S ALLEGRA ALLERGY
>D> + SANOFI AVENTIS US 30MG N020872 005 Jan 24, 2011 Jun DISC
>A> + @ 30MG N020872 005 Jan 24, 2011 Jun DISC
>D> CHILDREN'S ALLEGRA HIVES
>D> + SANOFI AVENTIS US 30MG N020872 006 Jan 24, 2011 Jun DISC
>A> + @ 30MG N020872 006 Jan 24, 2011 Jun DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

>A> AMNEAL PHARMS 600MG A207342 001 Jul 11, 2018 Jun NEWA
>A> 1.2MG A207342 002 Jul 11, 2018 Jun NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>A> AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM A207753 001 Jun 29, 2018 Jun NEWA
SALT
STRIDES PHARMA EQ 200MG FREE ACID AND POTASSIUM A204469 001 Mar 28, 2018 Mar NEWA
SALT

SUSPENSION;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD 100MG/5ML A209179 001 Apr 17, 2018 Apr NEWA

TABLET;ORAL

IBUPROFEN

>A> @ P AND L DEV LLC 200MG A070733 001 Sep 19, 1986 Jan CAHN
STRIDES PHARMA 200MG A206989 001 Jun 29, 2018 Jun NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD 5MG A210375 001 Jan 19, 2018 Jan NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>A> HAUPT PHARMA 1.5MG A204044 001 Jul 03, 2018 Jun NEWA

LORATADINE

SYRUP;ORAL

LORATADINE

>A> AUROBINDO PHARMA LTD 1MG/ML A208931 001 Jun 29, 2018 Jun NEWA

TABLET;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG A208314 001 Apr 16, 2018 Apr NEWA

PLD ACQUISITIONS LLC 10MG A075209 001 Jan 21, 2003 Jan CAHN

TABLET, CHEWABLE;ORAL

LORATADINE

SUN PHARMA GLOBAL 5MG A210088 001 Apr 16, 2018 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG A208477 001 Apr 11, 2018 Mar NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO PHARMS

2%

A074444 001 Jan 13, 1997 May CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS

2%,100MG

A076585 001 Mar 26, 2004 Jan DISC

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

>A>

PURACAP PHARM LLC

EQ 200MG BASE

A208363 001 Mar 15, 2018 Jun NEWA

TABLET;ORAL

NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC

EQ 200MG BASE

A074646 001 Jan 13, 1997 Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

THRIVE

@ GLAXOSMITHKLINE CONS

EQ 2MG BASE

A077658 001 Jun 19, 2007 Mar DISC

EQ 2MG BASE

A077658 001 Jun 19, 2007 Feb CAHN

EQ 4MG BASE

A077656 001 Jun 19, 2007 Feb CAHN

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002 Feb CTNA

+!

EQ 4MG BASE

N021330 002 Oct 31, 2002 Feb CTNA

NICOTINE POLACRILEX

>A>

WATSON LABS INC

EQ 2MG BASE

A209206 001 Jun 26, 2018 Jun NEWA

>A>

EQ 4MG BASE

A209206 002 Jun 26, 2018 Jun NEWA

>A>

WATSON LABS TEVA

EQ 2MG BASE

A209519 001 Jul 02, 2018 Jun NEWA

>A>

EQ 4MG BASE

A209519 002 Jul 02, 2018 Jun NEWA

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD

EQ 20MG BASE

A206877 001 Jun 06, 2018 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ZYDUS PHARMS USA INC

20MG;1.1GM

A203345 001 Mar 16, 2018 Mar NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

APNAR PHARMA LP

17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Mar CAHN

AUROBINDO PHARMA LTD

17GM/SCOOPFUL

A209017 001 Apr 09, 2018 Mar NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

VIVIMED GLOBAL

EQ 75MG BASE

A209160 001 Mar 05, 2018 Feb NEWA

EQ 150MG BASE

A209161 001 Feb 22, 2018 Feb NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS

1%

N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS

1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS

1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2018

NO JUNE 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	7459554	Nov 24, 2026	DS		ODE-175	Oct 31, 2024
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9399012	Sep 11, 2031		U-2261		
	9399012	Sep 11, 2031		U-2262		
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028		U-2263		
>A>	9987238	Nov 13, 2028		U-2261		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP	U-2249		
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Feb 10, 2025	DS DP	U-1263		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					I-763	Jan 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	9861771	Oct 11, 2020	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	9956205	Dec 28, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	9956205	Dec 28, 2031	U-2104			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					I-766	Mar 09, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001					NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002					NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003					NC	May 31, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		NCE	Feb 14, 2023
	8802689	Mar 27, 2027	U-2237			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9884054	Sep 23, 2033	U-2237			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	>A> 9974742	Sep 18, 2035	DP			
	>A> 9974793	Sep 18, 2035	DP			
	>A> 9974794	Sep 18, 2035	DP U-2161			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9941931	Nov 04, 2030	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	8999313	Sep 10, 2033	DP		NP	May 04, 2021
	9326969	Sep 10, 2033	U-2310			
	9592252	Aug 11, 2032	DP U-2310			
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001 >A>	9987231	Jan 02, 2033	U-2324			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002 >A>	9987231	Jan 02, 2033	U-2324			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001 >A>	7638536	May 05, 2025	DS DP		NCE	May 21, 2023
	>A> 8765764	Jan 15, 2023	U-2314			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9211259	Feb 28, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9901585	Jun 13, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	>A> 8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
	>A> 8420629	Mar 10, 2029	U-247			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2019	DS DP U-594			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	8791270	Jan 12, 2026	DP U-1790		>A> ODE-179	Dec 07, 2022
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001					>A> NCE	Jun 27, 2023
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
	9687443*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001					I-771	Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002					I-771	Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	8426391	Aug 27, 2028	U-1872			
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP U-2255			
	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	8222219	Apr 11, 2025	U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	8222219	Apr 11, 2025	U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2018	DP U-1715			
	6130208	Jun 29, 2019	DP U-1715			
	9925265	May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	>A> 7232818	Apr 14, 2025	DS DP			
	>A> 7417042	Jul 20, 2026	DS DP			
	>A> 7491704	Apr 14, 2025	U-2319			
	>A> 7491704	Apr 14, 2025	U-2320			
	>A> 7737112	Dec 07, 2027	DP			
	>A> 8129346	Apr 14, 2025	U-2319			
	>A> 8129346	Apr 14, 2025	U-2320			
	>A> 8207125	Apr 14, 2025	DS DP			
	>A> 8207126	Apr 14, 2025	DP			
	>A> 8207127	Apr 14, 2025	U-2319			
	>A> 8207127	Apr 14, 2025	U-2320			
	>A> 8207297	Apr 14, 2025	DS DP			
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9511109	Oct 21, 2029	U-1924			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	>A> 9993471	Mar 15, 2030	U-1680			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252		I-770	Mar 02, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001 >A>	8148374	Sep 03, 2029	DS DP U-1279			
	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COPANLISIB DIHYDROCHLORIDE - ALIOOPA</u>						
N 209936 001 >A>	RE46856	Oct 22, 2029	DS DP U-2124			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		>A> ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		>A> ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		>A> ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		>A> ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	9918973	Dec 13, 2024	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-164	Nov 09, 2024
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9949986	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001					>A> NP	Jun 21, 2021
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002					>A> NP	Jun 21, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	6960346	Jul 03, 2023	DP		NP	Feb 09, 2021
	7560120	Sep 05, 2022	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 003	>A> 9649296	Apr 20, 2036	DP			
	>A> 9717796	Apr 20, 2036	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 004	>A> 9649296	Apr 20, 2036	DP			
	>A> 9717796	Apr 20, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019	U-1384			
	7619001	Apr 01, 2019	U-1384			
	7803840	Apr 01, 2019	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8759393	Jul 04, 2018	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019	U-1384			
	7619001	Apr 01, 2019	U-1384			
	7803840	Apr 01, 2019	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8759393	Jul 04, 2018	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9937132	Feb 18, 2033	DP U-1382			
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS U-1571			
	7253185	Apr 29, 2022	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	9949998	Jun 11, 2034	U-2290			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949998	Jun 11, 2034	U-2290			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001				>A> NCE		Jun 27, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002				>A> NCE		Jun 27, 2023
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	>A> 9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	>A> 9180091	Dec 20, 2033	DP U-2317			
	>A> 9289382	Nov 21, 2032	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	>A> 9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	>A> 9180091	Dec 20, 2033	DP U-2317			
	>A> 9289382	Nov 21, 2032	DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-256			
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917*PED	Jun 13, 2021				
	>A> 7887845	Mar 25, 2019	DP			
	>A> 7887845*PED	Sep 25, 2019				
	>A> 8003789	Nov 01, 2019	DS DP			
	>A> 8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-256			
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917*PED	Jun 13, 2021				
	>A> 7887845	Mar 25, 2019	DP			
	>A> 7887845*PED	Sep 25, 2019				
	>A> 8003789	Nov 01, 2019	DS DP			
	>A> 8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-256			
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917*PED	Jun 13, 2021				
	>A> 7887845	Mar 25, 2019	DP			
	>A> 7887845*PED	Sep 25, 2019				
	>A> 8003789	Nov 01, 2019	DS DP			
	>A> 8003789*PED	May 01, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	>A> 5753706	Feb 03, 2019	DP	U-1577		
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS	U-1086	NPP	May 11, 2021
	5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027		U-1086		
	9187405*PED	Dec 25, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527	002				NS PED	May 11, 2021 Nov 11, 2021
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	>A> 7915243	Sep 08, 2023	DP		
		>A> 7939516	Sep 08, 2023	DP		
		>A> 8247395	Oct 25, 2022	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001	8534281	Mar 08, 2030	DP	NPP	May 17, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	002	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	003				NS	May 17, 2021
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	001	8534281	Mar 08, 2030	DP	I-775	Apr 24, 2021
		9750726	Nov 29, 2030	DP		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	003	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	>A> 9987229	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	002	>A> 9987229	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	003	>A> 9987229	Sep 01, 2024	DP		
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007	001	9730890	Jun 22, 2021	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP U-2265		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	8426450	May 23, 2032	DS DP		NCE	Apr 19, 2023
	8895586	May 23, 2032		U-2301		
	9186357	Nov 18, 2030		U-2301		
	9403772	May 23, 2032	DS	U-2301		
	9908907	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030		DP		
	8445485	Jun 17, 2026		DP		
	8652492	Nov 06, 2028		DP		
	8771648	Jul 27, 2032		DP		
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026		DP		
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030		DP		
	8445485	Jun 17, 2026		DP		
	8652492	Nov 06, 2028		DP		
	8771648	Jul 27, 2032		DP		
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026		DP		
<u>GADOXETATE DISODIUM - EOVISt</u>						
N 022090 002	6039931	Nov 13, 2021		U-1239		
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001	>A> 9375498	Aug 10, 2032	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366 7358366*PED	Apr 19, 2020 Oct 19, 2020	DS	Y		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366 7358366*PED	Apr 19, 2020 Oct 19, 2020	DS	Y		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366 7358366*PED	Apr 19, 2020 Oct 19, 2020	DS	Y		
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	>A> 9962359	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	9931304 9962338	Jun 27, 2021 Jun 27, 2021	DP DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	9931304 9962338	Jun 27, 2021 Jun 27, 2021	DP DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
N 210566 001					NDF	May 24, 2021
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361 7348361	Nov 06, 2020 Nov 06, 2020	DP U-1087 DP U-2250		M-220	Feb 15, 2021
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u>						
A 209556 001					PC	Aug 11, 2018
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	>A> 9980983	Apr 21, 2035	U-2205			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			
	RE44846	Aug 10, 2019	DP			
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					ODE-177	Dec 21, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2219		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8952015	Dec 28, 2026				U-2241
	8952015	Dec 28, 2026				U-2242
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031				U-1491
	8999999	Jun 03, 2031				U-1946
	8999999	Jun 03, 2031				U-2241
	8999999	Jun 03, 2031				U-2242
	9125889	Jun 03, 2031				U-1650
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034				U-2150
	9801881	Jun 03, 2031				U-1491
	9801881	Jun 03, 2031				U-2242
	9801883	Jun 03, 2031				U-2159
	9801883	Jun 03, 2031				U-2243
	9814721	Jun 03, 2031				U-1947
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9072661	Mar 16, 2032				U-2264
	9072710	Mar 16, 2032				U-2266
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026				U-1440
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026				U-1440
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9884094	May 01, 2033				U-2238
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			U-1832
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP			U-1855
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP			U-2146
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001 >A>	9717852	Apr 08, 2033	DP			
	9950039	Dec 10, 2035				U-2277
	9950039	Dec 10, 2035				U-2278
	9950039	Dec 10, 2035				U-2279
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003 >A>	9717852	Apr 08, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
>A>	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9943571	Aug 11, 2029			U-1537	
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9943571	Aug 11, 2029			U-1537	
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9943571	Aug 11, 2029			U-1537	
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	7495103	May 20, 2027	DS DP		NCE	Feb 12, 2023
	7645789	May 01, 2027	DS DP		ODE-173	Feb 12, 2025
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027			U-2246	
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027			U-2246	
	8598181	May 01, 2027			U-2246	
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025			U-2247	
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033			U-2248	
	9670163	Dec 28, 2026	DP		U-2246	
	9931334	Dec 28, 2026	DP		U-2275	
>A>	9974781	Apr 09, 2027	DP		U-2318	
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP		U-2276	M-218 Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9931334	Dec 28, 2026	DP		U-2276	M-218 Jan 25, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	>A> 9901546	May 17, 2019	DP			
	>A> 9901546*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	>A> 9901546	May 17, 2019	DP			
	>A> 9901546*PED	Nov 17, 2019				
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					ODE-165	Nov 08, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	9868739	Nov 09, 2031	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 001					>A> PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 002					>A> PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
	9925264	May 10, 2031	DP U-2267			
	9931403	May 10, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9968659	Jan 09, 2037	U-2313			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001					NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9861622	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	9861622	Mar 07, 2025	U-1316			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001					M-225	Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002					M-225	Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE ODE-166	Jan 26, 2023 Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	9943526	Apr 20, 2036	U-1643			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					>A> NCE	Jun 13, 2023
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8623826	Nov 18, 2030	U-2293			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	>A> 7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	>A> 7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	>A> 8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	>A> 8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
	>A> 8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	>A> 8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	>A> 8389537	Jul 18, 2026	DS DP U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DS DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DS DP U-1374			
	>A> 9061029*PED	Oct 07, 2032				
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	9926559	Jan 09, 2034	U-1943		M-226	May 14, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762	Jan 12, 2021
					>A> ODE-180	Aug 17, 2024
					>A> ODE-181	Aug 17, 2024
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762	Jan 12, 2021
					>A> ODE-180	Aug 17, 2024
					>A> ODE-181	Aug 17, 2024
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2019	DP			
	5948818	May 13, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024		U-1369		
	9855224	Feb 13, 2024		U-1370		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9968598	Sep 02, 2036		DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9968598	Sep 02, 2036		DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9968598	Sep 02, 2036		DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9968598	Sep 02, 2036		DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9968598	Sep 02, 2036		DP U-1556		
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	9974773	Jun 11, 2035		U-2306		
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032		DP U-805		
	9399014	Dec 15, 2029		U-805		
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					PC	Sep 19, 2018
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 001	9925212	Oct 08, 2033		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 002	9925212	Oct 08, 2033		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 003	9925212	Oct 08, 2033		U-1766		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001					>A> NCE	Apr 29, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8420674	Dec 18, 2027	U-2079			
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001				>A> NCE		Jun 25, 2023
				>A> GAIN		Jun 25, 2028
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-2230			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP	May 03, 2021
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Nov 17, 2022	U-2271			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9957232	Jul 09, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	9868739	Nov 09, 2031	U-1981			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					M-223	Feb 01, 2021
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	7173037	Dec 04, 2026	DS DP			
<u>RITONAVIR - RITONAVIR</u>						
A 202573 001					PC	Sep 16, 2018
<u>RITONAVIR - NORVIR</u>						
N 209512 001				>A>	ODE-184	Jun 07, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					D-171	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
>A>	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
>A>	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
>A>	9987285	Aug 17, 2035	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SOFOBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 002					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 003					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 004					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9968655	Nov 01, 2025	U-2308			
	9968656	Nov 01, 2025	U-2308			
	9968658	Nov 01, 2025	U-1320			
	9974835	Nov 01, 2025	U-1320			
	9974837	Nov 01, 2025	U-1320			
	9981014	Nov 01, 2025	U-1320			
	9981016	Nov 01, 2025	U-1320			
	9987334	Nov 01, 2025	U-1320			
	>A> 9987335	Nov 01, 2025	U-1320			
	>A> 9993528	Nov 01, 2025	U-1320			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	7696178	Sep 22, 2022	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	>A> 7842699	Dec 08, 2020	U-2322		I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	>A> 6956041	Dec 08, 2020	DP		I-780	May 30, 2021
	>A> 6965027	Mar 25, 2023	DS			
	>A> 7265221	Dec 08, 2020	DS			
	>A> 7301023	May 23, 2022	DS			
	>A> 7842699	Dec 08, 2020	U-2322			
	>A> RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181	Mar 14, 2034	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001	>A> 8895557	Jan 07, 2028	DP		>A> NCE	Oct 23, 2020
	>A> 8895557*PED	Jul 07, 2028			>A> ODE-100	Oct 23, 2022
					>A> PED	Apr 23, 2021
					>A> PED	Apr 23, 2023
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	>A> ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	>A> ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	>A> ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	>A> ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	>A> ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	>A> ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8497393	Dec 15, 2028	DS		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8497393	Dec 15, 2028	DS	Y		
<u>TRYPAN BLUE - VISIONBLUE</u>						
N 021670 001	>A> 6367480	Oct 26, 2019	U-2321			
	>A> 6720314	May 07, 2019	U-2321			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8534281	Mar 08, 2030	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	>A> 6258795	Jul 10, 2019	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	>A> 6258795	Jul 10, 2019	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9937223	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	>A> 9174982	May 26, 2030	U-1835		>A> I-782	Jun 08, 2021
	>A> 9174982	May 26, 2030	U-2323		>A> M-228	Jun 08, 2021
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	>A> 9174982	May 26, 2030	U-1835		>A> I-782	Jun 08, 2021
	>A> 9174982	May 26, 2030	U-2323		>A> M-228	Jun 08, 2021
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	>A> 9174982	May 26, 2030	U-1835		>A> I-782	Jun 08, 2021
	>A> 9174982	May 26, 2030	U-2323		>A> M-228	Jun 08, 2021
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7713999	May 30, 2024	DS DP U-2291			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm